
















The Dissertation Committee for Edward Kelly Merritt, Jr. Certifies that this is the 
approved version of the following dissertation: 
 
 
REPAIR OF SKELETAL MUSCLE  













REPAIR OF SKELETAL MUSCLE TRANSECTION  











Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 









Numerous people throughout the years have had a profound influence on my life. All of 
my family and friends obviously deserve to be recognized for everything that they have 
done for me, but I would like to dedicate this dissertation to all of my past teachers. I 
have been lucky to have received an incredible education from incredible educators 
starting with my kindergarten teacher Ms. Dinjar to my doctoral advisor Dr. Roger Farrar 
and everyone in between. Without the guidance, support, and advice given to me at every 
step along the way, this dissertation would not have been possible. My teachers’ devotion 





I am grateful to Dr. Roger Farrar for overseeing my education, research, and 
employment at The University. Dr. Tom Walters and others at the U.S. Army Institute of 
Surgical Research have been instrumental in helping me to develop this research and in 
helping to find outside financial support for myself as well as my studies. Special thanks 
to my committee members; Dr. Laura Suggs, Dr. Martin Adamo, and Dr. John Ivy for 
guiding me in the right direction. Thanks also to David Hammers, Matt Tierney, Rohit 
Gokhale, Long Le, Rosemary French, and Apurva Sarathy, and a host of great 
undergraduate lab assistants for the countless hours of technical assistance. Finally, thank 
you to Patty Coffman, Tan Thai, and the rest of the Department of Kinesiology & Health 
Education for helping me with anything and everything during my time at The 
University. 
 vi
REPAIR OF SKELETAL MUSCLE TRANSECTION  
INJURY WITH TISSUE LOSS 
 
 
Edward Kelly Merritt, Jr. Ph.D. 
The University of Texas at Austin, 2009 
 
Supervisor:  Roger Farrar 
 
A traumatic skeletal muscle injury that involves the loss of a substantial portion of 
tissue will not regenerate on its own. Little is understood about the ability of the muscle 
to recover function after such a defect injury, and few research models exist to further 
elucidate the repair and regeneration processes of defected skeletal muscle. In the current 
research, a model of muscle injury was developed in the lateral gastrocnemius (LGAS) of 
the rat. In this model, the muscle gradually remodels but functional recovery does not 
occur over 42 days. Repair of the defect with muscle-derived extracellular matrix (ECM), 
improves the morphology of the LGAS. Blood vessels and myofibers grow into the ECM 
implant in vivo, but functional recovery does not occur. Addition of bone marrow-derived 
mesenchymal stem cells (MSCs) to the implanted ECM in the LGAS increases the 
number of blood vessels and regenerating myofibers within the ECM. Following 42 days 
of recovery, the cell-seeded ECM implanted LGAS produces significantly higher 
isometric force than the non-repaired and non-cell seeded ECM muscles. These results 
suggest that the LGAS muscle defect is a suitable model for the study of traumatic 
skeletal muscle injury with tissue loss. Additionally, MSCs seeded on an implanted ECM 
lead to functional restoration of the defected LGAS. 
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Chapter I: General Introduction 
 Injuries to the soft tissue of the extremities comprise the largest number of 
wounds received by United States military personnel in war-time activities [1]. 
Operations performed on the extremities make up the greatest percentage of surgical 
procedures due to battlefield injuries [2, 3]. Some injuries are so traumatic that the only 
possible treatment for the victim is to amputate the entire limb [3]. However, even when 
the limb can be saved, the initial damage done to the skeletal muscle and the further 
debridement of muscle and surrounding tissue will leave the soldier with a physical 
handicap despite the fact that the limb is still predominantly intact. Ultimately, the 
functionality of the limb will depend on the remaining skeletal muscle. While skeletal 
muscle is capable of regeneration to a limited capacity, it is not able to fully repair itself 
after the loss of a significant amount of tissue. The current standard of care for these 
injuries attempts to repair the damaged area by autologous tissue transfer (muscle flaps) 
using donor tissue from other areas of the victim’s body. Recent reports describe 
functional free muscle transplantation in the forearm [4] and elbow [5], but these 
procedures are associated with significant donor site morbidity and are not yet applicable 
to large muscle defects. Individuals who have lost significant portions of muscle can 
expect to live the rest of their lives with a physical handicap. As such, addressing the 
need for a suitable treatment to better return function to limbs that have lost large 
portions of skeletal muscle is important. 
 The development of a muscle defect model in a load bearing muscle is important 
to understanding the potential for regenerating large segments of muscle and restoring 
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function. Currently, several skeletal muscle defect models have been established [6-9]. 
These models, however, are limited in their application to regeneration of large segments 
of muscle necessary for restoration of normal function. 
OBJECTIVES 
 The overall objective of this study was to develop a defect model of skeletal 
muscle injury, repair it surgically, and characterize the regenerated muscle functionally 
and morphologically. To accomplish this, the specific aims for the study were as follows: 
1.  Develop a skeletal muscle defect injury model that results in a permanent deficit in 
function and also allows for implantation of tissue engineered constructs and long 
term functional analysis of the constructs. 
2.  Functionally characterize the defect injury model in a load bearing muscle that is 
critical for mobility such as the lateral gastrocnemius (LGAS) muscle. 
3.  Develop a biocompatible, extracellular matrix (ECM) implant that can be used to 
repair missing tissue in injured skeletal muscle, which will transmit mechanical force 
between the remnants of damaged muscle and also serve as a platform for muscle 
progenitor cells to proliferate and differentiate into functional muscle. 
4.  Both functionally and morphologically, assess muscle regeneration in the muscle 
repaired with an ECM.  
5.  Functionally and histologically characterize the skeletal muscle defect repaired with 
an ECM seeded with bone marrow-derived mesenchymal stem cells. 
 3
HYPOTHESES 
1.  Removal of a large portion of the LGAS will prevent regenerating myofibers from 
spanning the gap and the area will be left permanently devoid of tissue. The remaining 
segments of the muscle will remodel, but permanent loss of function will be related to 
the loss of muscle mass. 
2.  The ECM implant groups will maintain structure and function better than non-repaired 
defect groups. 
3.  Complete muscle regeneration in the defect area will be limited by fibrosis which will 
limit vascular supply to the regenerating area. 
4.  Bone marrow derived mesenchymal stem cell-seeded ECM groups will regenerate 
muscular structure and function better than ECM repair alone due to the regenerative 
stimulus provided by mesenchymal stem cells. 
SIGNIFICANCE 
The prevalence of injuries to skeletal muscle that result in loss of muscle tissue 
and concomitant loss of function demonstrates the importance for research that identifies 
useful surgical and therapeutic mechanisms to improve muscle regeneration. Current 
treatment methods do little to combat the permanent loss of muscle function which 
results from these injuries.  
 Research is needed to better understand the regenerative process after loss of a 
large volume of muscular tissue. Limited data exists on muscle repair mechanisms 
utilizing implantable, acellular, skeletal muscle ECM with stem cells in order to 
regenerate myofibers and restore function following injury. The available literature on 
repair of lost skeletal muscle tissue is limited to repair of abdominal wall defects with 
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ECM and unipotent progenitor cells. Studies that directly measure the function of 
muscles with cell-seeded ECM implants are virtually nonexistent. The findings from this 
study will help determine the effectiveness of muscle repair with ECM and multipotent 
cells with regard to restoration of function and morphology. Ideally the findings will 
identify promising routes for research that will ultimately lead to clinical applications. 
The techniques established should serve as a path forward for the restoration of function 
for patients with traumatic muscle injuries. While a person who is injured today might 
have a permanent disability, in several years a person with the same injury might have no 
noticeable impairment due in part to findings established by this study.  
DELIMITATIONS AND LIMITATIONS 
 This study was performed on 5-9 month old male Sprague-Dawley and Lewis 
rats. The portion of muscle removed from the LGAS accounted for nearly 20% of the 
total mass in this model, but this creates only a one centimeter wide defect. Regeneration 
of skeletal muscle after the removal of 20% of the muscle mass in the muscle of a human 
might be limited by diffusion distances, extent of neural regeneration, and degree of 
fibrosis in a larger muscle mass. Therefore, the animal subject pool limits applicability to 
human beings, but can be used to theorize the process of skeletal muscle regeneration. 
 During the recovery period, animals were confined to their home cages, but the 
activity levels of the animals was not controlled or monitored. Activation and 
mobilization of skeletal muscle following injury can have dramatic effects on the 
muscle’s ability to regenerate; however, there is no reason to believe that animals in any 
group of this study had significantly different activity levels. Skeletal muscle function 
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was only measured during isometric contractions. Generally isometric function is a good 
measure of overall function, but care should be taken when interpreting the results in 
regards to dynamic muscle function. Lastly, the injected bone marrow derived cells were 




Chapter II: Review of the Literature 
SKELETAL MUSCLE INJURY 
The plasticity of skeletal muscle is well known. It has a remarkable capacity to 
regenerate in response to damaging stimuli. A skeletal muscle can be completely 
removed, minced into small bits, and placed back into its compartment, and it will 
regenerate enough to contract and produce force [10]. But even in less severe injuries, the 
repair process takes time and is not always 100% efficient. The ability of a muscle to 
recover following damage depends on the type and severity of the injury, but once the 
damage has occurred, the regeneration process proceeds in the same manner no matter 
what the type of injury. The healing process can be divided into three main phases which 
exist in an overlapping continuum and begin immediately after an injury has occurred: 
the destruction/ inflammatory phase; the repair phase; and the remodeling phase.  
 The Destruction/Inflammatory Phase 
 Immediately following an injury to skeletal myofibers, such as a 
laceration/transection injury, myofibers are sheared and torn apart allowing the contents 
of the cell to interact with the extracellular environment. Single myofibers are often many 
centimeters long and following transection, run the risk of being necrotized completely. 
The death of the full myofiber is normally prevented by a structure known as the 
contraction band. Cytoskeletal materials flow to the edge of the injury and form a barrier 
to seal off the cell from the outside environment [11]. Due to their elastic nature, the torn 
fibers will retract and a gap will form between the two ends.  
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Due to skeletal muscle’s high vascularity, the capillaries that surround each fiber 
will also be damaged. Damage to the vessels will allow for blood to leak out creating a 
hematoma in the recently formed gap. The hematoma is comprised of blood components 
including clot forming proteins, which will form the beginnings of the connective tissue 
scar, as well as various types of white blood cells. The white blood cells will digest the 
necrotic tissue and activate other cell types to start the regeneration process. Neutrophils 
are typically the first inflammatory cell to the site [12]. These cells begin the process of 
digesting the necrotic myofibers and cellular debris by phagocytosis. They also release 
cytokines which further amplify the inflammation process by signaling other cells. These 
cytokines also play a role in repair by stimulating muscle satellite cells, which are a group 
of normally quiescent muscle progenitor cells found beneath the basal lamina [13] The 
satellite cells proliferate and move to the damaged area [14]. Monocytes attracted to the 
injured area are converted into macrophages. The macrophages are the dominant cell type 
present during the later phases of the inflammatory reaction and continue the process of 
proteolysis and phagocytosis of damaged tissue [12]. They are selective in the breakdown 
of tissue and the basement membrane is generally left intact [15]. Satellite cells also 
receive signaling factors from the macrophages that will insure their continued survival 
[16]. More signals are triggered by the disruption of the integrity of the extracellular 
matrix (ECM).  Several growth factors are known to reside in inactivated forms on the 
ECM, but upon mechanical disruption of the ECM, these factors are activated and act on 
surrounding cells to enhance the repair response [17]. 
Repair Phase 
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 While damaged tissue is being removed, the repair process has already been 
started by the growth factors and signals coming from the macrophages, ECM, and 
activated satellite cells. Nerves, blood vessels, and muscle begin to infiltrate the wound 
area [17]. The process is characterized by the activity of satellite cells. Upon activation, 
the satellite cells will migrate to the injured area, become myoblasts and proliferate, 
differentiate, and fuse to existing myofibers or with each other to form myotubes to 
replace damaged fibers [15, 18].  Specific markers are expressed by quiescent satellite 
cells (Pax 7, cMET-R). Once they become activated, they differentially express other 
markers (MyoD, myf5, myogenin, MRF4, etc) such that the sequence leading to addition 
of nuclei to existing fibers or the formation of new fibers altogether can be tracked 
throughout the repair process [19].  
While satellite cells are the predominant cell used for repair of skeletal muscle 
following injury, they are not the only group of progenitor cells capable of contributing to 
regeneration. Other groups of muscle derived cells known as muscle derived stem cells, 
as well as cells from other tissues like bone marrow can contribute nuclei to the injured 
area [20, 21].  The cells can arrive from remote locations and contribute to the healing 
process by undergoing myogenic differentiation or by releasing paracrine growth factors 
that act on the surrounding cells [22, 23]. 
 Another aspect of the repair phase is the formation of a connective tissue scar. 
The scar acts to bridge the gap between the ends of the myofibers. This bridge allows for 
the transduction of force along the muscle length and also acts as a conduit for 
regenerating myofibers [17]. The scar is initially composed of fibrin and fibronectin from 
the blood, and as time progresses the area is infiltrated by fibroblasts which, under the 
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control of the growth factor TGF-β, help produce the ECM for the rebuilding phase [11, 
24, 25]. While the connective tissue scar initially serves the purpose of holding the ends 
of the myofibers together and preventing further damage from occurring, the scar formed 
in more severe injury cases can actually become a barrier to complete regeneration of the 
muscle by blocking the fibers from bridging the gap and connecting to regenerating fibers 
on the other side [26, 27]. The scar ultimately forms another myotendinous-type junction 
to bridge the cut ends of the muscle, effectively creating two muscles in series [28, 29]. 
 Critical to the survival of the regenerating area of muscle is the reintroduction of a 
sufficient blood and nerve supply. Since skeletal muscle is highly vascularized, the cut 
ends of blood vessels are in close proximity to the regenerating area. After only several 
days, new capillaries have sprouted into the damaged area [30]. While regeneration of the 
myofibers will proceed for a period of time without innervation, reinnervation of the 
fibers (especially those distal portions of the transected fibers) is necessary for them to 
survive; otherwise they will atrophy and ultimately die [31]. If the transected ends of the 
fibers remain in close proximity, nerve outgrowths from nearby surviving neuromuscular 
junctions (NMJ) will normally reinnervate the fibers after only fifteen days [32, 33]. 
Remodeling Phase 
 The remodeling phase is essentially a continuation of the repair phase. This 
process is characterized by the appearance of centrally nucleated myofibers created when 
satellite cells convert to myotubes and fuse with each other or existing myofibers. The 
fibers grow and begin to penetrate the scar and form adhesions with the ECM [11, 28]. 
Approximately ten days after injury, the connective tissue scar is stronger than the 
surrounding myofibers and is not likely to be pulled apart by muscle contractions [34]. 
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As the myofibers grow and penetrate into the scar they form adhesions with the 
connective tissue, and the scar gradually shrinks [28, 34]. Depending on the size of the 
gap, the fibers from each end ultimately reach each other, interlace with the ECM and 
possibly re-fuse [29, 35]. The myofibers continue to mature, and the expression of 
proteins in the reorganizing muscles, such as myosin heavy chain (MHC), transition from 
developmental isoforms to mature isoforms until they are phenotypically similar to 
normal myofibers [36].  
The regeneration process is sufficient for complete recovery much of the time and 
no permanent loss of function will result. However, traumatic muscle injuries caused by 
extraordinary events such as car accidents, gun shots, and explosive devices often require 
more than the body is capable of by itself. The remainder of this review will focus on 
muscle injuries unlikely to fully heal on their own. 
TRANSECTION INJURY 
Skeletal muscle transection injuries that also involve loss of significant portions 
of muscle tissue are often irreparable. But until the last several years, most of the research 
regarding traumatic muscle injury did not involve any actual loss of tissue. Most studies 
focused on severe injuries that left the muscle mass predominantly intact such as 
contusion and ischemia/ reperfusion injuries. Most of the research that involved myofiber 
transection used various types of laceration models where the tissue was severely 
damaged, but the full mass of the muscle was still present. The laceration model research, 
however, does prove to be a good starting point for the more serious injuries that include 
tissue loss. 
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The functional outcome of a muscle laceration depends on where the muscle is 
located, where it is lacerated, the depth and length of the laceration, as well as whether or 
not the lacerated muscle has synergists. Comparison between functional studies can be 
difficult because no single muscle laceration model is used by all researchers. Some 
researchers use a partial laceration model, while some use a full laceration model and cut 
the muscle into two separate pieces. A complete transection of a muscle will obviously 
lead to loss of normal function, but in many cases both parts of the muscle will survive 
and even contract with nervous input, although if they are not connected, the ends will 
simply contract and pull away from each other with no external work done [37]. The 
connective tissue scar might bridge the gap between transected segments, but full 
functional recovery is nearly impossible even if the muscle has been repaired by suturing 
the transected ends together [38]. 
 Repair is critical to functional recovery in laceration injuries of significant depth 
and length, even if the muscle has not been fully transected. A skeletal muscle is 
normally under passive tension even at rest, and it is this tension that will cause the ends 
of myofibers to retract when there is a break in the continuity due to a laceration injury. 
The larger the gap between the two ends, the larger the subsequent scar, and the less 
functional recovery [35, 39]. To decrease the size of the gap and connective tissue scar, 
the ends of the muscle can be sutured together [40]. Significant improvements in muscle 
function occur if the ends can be brought together with suturing techniques soon after 
injury [37, 38, 41]. Even though repair will improve the recovery of transected skeletal 
muscle, severely damaged muscle does not normally regain full functionality. To address 
this problem, other treatments have been developed which aim to increase the regrowth 
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of myofibers through the connective tissue scar by decreasing the size of the scar and 
inducing fibers to grow into the area. 
 Much of the focus to improve muscle regeneration following transection has been 
to decrease the connective tissue scar formation and fibrosis that occurs. Early after 
laceration injury, the formation of the connective tissue scar is important to help prevent 
the injury from recurring and creating more damage [17]. However, with the most severe 
laceration injuries, the scar formation becomes excessive and creates a barrier that 
impedes regenerating myofibers and decreases functional improvements [27]. Formation 
of the connective tissue scar and excessive fibrosis is closely associated with an increase 
in TGF-β signaling, and controlling this growth factor can play a part in modulating the 
amount of fibrosis that occurs after injury [25]. Multiple studies have been performed 
using compounds capable of inhibiting or upregulating TGF-β. Inhibition of TGF-β by 
compounds such as relaxin, suramin, and decorin, can, depending on the time of 
injection, significantly decrease the amount of fibrosis seen in regenerating muscles. 
With less fibrosis, functional improvement is observed in the regenerating muscles as 
well [42-45]. Upregulation of TGF-β has the opposite effect. It increases fibrosis and 
delays functional recovery [36].  
 Another method to promote the growth of myofibers across the lacerated area and 
prevent the scar tissue from impeding the regeneration process is to help the myofibers 
regrow with factors that promote their regeneration. A multitude of growth factors act on 
skeletal muscle as mitogens and can be used in a therapeutic manner to enhance healing 
following injury. Normally growth factors are released by inflammatory cells, satellite 
cells, and other nearby cells.  Basic fibroblast growth factor (bFGF), insulin-like growth 
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factor-1 (IGF-1), and nerve growth factor (NGF) are some of the signals that can improve 
muscle healing and function after strain injuries [46]. When injected directly into the 
laceration site in mice, each is individually capable of improving functional measures 
significantly [22, 47]. The mechanism by which some growth factors, such as IGF-1 act, 
is through the stimulation of satellite cell proliferation and differentiation [48]. If the 
growth factors can help to stimulate more growth from nearby satellite cells, the lacerated 
muscle stands a better chance of healing completely. The potential therapeutic effect of 
being able to turn on mitogenic signals and activate muscle progenitor cells has great 
implications in healing skeletal muscle injuries. 
LACERATION AND TISSUE LOSS  
A unique challenge arises when the skeletal muscle is injured such that muscle 
tissue is actually lost from the injured area. This type of injury is similar to the laceration 
injury, because the myofibers are transected. But with an injury that creates a defect in 
the muscle, suturing the ends back together and promoting regeneration is not always 
possible. A defect that creates a gap of significant size will be too large for skeletal 
myofibers or even scar tissue to bridge across and repair [39]. Without the ability to 
regrow across the defect and reconnect the transected fibers, the muscle will not function 
properly. The surgical repair of a skeletal muscle defect is dependent on the ability of an 
implant to bridge the gap between the transected muscle segments and allow transmission 
of force between the two ends, as it is necessary for the proper orientation of regenerating 
myofibers and subsequent return of function [10]. The tension developed in the 
regenerating muscle also stimulates autocrine/paracrine release of growth factors that will 
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further enhance regeneration [49]. Ideally, the implant should also serve as a scaffold 
which will allow the incorporation of blood vessels and regenerating muscle, connective, 
and nervous tissue. 
DEFECT REPAIR 
Surgeons and tissue engineers have long used various materials both natural and 
synthetic to patch injuries with sizeable defects when the body’s natural mechanisms are 
unable to repair them. Synthetic materials, both permanent and absorbable, have been in 
clinical use for decades. Clinically available materials such as Dacron, Silastic, Marlex, 
Vicryl and others are often used to repair large muscular defects of the abdominal wall, 
but the success of these grafts varies due to issues with biocompatibility [50]. The grafts 
are considered successful when they contain the bowels and look aesthetically normal, 
but most do not allow for the full incorporation of the original tissue that they replace. 
Natural materials for repair are theoretically better for biocompatibility and host cell 
incorporation, but as with all implants, the issue of tissue rejection due to a hyper-
immune response is always a possibility. Natural grafts such as skin grafts have been 
used to repair wounds for centuries, and recent evidence suggests that a variety of tissue 
types including skeletal muscle could benefit from similar types of surgeries as well.  
One natural material that could be used to create the proper environment for the 
regeneration of a large portion of tissue is ECM. The ECM is the structural framework 
that supports tissues in the body and also has important roles in growth and wound 
healing. Evidence that the ECM is important in skeletal muscle formation has been 
determined by several different methods. If ECM synthesis is blocked, cultured skeletal 
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muscle cells will not differentiate [51], but will differentiate normally after the addition 
of exogenous ECM. Myogenic cells plated on ECM- coated culture dishes proliferate and 
differentiate more readily than those same cells cultured under normal conditions [52]. 
Furthermore, addition of an ECM coating to tissue engineered scaffolds, such as poly L-
lactic acid fibers, increases the attachment of myoblasts to the scaffold [53]. An 
important role also exists for the ECM in muscle regeneration. During the regeneration 
process, the ECM degrades and remodels. The degradation process releases molecules 
that recruit progenitor cells to the area and also increase the proliferation of these cells 
[54] [55]. Evidence also exists that these degradation products possess antimicrobial 
properties and can therefore help to prevent wound infection during regeneration [56]. 
To obtain a 3-dimensional ECM suitable for implant, removal of all cellular 
components from the tissue is necessary so that only the ECM in its natural shape 
remains. The ECM of decellularized tissue can be advantageous for a number of reasons. 
The implanted ECM will have physical properties similar to those seen by cells in vivo, 
and the ECM will naturally direct cells to align in the proper orientation.  This is 
important for cells such as muscle progenitor cells activated during the repair process, 
because they develop best on substances that are most similar to muscle tissue [57]. 
Skeletal myofibers are only useful functionally if they are aligned correctly and the 
ECM’s orientation should be conducive to that alignment. A properly derived ECM 
scaffold is also non-immunogenic. When implanted, the ECM will not elicit an immune 
response that would otherwise lead to its rejection because the decellularization process 
also removes immune reactive antigens on the cells. [58]. In vitro, ECM constructs are 
capable of supporting the growth of myofibers [59]. Borschel et al. were even able to 
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produce skeletal muscle capable of contraction by seeding myoblasts on a decellularized 
ECM in vitro. 
Decellularized ECM constructs have been successfully used as a patch to repair 
defects in a number of tissues other than skeletal muscle including tendons and cardiac 
muscle. Implanted ECM scaffolds are effective at repairing tendon injuries of the rotator 
cuff and Achilles tendon [60, 61]. The ECM scaffold is not only effective at bridging the 
gaps in the tendon, but it also allows incorporation of cells from the native tissue. Similar 
results have been observed in cardiac muscle with ECM repair. A myocardial ventricular 
wall defect patched with ECM incorporated more myocardial tissue into the defected area 
than a synthetic expanded polytetrafluoroethylene patch used clinically [62] Better 
functional improvement is observed in ventricular wall defects repaired with ECM when 
compared to another clinically available synthetic material known as DACRON [63]. 
With the promising results in myocardial tissue, decellularized ECM has recently 
been used as a patch to repair skeletal muscle defects. A 3 x 3 cm abdominal wall defect 
was created and a piece of decellularized skeletal muscle ECM was sutured into its place 
[7]. The ECM maintained the structural integrity of the defect area and some evidence of 
vascularization and new collagen growth was observed, but ingrowth of myofibers after 
ninety days was not evident. A similar defect model was created in the rabbit vastus 
lateralis [8]. An acellular collagen scaffold was surgically fitted to repair the 1 x 1 cm 
defect and the muscle was evaluated histologically over the course of 24 weeks. The 
macroscopic morphology of the vastus lateralis was well maintained in the repaired 
defect group compared to the untreated group. Some ingrowth of myofibers into the 
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middle of the defect was seen, but the fibers were unable to fully regrow to fill the entire 
defect area. Functional analysis was not performed. 
The results from the above studies prove that the repair of a muscle defect with 
decellularized ECM alone is preferred to nothing, but the ability to regenerate new 
myofibers into the area is very limited. While it is known that skeletal muscle capable of 
contraction can be grown on decellularized ECM in vitro, it appears that this only 
happens to a limited extent in vivo when ECM is implanted into a defect [58]. A method 
to improve the regeneration of an ECM-repaired defect is to seed the ECM with cells 
capable of enhancing the regeneration process and growing to replace the missing tissue. 
Stem cells and other muscle progenitor cells are obvious candidates. 
CELL THERAPY 
 The potential for cell-based therapies to aid in the regeneration of muscle is 
tremendous. Early research has shown the ability of myoblasts to partially restore the 
dystrophin protein absent from skeletal muscles of dystrophic mice and even humans [64, 
65]. Injection of myoblasts into muscles prior to transplant improves the functional 
capacity and morphology of the muscles and enhances regeneration compared to non-
seeded control transplant muscles [66, 67]. Satellite cells and muscle-derived stem cells, 
which are distinct from satellite cells, are also capable of aiding in the regeneration 
process when given exogenously to compromised skeletal muscle [21, 68-70]. Cell-
seeded ECM constructs used to repair defects in skeletal muscle are a very recent 
research endeavor, however, and only a handful of studies have been undertaken in the 
area. The most researched model is a defect in the skeletal muscle of the abdominal wall. 
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This model mimics congenital abdominal wall defects that occur in infants during 
prenatal development. Several groups have attempted to reconstruct the abdominal wall 
muscle by using acellularized ECM seeded with autologous myoblasts [9, 71-73]. 
Implanted acellularized ECM alone showed signs of contracture and was replaced with 
fibrous scar tissue after only one month [71, 73]. However, with the addition of the 
cultured myoblasts into the ECM, less contracture occurred and vessel ingrowth was 
detected [73]. Myoblasts were still present in the ECM after one month in a study by 
Conconi et al., but after ninety days the number of surviving myoblasts was less than at 
thirty days [71]. Evidence for the long term survival of myoblasts in the ECM implant 
has been observed though. Male, XY-karyotyped satellite cell-derived myoblasts were 
seeded on an ECM implanted into female rats and the male myoblasts were still present 
nine months post-defect injury [72]. Increased myofiber regeneration occurs in the defect 
area when surrounding tissue is damaged with Marcaine to stimulate regeneration [9]. 
The damage to the muscle bordering the implant is hypothesized to stimulate the 
proliferation, differentiation, and migration of satellite into the implant.  
In addition to cells already committed to the myogenic lineage and found within 
the muscle, other cell types could theoretically be used to enhance muscle regeneration in 
a defect area. Due to their omnipotency, embryonic stem cells (ESCs) are an obvious 
candidate for many cell-based therapies, including those involving muscle. When 
implanted on a polyglycolic acid patch, green fluorescent protein (GFP) labeled ESCs 
improved functional parameters of the infracted left ventricle [74]. GFP- positive cells 
were also seen in the defect area indicating that the stem cells might have been 
incorporated into the regenerating tissue.  Limitations exist with ESCs, however. They 
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are difficult to obtain and ethical issues prevent many researchers from using these cells. 
Other cells with myogenic potential are found within the body though. One group of cells 
with myogenic potential is found in the bone marrow. 
Interestingly, bone marrow-derived cells partake in muscle regeneration naturally. 
In the MDX mouse model of muscular dystrophy, desmin and GFP-positive myofibers 
incorporated into skeletal muscle in mice that received bone marrow transplants, and 
GFP positive fibers were found occupying the satellite cell niche as well [23]. LaBarge 
and Blau further elucidated the mechanism and showed that in response to injury, bone 
marrow cells progressed to functioning muscle satellite cells prior to becoming 
differentiated myofibers [20]. Using parabiotically joined mice, Palermo et al. has shown 
that bone marrow cells can even incorporate into muscle in response to normal 
physiologic stressors such as exercise [75]. 
Bone marrow contains a population of cells known as mesenchymal stem cells 
(MSCs) that are multipotent. MSCs could be advantageous compared to ESCs, because 
no ethical issues exist with obtaining them and they are relatively easy to culture and 
expand in vitro. MSCs adhere to culture plates or flasks and will proliferate for multiple 
population doublings, which gives them great clinical potential [76]. In vitro MSCs are 
capable of differentiating into mesenchymal tissues including bone, cartilage, tendon, 
adipose tissue, and muscle [77-79] [80]. Evidence also exists that they can differentiate 
into hepatocytes and neurons which are of the endodermal and ectodermal lineages 
respectively [81-83]. These multipotent cells could be advantageous to an injury 
involving significant loss of tissue, because multiple types of cells including; muscle, 
connective tissue, and nerve might need to be replaced.  
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Research has determined that exogenous bone marrow-derived cells can partake 
in muscle repair as well. Ferrari et al. injected bone marrow-derived cells into the 
damaged muscles of mice and they were found to have incorporated into the newly 
formed myofibers of the regenerating skeletal muscles [84]. Dezawa et al. cultured 
MSCs, differentiated them into myocytes using Notch1, and implanted them into 
degenerating muscles of immunodeficient mice and MDX mice [85]. The myocytes 
incorporated into the muscles with some differentiating into multinucleated fibers and 
others remaining in the satellite cell domain. Muguruma et al. has shown that bone 
marrow derived progenitor cells can differentiate into myocytes without the use of 
demethylation agents or gene transfers, and still participate in regeneration of skeletal 
muscle [86]. Contractile force is restored more effectively with the implantation of bone 
marrow derived cells following crush injury [87]. Evidence even exists that some stem 
cell based muscle therapies using bone marrow derived stem cells will improve muscle 
regeneration after laceration injury without the stem cells even incorporating into 
myofibers [88]. The stem cells are hypothesized to release growth factors and other 
compounds which may facilitate regeneration of existing fibers and satellite cells.  
Limited research has been performed using bone marrow-derived cells in defected 
skeletal muscle, but in the myocardium, BrdU labeled MSCs were implanted in an 
acellular pericardial ECM [89]. While function between the ECM alone and the cell-
seeded ECM was no different, cells positive for BrdU and a specific muscle protein, α-
sarcomeric actin, were located in the implanted ECM. The stem cells might have become 
cardiomyocytes and contributed to the partial regeneration of the defect area. These 
 21
studies indicate the tremendous potential for bone marrow-derived cell therapy for 
replacement of lost muscle tissue and regeneration of damaged muscle tissue. 
Taken together, the work proving bone marrow derived multipotent progenitor cells are 
capable of aiding in muscle regeneration establishes these cells as a suitable cell type for 
research into the repair of a skeletal muscle injury with tissue loss.  
SUMMARY 
As the literature currently stands, a limited but useful amount of knowledge can 
be gained regarding the regeneration of defected muscle. The ECM is advantageous to 
synthetic materials because of its ability to incorporate the host tissue and become a 
functioning component, while most synthetic materials just serve to fill a tissue void. 
Many synthetic materials also run the risk of immune rejection, which is less likely to be 
the case with acellular ECM since its reactive components were stripped off during 
decellularization. Undoubtedly, different methods of ECM isolation will lead to different 
ECM environments, so it is necessary to understand what the differences might be and 
how they can be corrected to more closely mimic a muscle progenitor cell’s natural 
environment. Cell seeding of ECMs is a technique which is proven to be better than 
simply filling the defect, but further research to determine the optimal cell type and 
number for seeding is necessary. Since a number of tissues will need to repopulate the 
defect area, cells which are unipotent might be of limited use, whereas a multipotent stem 
cell, such as those found in bone marrow, could possibly give rise to more tissue types 
needed for complete regeneration. Ultimately the main goal of these types of treatments 
will be to return function to traumatic skeletal muscle injuries, but research regarding the 
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contractile properties of damaged muscles undergoing treatment with ECM and stem 
cells is lacking. The potential to treat genetic skeletal muscle diseases as well as muscle 
injuries with stem cells is immense but further study is required. 
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Chapter III: Functional Assessment of Skeletal Muscle Regeneration 
Utilizing Homologous Extracellular Matrix as Scaffolding 
 
ABSTRACT 
The loss of a portion of skeletal muscle poses a unique challenge for the normal 
regeneration of muscle tissue. A transection injury with tissue loss will not heal due to the 
gap between muscle segments. A damage model was developed by removing a portion of 
the lateral gastrocnemius (LGAS) of Sprague-Dawley rats. Maximal isometric tetanic 
tension (Po) was measured following the removal of either a small, 0.5cm x 1.0cm, defect 
(SDEF) or a large 1.0cm x 1.0cm (LDEF) piece of the GAS. In situ Po immediately after 
creation of the defect was 88.3 ± 2.0% of the non-operated contralateral GAS force for 
SDEF and 76.9 ± 3.2% of control for LDEF. No functional recovery occurred in either 
group over the course of 28 days. To enhance recovery, a homologous, decellularized, 
muscle extracellular matrix (ECM) was implanted into the 1 x 1 cm defect of the LGAS 
of Lewis rats. After 42 days, growth of blood vessels and myofibers into the ECM was 
apparent, but no restoration of Po occurred. These data demonstrate the ability of the 
ECM to support muscle and blood vessel regeneration, but full recovery of function does 
not occur after 42 days. 
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INTRODUCTION 
 Skeletal muscle injuries including strains, contusions, and lacerations are well 
documented (For review see [17, 19]). Most of these injuries, if given sufficient time, will 
repair themselves with partial or total restoration of function [17]. The repair of the 
muscular tissue is largely the result of proliferation of resident satellite cells, muscle 
progenitor cells, and even bone-marrow mesenchymal stem cells (MSCs), which are 
capable of migrating to the area and differentiating into muscle, connective, and vascular 
tissues [20, 75]. 
 Severe skeletal muscle injuries, such as those involving the loss of a substantial 
portion of muscle, connective tissue, and blood vessels, however, are not capable of full 
regeneration on their own. These types of injuries are seen in military personnel 
wounded-in-action, car accident and gun shot victims, and patients having undergone 
surgeries where the debridement of muscle tissue was necessary [90]. The remnants of 
the muscle remaining do not have an ECM scaffolding and connective tissue to transmit 
force between the remaining muscle segments.   
Surgical repair of a skeletal muscle defect is dependent on the ability of an 
implant to bridge the gap between the transected muscle segments and allow transmission 
of force between the two ends as it is necessary for the proper orientation of regenerating 
myofibers and subsequent return of function [10]. The tension developed in the 
regenerating muscle also stimulates autocrine/paracrine release of growth factors that will 
further enhance regeneration [49]. The implant should also serve as a scaffold which will 
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allow the incorporation of regenerating muscle, connective, nerve, and blood vessel 
tissues. 
Several types of constructs suitable for skeletal muscle repair are commercially 
available. Materials such as Dacron, Silastic, Marlex, Vicryl and others are often used to 
repair congenital muscular defects of the abdominal wall, but the success of these grafts 
varies due to issues with biocompatibility [50] and inability to allow for cell ingrowth 
[91]. The grafts are considered successful when they contain the bowels and look 
aesthetically normal, but most do not allow for the full incorporation of the original tissue 
they replace. Natural materials for repair can be better for biocompatibility, host cell 
incorporation, and for reducing infection risks. These have been used successfully for 
repair of abdominal wall defects and may well be applied to load-bearing muscle grafts in 
the future. 
In skeletal muscle the ECM is an important structural component for the 
development of myofibers [51], providing the proper mechanical and chemical 
environment for the proliferation and differentiation of myogenic progenitor cells [52, 57, 
92] as well as releasing chemical signals to the surrounding environment that attract 
macrophages and progenitor cells that aid in the repair process [54, 55, 93].  Allografts 
and xenografts of ECM from the integument, urinary bladder and small intestine have 
been employed in research to repair tissues in the clinical setting (For review See [94]).  
 This study was designed to evaluate whether a homologous graft of ECM from 
skeletal muscle could be cut to the size, shape, and orientation of a large muscle defect, 
and provide the tensile strength for muscular force transmission, as well as the proper 
environment for growth and differentiation of regenerating muscle tissue.  While some 
 26
researchers have studied ECM implantation into non-load bearing, defected muscles such 
as those of the abdominal wall [7, 71, 72], functional analysis and implantation of ECM 
into a skeletal muscle defect of an active, load bearing muscle has not been attempted. 
Therefore, the purpose of this study was to develop a model to study the regeneration of a 
skeletal muscle defect involving replacement of lost tissue with a decellularized ECM 
that could be readily assessed functionally, morphologically, and histologically.  
METHODS 
Animals 
 The study was done in two stages. The first stage consisted of establishing the 
muscle defect model in male, Sprague Dawley (S-D) rats. Initial work in isolating the 
ECM through decellularization, as well as development of the in vivo model of 
assessment of muscular function was established in the S-D rat strain.  In order to be 
consistent, the laceration model and defect model were established in this same strain.  
The second phase was conducted in Lewis rats, an inbred strain, bred for transplantation 
experiments.   
Both male, S-D rats from colonies provided by the University of Texas at Austin 
Animal Resource Center and male, Lewis rats obtained from Charles River Laboratories 
(Wilmington, MA) 6-9 mo. of age were used in this study. Rats were housed individually 
and maintained on a 12-hour light/dark cycle. Rats were allowed ad libitum access to 
food (Rodent Chow, Harlan Teklad) and water. Rats were randomly assigned to 
experimental groups. All experimental procedures were approved and conducted in 
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accordance with guidelines set by the University of Texas at Austin Institutional Animal 
Care and Use Committee. 
Experimental Groups 
 S-D rats were divided into one of four groups; sham operated (SHAM), laceration 
only (LAC), small defect (SDEF), and large defect (LDEF). Surgeries were performed 
under aseptic conditions and the rats anesthetized with IP injections of sodium 
pentobarbital (65 mg/kg). Rats in the LAC group had a 2 cm incision made on the lateral 
side of the lower limb parallel to the tibia. The biceps femoris muscle was separated from 
the tibia to expose the lateral side of the LGAS muscle. The muscle was lacerated with a 
#9 scalpel blade distal to the neuromuscular junction in line with the tibial tuberosity. The 
incision was 1 cm in length through the lateral side of the LGAS and through the full 
thickness of the muscle. The two contiguous portions of the LGAS were not sutured 
together. To close the wound, the biceps femoris muscle was reattached to the tibia using 
simple, interrupted, polypropylene suture (Prolene 5-0; Ethicon), and the incision in the 
skin was closed with silk suture (Ethicon 4-0). Rats in the LAC groups were placed back 
in their home cages and allowed to recover for 42 days. 
 Rats in the SDEF and LDEF groups underwent the same procedure as those rats 
in the LAC groups; however, instead of a laceration, a full thickness defect was created 
with two #9 scalpel blades separated by 0.5 cm (SDEF) or 1.0 cm (LDEF). The result is 
two lacerations each 1 cm in length and 0.5 cm or 1.0 cm apart. The tissue between the 
lacerations was excised with fine surgical scissors, and the free section of muscle 
removed and weighed. The wound was closed as in the LAC group. Rats in the SDEF 
groups were immediately subjected to functional analysis (n = 6) or recovered for 14 days 
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(n = 6). Rats in the LDEF groups were immediately subjected to functional analysis (n = 
8) or allowed to recover for 14 days (n = 7), or 28 days (n = 6). 
 The surgery for the SHAM group (n =6) was identical to that of the defect groups 
except no incision or defect was created in the LGAS. An incision in the skin and the 
biceps femoris was made and the LGAS exposed and separated from the soleus. The 
biceps femoris and skin incisions were sutured as in the other groups, returned to their 
cages, and allowed to recover for 14 days. 
Following development of the model in the S-D rats, further experiments were 
conducted using the exact same defect model in Lewis rats, because they are better suited 
for transplantation experiments. The previously described defect surgery was performed 
on 48 Lewis rats and 1 x 1 cm piece of the LGAS was removed. The average mass of the 
muscle defect removed from the Lewis rats was 238 ± 6 mg and 224 ± 6 mg for the DEF 
ONLY and DEF/REP groups respectively. The difference was not statistically significant. 
The defect removed accounted for approximately 20% of the total mass of the LGAS. No 
repair surgery was performed on 24 rats (DEF ONLY), but the other 24 rats were 
subjected to a repair of the defect (DEF/REP) with a homologous ECM cut to the 
dimensions of the injury as described below. Six rats from each group were evaluated 
functionally and histologically at each of the following days of recovery; 7, 14, 28, and 
42. 
ECM Isolation 
GAS muscles were removed from a separate group of male Lewis rats and 
decellularized using a method similar to Borschel et al. [58], but with several 
modifications.  Upon extraction the muscles were placed in deionized water at 4° C for 
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one day to cause cell swelling and membrane rupture. The muscle was placed in 
chloroform and continuously agitated for four to five days depending on its size. The 
muscle was rinsed with water and submerged in 2% sodium dodecyl sulfate (SDS) and 
agitated continuously. The SDS solution was changed twice per week until the cellular 
components were washed out. The remaining ECM was rinsed in a large volume of 
deionized water (10:1 v/w) over several days with solution changes each day to rid the 
ECM of SDS. To completely insure removal of SDS, the ECMs were rinsed for 4 hours 
in a 0.1 M tris buffer solution of pH 9.0. The ECM was then submerged in phosphate 
buffered saline with 1% penicillin/streptomycin (Sigma-Aldrich; St. Louis, MO), exposed 
to ultraviolet light for at least twelve hours, and stored at 4°C until ready for 
implantation. To insure complete decellularization, samples of prepared ECM were 
stained with hematoxylin and eosin. Samples were run on an SDS-PAGE gel and stained 
with Coomassie Blue to determine whether all soluble proteins were removed. 
Additionally, mass spectrophotometer analysis (Maldi TOF Voyager DE STR) was used 
to identify the components of the ECM, and a scanning electron microscope (Zeiss Supra 
BP at UT-Austin ICMB Core Facility) was used to obtain high magnification images of 
the ECM (Figure 3.1). A colorimetric assay described by Arand et al. [95] to measure the 
content of SDS was performed to insure complete removal of SDS from the ECM. 
The ECM was implanted in the muscle with the defect using a modified Kessler 
stitch (5-0 Prolene; Ethicon) with simple interrupted sutures on each of the three borders 
to hold the cut ends together and serve as markers for later analysis. The modified 
Kessler stitch was used because it has been shown to be the most effective way to suture 
the transected muscle segments back together [96]. 
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Force Measurements 
After the designated recovery time, the GAS muscles were isolated and subjected 
to functional measurements. A skin incision was made down the midline of the posterior 
portion of the lower limb from the popliteal area to the calcaneus. The skin was reflected 
to expose the biceps femoris which inserts along the distal portion of the tibia in rats. The 
biceps femoris was cut and reflected to expose the medial and lateral GAS. With care to 
minimize bleeding and damage to surrounding tissues, the GAS was isolated from the 
superficial skin and biceps femoris as well as the deep soleus and plantaris. In order to 
attach the GAS to the muscle lever for force measurements, the Achilles tendon with an 
attached portion of the calcaneus was cut and tied to the lever arm of a dual-mode 
servomotor (model 310 B, Aurora Scientific). The muscle was stimulated to contract 
utilizing a stimulator (Model 2100, A-M Systems) with leads applied to the tibial nerve 1 
cm proximal to its insertion into the GAS. The muscle was kept wet in mineral oil, and 
the temperature maintained at 36°C with a radiant heat lamp and monitored on the muscle 
surface with a thermometer. The muscle length was adjusted to the length that produced 
the highest twitch force, and maximal twitch tension determined using stimulation at 0.5 
Hz and 7V. The muscle was stimulated at 150 Hz and 20V for peak tetanic tension (Po). 
Each contraction was followed by two minutes of rest. The servomotor was interfaced 
with the computer and equipped with a National Instruments A/D board. The data were 
stored and analyzed using LabView software. After the completion of contractile 
measurements, the muscle was dissected free and weighed. 
Lateral Gastrocnemius in situ Force Measurements  
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Functional analysis of the DEF ONLY and DEF/REP was identical to the analysis 
done to the S-D rat muscle samples except that the medial GAS of the Lewis rats was 
denervated, so that only the LGAS was contributing to force production. 
Histology and Immunohistochemistry 
DEF ONLY and DEF/REP muscles were removed, weighed, and placed in 10% 
neutral buffered Formalin (Protocol, Fisher Scientific; Waltham, MA) for 24 hours, and 
stored in 70% ethanol until further analysis. Samples were embedded in a Tissue Tech 
paraffin embedding system prior to sectioning on a Reichert-Jung microtome. Within the 
defect area, at least six, 5 µm sections per muscle were subjected to histologic and 
immunohistochemical treatment. Hematoxylin and eosin staining was performed, as was 
Masson’s trichrome (Sigma-Aldrich; St. Louis, MO) staining to identify regions of 
collagen-containing ECM, myofibers and other cytoplasmic cells, and nuclei. To 
visualize blood vessels, the rabbit anti-human von Willebrand Factor (vWF) polyclonal 
antibody (1:300: Dako; Carpinteria, CA) was used to identify endothelial cells. The 
signal was enhanced with biotinylated polyclonal goat-anti-rabbit IgG with streptavidin-
HRP. Color was developed after incubation with 3,3-diaminobenzidine (DAB). Muscular 
infiltration into the ECM was further confirmed by immunofluorescent staining for the 
muscle specific cytoskeleton protein, desmin. Sections were exposed to mouse 
monoclonal anti-desmin antibody (1:500: Sigma-Aldrich; St. Louis, MO). Sections were 
then incubated with F(ab’)2 Goat Anti-Mouse IgG Fluorescein (1:100, λ = 495nm: 
Thermoscientific; Waltham, MA) and counterstained with Hoescht 33258 (λ = 395 nm: 
AnaSpec; San Jose, CA) to identify nuclei. H&E, trichrome, and vWF sections were 
visualized with a Nikon Diaphot microscope mounted with an Optronix Microfire digital 
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camera interfaced with a Dell 8250 computer for storage and analysis of images. 
Immunofluorescent desmin was visualized with a fluorescence microscope (Leica DM 
LB2) and photographed with a digital camera (Leica DFC340FX). 
Statistical Analysis 
Means of all measurements were analyzed utilizing Student’s t-tests for 
comparison between samples sets or ANOVA with Tukey’s post hoc analysis for analysis 
of groups of samples. Data are represented as mean ± SEM. Significance is defined as p < 
0.05. 
RESULTS 
Immediately upon laceration, the transected myofibers retracted to form a small 
gap. In LAC, no sign of laceration was apparent macroscopically after 42 days of 
recovery. No difference in isometric tetanic force or muscle weight was apparent between 
lacerated and control muscles following 42 days of recovery (Table 3.1). 
The average mass of the removed muscle defect from the S-D rats was 152 ± 10 
mg and 306 ± 10 mg for the SDEF and LDEF groups respectively and was statistically 
significant. The mass of the small defect was approximately 5% of the total mass of the 
GAS, and the mass of the large defect was approximately 10% of the total mass of the 
GAS. Immediately upon removal of the muscle defect, the remaining portions of the 
transected myofibers retracted forming a gap larger than the original defect (Figure 3.2a). 
A gradual remodeling of the LGAS occurred such that at 28 days post-defect injury, little 
if any of the original defect wound was recognizable (Figure 3.2b). Wet muscle weight of 
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the defected LGAS was significantly decreased at all time points relative to the non-
operated contralateral LGAS (Table 3.2). 
Maximal isometric, tetanic tension (Po) of the whole GAS immediately following 
the defect injury was 88.3 ± 2.0 % and 76.9 ± 3.2% of the contralateral limb for SDEF 
and LDEF respectively. After 14 days of recovery Po was 88.1 ± 5.6% (SDEF) and 80.7 ± 
3.5% (LDEF) of the contralateral limb. Twenty-eight days post-injury Po of LDEF was 
79.4 ± 4.0% (Figure 3.3). The Po of the SDEF group was significantly higher than that of 
the LDEF group at all recovery time points (p < 0.05). No significant difference was 
found at the different recovery time points within each group. 
The average mass of the muscle defect removed from the Lewis rats was 238 ± 6 
mg and 224 ± 6 mg for the DEF ONLY and DEF/REP groups respectively. The 
difference was not statistically significant. The defect removed accounted for 
approximately 20% of the total mass of the LGAS. As seen in the S-D rats, immediately 
upon removal of the defect, the transected myofibers retracted, and if the defect was not 
repaired, a gradual remodeling took place such that the original defect area was hard to 
define by 42 days. However, repair with the ECM maintained the overall morphology of 
the LGAS (Figure 3.2d). 
Prior to implant, mass spectrophometric analysis of samples of decellularized 
ECM demonstrated that it was composed of approximately 99% collagen. No nuclei or 
cytoplasm were evident within the decellularized ECMs used for implant as evidenced by 
Masson’s trichrome staining. The decellularization protocol removed all soluble proteins 
as determined by the Bradford Assay and Coomassie Blue staining. Preparation of the 
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ECM for implantation also completely removed any residual SDS as determined by 
Arand’s colorimetric assay. 
 Functionally, the maximal, isometric, tetanic tension produced by the LGAS of 
the DEF ONLY group was significantly lower than that of the non-operated, contralateral 
limb at all recovery time points, and no recovery of force occurred as recovery time 
increased (Table 3.3; Figure 3.4). The tetanic tension of the ECM-repaired LGAS did not 
significantly recover over the course of 42 days (Table 3.4; Figure 3.4). A statistically 
significant difference between the DEF ONLY and DEF/REP groups was seen at 7 days 
post injury, but not at any subsequent time point. As shown in Tables 3.3 and 3.4, the 
average mass of the defected LGAS with the exception of one were significantly lower 
than the non-operated, contralateral LGAS. While the mass of the DEF/REP LGAS 
tended to be higher relative to the contralateral limb than the mass of the DEF ONLY 
LGAS, the difference was not statistically significant. 
  Histological analysis of the defect area with ECM at 7, 14, 28, and 42 days shows 
a progression of regeneration from inflammation to the appearance of small blood vessels 
and central-nucleated myofibers that increase in number at each time point (Figure 3.5). 
Immunohistochemistry confirmed the presence of vWF positive endothelial cells and 
desmin positive myofibers (Figure 3.6). Myofibers and blood vessels were found deeper 
in the ECM as recovery time increased. The area of ECM closest to the border with the 
transected myofibers appeared most dense with regenerating fibers and blood vessels 
indicating approximately 1 mm of growth (Figure 3.7a). Fewer fibers and blood vessels 
were seen in the areas deeper into the ECM that were 2-3 mm from the cut muscle 
surface (Figure 3.7b).  
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DISCUSSION 
Little to no regeneration occurs in skeletal muscle following a transection of the 
myofibers when a substantial amount of the tissue is lost. Regrowth across the muscle 
defect gap does not occur over the course of 42 days following injury. The remodeling 
process that takes place during this time makes it unlikely that the muscle would ever 
return to its original size and shape. Since the maximal, isometric, tetanic force 
immediately post-defect injury is the same regardless of the recovery time allowed, it is 
likely that permanent functional damage was incurred. Without any significant functional 
recovery of the muscle and the morphological changes it undergoes, this muscle defect 
model is a suitable model for use in further investigations into skeletal muscle’s 
regenerative capacity. Since the laceration-only injury showed no functional deficit after 
42 days, and the defect injury had not recovered function after 42 days, the defect model 
presented here could be a better model for the study of skeletal muscle regeneration,  and 
surgical and tissue engineering interventions aimed at regenerating significant amounts of 
skeletal muscle than a laceration injury model. 
Researchers have used GAS laceration models that resulted in a more severe loss 
of function which, if left unrepaired, persisted for weeks [38, 41, 97]. Others, however, 
have seen functional recovery after only 25 days even in full transection laceration 
models of the soleus [35]. The lack of an apparent functional deficit in this LGAS model 
after 42 days is likely due to the size and location of the laceration. The laceration 
occurred only on the LGAS and did not transect the medial GAS. Additionally, nerve and 
major blood vessels in the area were left intact which likely explains the full functional 
recovery and return of muscle mass that occurs in this model, but does not occur in other 
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models where a complete transection of the muscle is performed [38, 97]. However, in 
the context of our work, we were only attempting to create a laceration as a control injury 
that was at the same site and to the same depth as the muscle defect. The lack of a 
functional deficit 42 days post-laceration injury underscores the importance of a defect 
model that has no functional improvement over the same timeframe. 
 During development of the muscle defect model, two different defect sizes were 
utilized to determine the critical size for establishing significance of our treatment 
techniques. The 0.5 cm x 1.0 cm (~ 150 mg) defect was not large enough to allow for 
easy determination of the effectiveness of surgical repair. Although there was a decrease 
in function that did not begin to return to normal by 14 days, it was not a significant 
enough functional deficit to allow for definitive evaluation of different repair techniques. 
The decrease in mass in the SDEF from 92% of contralateral weight to 82% of 
contralateral weight at day 14 might be explained by the potential for atrophy of the 
remaining transected myofibers in SDEF. A larger portion of the transected fibers 
remained in the SDEF and could subsequently experience more atrophy, whereas more 
mass was initially removed in the LDEF so smaller portions of transected fibers remained 
and less mass might be lost due to atrophy.  The superior and inferior portions of the 
LGAS (above and below the defect) were not assessed, however. The 1.0 cm x 1.0 cm (~ 
306 mg) defect was the maximum size allowed by the rat’s anatomy without cutting 
nerve or major blood vessels and the function did not change from 0 to 28 days of 
recovery. This larger defect allowed for a thorough evaluation of the subsequent repair 
technique. 
 37
 Following the development of the defect injury model in the S-D rats, further 
experiments were performed on the Lewis rat, an inbred-strain of rat more suited for 
surgical implantation research. Another set of defect surgeries was performed to confirm 
the lack of functional recovery seen in the S-D rats. Due to minor anatomical differences 
of the Lewis rat, the 300+ mg defect removed from the S-D rats could not be achieved, 
and the Lewis rat defect mass was approximately 230 mg. To better isolate the functional 
effect of the defect on the LGAS, the medial GAS was denervated in the Lewis rats 
immediately prior to force analysis, so that only the LGAS was contributing to force 
production. 
To repair the muscle defect, an implantable material was needed that could bridge 
the gap between the transected ends of the myofibers and allow mechanical transduction 
of force. The material also needed to be capable of supporting the growth of myofibers 
and other muscle associated cell types. Skeletal muscle ECM was chosen for this reason. 
The process of decellularizing skeletal muscle to obtain an ECM is possible. The 
decellularization process removes all cellular components from the tissue so that only the 
ECM scaffold is left. Acellular tissue is advantageous for a number of reasons; the 
implanted ECM scaffold has physical properties similar to those seen by cells in vivo, and 
the ECM should naturally direct cells to orient in the proper direction.  This is important 
for cells such as muscle progenitor cells activated in the repair process, because they 
develop best on substances that are most like muscle tissue [57]. Proper alignment of the 
scaffolding is also important for the transmission of force. A properly derived ECM 
scaffold is also non-immunogenic. When implanted, the tissue did not elicit an immune 
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response that would otherwise reject the implant and render it ineffective, because its 
immune reactive antigens were stripped off with the cells [58]. 
Borschel et al. have had success growing viable muscle tissue in vitro on an ECM 
derived from decellularized skeletal muscle [58]. Implantation of acellularized skeletal 
muscle into muscle defects of the abdominal wall has been performed by several groups 
with varying levels of success, although the functional outcome has not been assessed 
[9]. Evidence that the ECM is infiltrated by blood vessels is apparent and some 
researchers have seen infiltration of skeletal myofibers as well [9], but more successful 
repair with ECM of non-load bearing muscles occurs when myoblasts or satellite cells are 
seeded onto the ECM prior to implantation [71-73]. Acellular ECM has been successfully 
employed as a patch to repair defects in a number of tissues including tendons and 
cardiac muscle. Implanted ECM scaffolds implanted with no other treatment are effective 
at repairing tendon injuries of the rotator cuff and Achilles tendon [60, 61]. The ECM 
scaffold is not only effective at bridging the gaps in the tendon, but it also allows 
incorporation of cells from the native tissue. Similar positive results have been shown in 
cardiac muscle with ECM repair. A myocardial ventricular wall defect patched with 
ECM incorporated more myocardial tissue into the defected area than a synthetic, ePTFE 
patch used clinically [62]. Defects of the ventricular wall repaired with ECM also lead to 
increased functional improvements compared to DACRON [63]. 
As evidenced by this study and others, the muscle-derived ECM used here to 
repair skeletal muscle tissue lost due to injury is capable of supporting the growth of 
blood vessels and myofibers, and is a promising model for the study of muscle 
regeneration [58]. As recovery time increased, an increase in the number of blood vessels 
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and myofibers was apparent in the ECM at progressively deeper levels, suggesting that 
the fibers and vessels are growing into the ECM from the transected ends of the surviving 
myofibers. After 42 days, however, the middle of the ECM was not yet populated with 
myofibers or blood vessels. The ingrowth of blood vessels seen in the ECMs used in this 
study has been seen in studies performed on the repair of abdominal wall musculature 
with similarly derived ECMs [7, 9]. Limited ingrowth of myofibers has been confirmed 
in some of the abdominal wall defect ECM implants [9], but not all [7, 71, 73]. The 
myofiber ingrowth observed in the present study might be due to the difference of the 
muscles chosen. Functionally, the LGAS is very active and is subjected to a relatively 
high amount of mechanical stress during normal activity, while the abdominal wall 
musculature does not see the same demands. An increase in the activity level of an 
injured muscle can expedite the healing process [98]. Functionally, the matrix-repaired 
muscle was not different from the unrepaired muscle up to 42 days post-injury, although 
longer recovery times were not studied.  The lack of functional recovery could be due to 
the small size and limited number of fibers growing into the ECM, insufficient 
vasculogenesis throughout the ECM, and possibly incomplete nerve reinnervation of 
fibers.  
In conclusion, the LGAS defect injury model allows for a uniform standard for 
the study of the regeneration potential following traumatic skeletal muscle injury. This 
model has tremendous potential to aid researchers in the best treatments to restore 
function and aesthetics to severely damaged skeletal muscle. The muscle defect area 
could easily be replaced with any of a number of natural or engineered replacement 
tissues, and their growth and function could be monitored in the in vivo environment as 
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was done with the ECM in this case. The morphology of the repaired LGAS and aesthetic 
appearance were well maintained over 42 days despite the fact that functional recovery 
did not occur. However, it is evident that the ECM was a suitable environment for blood 
vessel and myofiber ingrowth indicating a promising future as an implant material. 
Further research should focus on increasing the number and size of myofibers in and 
throughout the ECM and improving the functional outcome. 
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LAC 42 Day Recovery   
 
Force (LAC % of Control) 103.5 ± 6.3% 
Control GAS Mass 2883 ± 88 mg 
LAC GAS Mass 2950 ± 108 mg 




DEF LGAS Mass (% of Control) 
   0 days 14 days 28 days 
SDEF  92%  82%  - 
LDEF  85%  84%  81% 


















7 70.4 ± 3.4 15.6 ± 0.7 22.2 ± 0.4 1054.2 ± 23.9 1271.3 ± 19.8 17.5 ± 0.9 21.7 ± 0.4
14 72.9 ± 2.3 16.1 ± 0.6 22.1 ± 0.5 1066.1 ± 29.5 1264.4 ± 20.8 18.6 ± 0.5 21.1 ± 0.7
28 77 ± 0.8 17.2 ± 0.4 22.4 ± 0.6 1115.5 ± 40.3 1302.8 ± 35.0 19.7 ± 0.4 21.5 ± 0.4
42 74.1 ± 4.4 16.4 ± 1.6 21.9 ± 0.8 1054.7 ± 74.1 1283.8 ± 65.9 19.5 ± 0.9 21.1 ± 0.6
 



























7 75.7 ± 5.8 16.5 ± 1.4 21.8 ± 0.6 1377 ± 129 1164 ± 67 17.4 ± 1.0 24.2 ± 0.9
14 75.6 ± 2.6 15.7 ± 0.3 20.9 ± 0.6 1125 ± 43.4 1242 ± 18 18.1 ± 0.7 21.7 ± 0.8
28 77.3 ± 2.7 15.7 ± 0.4 20.4 ± 0.3 1073 ± 14.9 1279 ± 18 18.3 ± 0.6 20.1 ± 0.5
42 74.7 ± 2.2 17.0 ± 0.6 22.7 ± 0.5 1137 ± 33.3 1277 ± 30.7 18.9 ± 0.9 22.4 ± 0.6
 








FIGURE 3.2: MORPHOLOGY - A) Defect Creation B) 28 Day Post-Defect C) 42 Day 
Post-Defect D) ECM Repair 42 Day Post-Defect. Scale bar = 1.0 cm 
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FIGURE 3.4: FUNCTION POST-DEFECT INJURY - Maximal isometric, tetanic tension of 
defect LGAS relative to contralateral limb 14, 28, and 42 days post injury. No significant 




FIGURE 3.5: HISTOLOGY MASSON’S TRICHROME - defect/ECM at A) 7, B) 14, C) 28, 
D) 42 Days of recovery showing progressive regeneration as evidenced by increase in red 
staining myofibers (Confirmed with desmin immunofluorescence). Circular spaces are 




FIGURE 3.6: HISTOLOGY COMPARISON -  Neighboring sections of ECM implant after 
42 days recovery stained with (A) H&E, (B) Masson’s Trichrome, (C) immunoflurescent 




FIGURE 3.7: TRICHROME SERIAL SECTIONS - ECM implant at 28 days recovery 
stained with Masson’s Trichrome. A) 1-2 mm from muscle/ECM border, B) 2-3 mm 






Chapter IV: Repair of Traumatic Skeletal Muscle Injury with Bone 
Marrow Derived Mesenchymal Stem Cells Seeded on Extracellular 
Matrix 
ABSTRACT 
Surgical repair of a skeletal muscle injury resulting in tissue loss poses unique 
challenges for surgical repair. Despite the regenerative potential of skeletal muscle, if a 
significant amount of tissue is lost, skeletal myofibers will not grow to fill the injured 
area completely. Prior work in our lab has shown the potential to fill the void with an 
extracellular matrix scaffold (ECM) but functional recovery is limited. To improve the 
functional outcome of the injured muscle, a muscle-derived ECM was implanted into a 1 
x 1 cm2 defect in the lateral gastrocnemius (LGAS) of Lewis rats and seeded with bone 
marrow derived mesenchymal stem cells. Without the addition of cells, the ECM repaired 
LGAS produced 74.7 ± 2.2% of the maximal force of the contralateral LGAS after 42 
days of recovery. The LGAS repaired with ECM and cells was significantly higher 
producing 85.4 ± 3.6% of the contralateral LGAS. The specific tension was 84% and 
94% of the contralateral limb for the ECM and ECM with cells groups respectively. The 
implanted ECM with cells had more blood vessels and regenerating skeletal myofibers 
than the ECM without cells (p < 0.05). The data suggest that the repair of a skeletal 
muscle defect injury by the implantation of a muscle-derived ECM seeded with bone-
marrow derived cells can improve functional recovery after 42 days. This might be due to 
an increase in the number of blood vessels providing better oxygen and nutrient supply to 




Traumatic injury to a skeletal muscle that involves the loss of a portion of the 
tissue presents a unique challenge to the normally robust regenerative capacity of skeletal 
muscle. Injuries such as these are often seen in military personnel wounded in action by 
gunshots and blasts [3, 90]. In response to damage, skeletal muscle goes through a well 
defined series of events including inflammation, repair, and remodeling (For Review: 
[17, 19]). Ultimately, repair is the result of resident muscle stem cells, known as satellite 
cells, which proliferate, differentiate, and fuse with existing myofibers or form new 
myofibers [13, 99]. The normal repair mechanisms, however, are not sufficient for the 
repair of injuries involving significant tissue loss [8, 100].  The remaining myofibers are 
incapable of bridging across gaps created by the injury and scar tissue will fill the area or 
the muscle will remodel such that an area is permanently devoid of tissue [39]. In the 
case of injuries such as these, the victim is often left with a permanent handicap. 
Complete repair of a large muscle defect is dependent on the ability of an implant 
to fill the void in the tissue while allowing for the growth and development of functional 
myofibers, blood vessels, and nerves. The current standard of care for these injuries 
attempts to accomplish this by autologous tissue transfer (muscle flaps) using donor 
tissue from other areas of the victim’s body. Recent reports describe functional free 
muscle transplantation in the forearm [4] and elbow [5], but these procedures are 
associated with significant donor site morbidity and are not yet applicable to large muscle 
defects. The implantation of a scaffold seeded with progenitor cells to repair the defect 
and allow for the growth of new tissue into the area could be a way around the morbidity 
associated with autologous tissue transfer. 
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The extracellular matrix (ECM) is a scaffold, comprised predominantly of 
collagen that naturally occurs in the body and is critical in the development and growth of 
skeletal muscle [51]. Skeletal muscle tissue can be decellularized such that all that 
remains is a three-dimensional ECM [58, 94]. Using a three-dimensional ECM derived 
from skeletal muscle as a scaffold is advantageous because differentiation of muscle 
progenitor cells is stimulated by numerous factors including their three dimensional 
configuration and chemical and mechanical environment [57]. The decellularized ECM 
serves as a platform for the growth of functional muscle, blood vessel, and nervous tissue 
[58, 101, 102]. The three dimensional configuration of the ECM allows it to translate 
linear forces throughout the construct thus applying tension through the adhesion 
molecules to developing cells and further simulating the developmental environment of 
skeletal muscle. 
In myocardial damage models, defects repaired with ECM-derived implants 
incorporate myocardial cells and improve function [62, 63]. Implanted into skeletal 
muscle in vivo, the ECM is capable of supporting limited growth of new myofibers while 
maintaining the overall morphology of the area, but functional recovery does not occur 
[8, 9, 103]. The addition of muscle precursor cells, such as myoblasts and satellite cells, 
to acellular ECM implants used to repair abdominal wall defects, however, increases the 
amount of muscle tissue incorporated into the ECM, although the functional significance 
of this has yet to be determined [9, 71-73].  
The full repair of a large defect in a skeletal muscle will obviously require the 
growth of myofibers, but it also requires blood vessel integration and nerve innervation of 
the myofibers. The implantation of myoblasts or other myogenically committed cells 
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might not be capable of regenerating vessels and nerve. A pool of cells, known as 
mesenchymal stem cells (MSCs), that is multipotent and easily expandable in culture is 
found in the red bone marrow. Cells from the bone marrow are known to participate in 
skeletal muscle regeneration naturally [20, 75]. Dystrophin positive myofibers are found 
in dystrophic skeletal muscle of mice after the addition of donor bone marrow cells [23]. 
Bone marrow derived cells, isolated by adherence to the plastic cell culture vials through 
repeated passage, are termed MSCs.  These cells were originally described by 
Friedenstein [104] and are capable of differentiating into a number of other tissues 
including nerve, muscle, and vascular tissue that are necessary for viable muscular 
regeneration following muscle defect injury [80, 83, 85, 105]. Addition of bone marrow 
derived MSCs aids in the functional regeneration of skeletal muscle following both crush 
and laceration injury [87, 88]. The addition of MSCs to acellular ECM implants in the 
defected myocardium has shown the ability of MSCs to differentiate into cardiomyocytes 
and engraft into the ventricular wall, preserving its structure and demonstrating the 
potential of this technique to be beneficial for cardiac and skeletal muscle regeneration 
[89, 106]. 
Although bone marrow derived cells can aid in the repair of injured muscle and 
that muscle tissue can incorporate into an implanted ECM in vivo, the defect models 
studied to date, do not allow for functional analysis to determine physiological 
significance of large defect repair. Therefore, the purpose of this study was to determine 
the functional and morphological regeneration potential of an injured skeletal muscle 
with tissue loss and subsequent surgical replacement of the lost tissue with decellularized 
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 Male Lewis rats from colonies maintained by the Charles River Company 
(Wilmington, MA) were used in experimental procedures. The rats were approximately 
six to nine months of age at the beginning of treatment and weighed at least 400 grams. 
Rats were allowed ad libitum access to food (Rodent Chow, Harlan Teklad) and water. 
Rats were randomly assigned to experimental groups. All experimental procedures were 
conducted in accordance with guidelines set by the University of Texas at Austin 
Institutional Animal Care and Use Committee. 
For all surgical procedures, rats were under general anesthesia. Animals were 
anesthetized with an intraperitoneal injection of sodium pentobarbital (55 – 65 mg/kg 
body weight). Following experimental procedures, animals were overdosed with a bolus 
injection of sodium pentobarbital (80 mg/kg body weight) to the heart. 
Experimental Groups 
Lewis rats were randomly assigned to two groups; ECM-ONLY (n = 27) or ECM-
CELL (n = 20). ECM-ONLY rats were divided into 4 recovery groups; 7-day (n = 6), 14-
day (n = 6), 28-day (n = 6), and 42-day (n = 9). Rats in the ECM-CELL group were 
divided into 3 recovery groups; 14-day (n = 6), 28-day (n = 6), and 42-day (n = 8). Since 
the cells were not injected into the ECM-CELL group until 7-days post-defect/ECM 
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implant, no 7-day recovery group was necessary. Rats in each group underwent 
procedures as described below. 
ECM Isolation 
 GAS muscles were removed from donor male Lewis rats and decellularized. 
Under sterile conditions, muscles were dissected free and placed in 4° C dH2O water for 
one day. The muscle was placed in chloroform and continuously agitated for four to five 
days depending on size. The muscle was rinsed with water and submerged in 2% sodium 
dodecyl sulfate (SDS: Sigma-Aldrich; St. Louis, MO) and agitated continuously. The 
SDS solution was changed twice per week until the cellular components were washed 
out. The remaining ECM was rinsed in a large volume of deionized water (10:1 v/w) over 
several days with solution changes each day to rid the ECM of SDS. To completely 
insure removal of SDS, the ECMs were rinsed for 4 hours in a 0.1 M tris buffer solution 
of pH 9.0. The ECM was then submerged in phosphate buffered saline with 1% 
penicillin/streptomycin (Sigma-Aldrich; St. Louis, MO), exposed to ultraviolet light for 
at least twelve hours, and stored at 4°C until ready for implantation. Previously, the 
decellularized ECM was determined to be composed of approximately 99% collagen. No 
nuclei or cytoplasm were evident within the decellularized ECMs used for implant as 
evidenced by Masson’s trichrome staining. The decellularization protocol removed all 
soluble proteins as determined by the Bradford Assay and Coomassie Blue staining. 
Preparation of the ECM for implantation also completely removed any residual SDS as 
determined by Arand’s colorimetric assay [95]. 
Defect Creation & ECM Implantation 
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 Rats were anesthetized and a two centimeter incision was made on the lateral side 
of the lower limb parallel to the distal portion of the tibia. The biceps femoris muscle was 
separated from the tibia to expose the lateral side of the LGAS muscle. The LGAS was 
separated from the soleus muscle along a one centimeter portion just above the Achilles 
tendon. A small metal plate was placed between the gastrocnemius and the soleus to 
prevent the soleus from being damaged during creation of the defect. To create the defect, 
two #9 scalpel blades separated with a spacer were inserted distal to the neuromuscular 
junction with the proximal most scalpel blade in line with the tibial tuberosity. The 
LGAS was cut such that there were two lacerations through the full thickness of the 
muscle. The medial edge still connected to the rest of the muscle was excised with fine 
surgical scissors (Figure 4.1). The portion of muscle excised was weighed and measured. 
A portion of ECM cut to the dimensions of the defected area was implanted in the muscle 
using a modified Kessler stitch (5-0 Prolene; Ethicon) with simple interrupted sutures on 
each of the three borders to hold the cut ends together and serve as markers for later 
analysis. The modified Kessler stitch was used because it has been shown to be the most 
effective way to suture the transected muscle segments back together [96]. The wound 
was closed by suturing the cut area of the biceps femoris back together with simple 
interrupted polypropylene sutures (5-0, Prolene, Ethicon). The skin incision was closed 
with simple interrupted stitches of silk suture (4-0, Ethicon) tied with the knot underneath 
the skin to prevent the stitches from being chewed out. 
Isolation of Bone Marrow Derived Mesenchymal Stem Cells and Culturing 
 MSCs were isolated from Lewis rats using a procedure similar to that described 
by Friedenstein to isolate the adherent fraction of cells [104]. The femurs and tibias of 
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both legs of 2-3 month old Lewis rats were removed and trimmed of all muscle and 
connective tissue. The epiphyses were cut and the marrow flushed out with a Dulbecco’s 
Modified Eagle’s Medium (Invitrogen; Carlsbad, CA), 10% Fetal Bovine Serum 
(Invitrogen; Carlsbad, CA), 1% antibiotic/antimyctotic (Invitrogen; Carlsbad, CA) 
solution. The resulting cell suspension was centrifuged and the cells in the pellet plated at 
a density of 5 x 107 cells/ 100 mm2 on a culture dish and incubated at 37° C with 5% 
CO2. Media was changed every 2-3 days until cells reach 70% confluency. Cells were 
removed from the flask with 0.25% trypsin in 1mM EDTA at 37°C for five minutes, 
centrifuged at 1000g, resuspended in serum-supplemented medium, and replated at 5 x 
105 cells/ 100 mm2 on a culture dish. Culturing of the cells continued for 3-5 more 
passages at which time they were again removed from the flask and prepared for injection 
into the ECM at the defect site.  
Flow cytometry was performed on cells from the 5th passage to determine the cell 
population. Cells in culture were washed with PBS, trypsinized, and resuspended at 0.5 X 
106 cells/ mL in PBS with 1% BSA. Cells were incubated for 30 min at 4º C in the 
following fluorochrome-conjugated antibodies; CD34-PE (Santa Cruz Biotechnologies, 
Santa Cruz, CA), CD45-FITC (BD Biosciences, Franklin Lakes, NJ), CD90-PerCP (BD 
Biosciences, Franklin Lakes, NJ), CD146-APC (R&D Systems, Minneapolis, MN). Cells 
were washed in PBS and fixed in 1% para-formaldehyde. Detection of fluorochrome 
labeling was performed on a FACS Calibur cytometer (BD Biosciences, Franklin Lakes, 
NJ). Analysis was conducted using CellQuest Pro software at the ICMB Flow Cytometry 
Core Facility of The University of Texas at Austin.  
Injection of Bone Marrow Derived Mesenchymal Stem Cells into ECM 
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 One week following the defect repair with ECM, rats in the ECM-CELL 
treatment groups were given an injection of 1.5 – 2 million MSCs. Cells were trypsinized 
and removed from the cell-culture flask, centrifuged at 1000g and resuspended in 300 µl 
of phosphate buffered saline. The rat was anesthetized and prepared for the injection of 
cells. The original skin incision was opened up to visualize the ECM in the defect of the 
LGAS. Using a 21 gauge needle, MSCs were injected in 4-6 locations throughout the 
ECM/defect area. Following injection, the skin was once again stitched closed as before. 
Force Measurements 
After the designated recovery time, the LGAS muscles were isolated and 
subjected to functional measurements. A skin incision was made down the midline of the 
posterior portion of the lower limb from the popliteal area to the calcaneus. The skin was 
reflected to expose the biceps femoris which inserts along the distal portion of the tibia in 
rats. The biceps femoris was cut and reflected to expose the medial and lateral GAS. 
With care to minimize bleeding and damage to surrounding tissues, the LGAS was 
isolated from the superficial skin and biceps femoris as well as the deep soleus and 
plantaris. In order to attach the LGAS to the muscle lever for force measurements, the 
Achilles tendon with an attached portion of the calcaneus was cut and tied to the lever 
arm of a dual-mode servomotor (model 310 B, Aurora Scientific, Aurora, ON, Canada). 
The muscle was stimulated to contract utilizing a stimulator (Model 2100, A-M Systems, 
Calsborg, WA) with leads applied to the tibial nerve 1 cm proximal to its insertion into 
the GAS. The muscle was kept wet in mineral oil, and the temperature maintained at 
36°C with a radiant heat lamp and monitored on the muscle surface with a thermometer. 
The muscle length was adjusted to the length that produced the highest twitch force, and 
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maximal twitch tension determined. The muscle was stimulated at 150 Hz and 20V for 
peak tetanic tension (Po). Each contraction was followed by two minutes of rest. The 
servomotor was interfaced with the computer and equipped with an A/D board (National 
Instruments, Austin, TX. The data were stored and analyzed using Lab View software. 
After the completion of contractile measurements, the muscle was dissected free and 
weighed. 
Histology and Immunohistochemistry 
The implant region of the LGAS muscles was removed and divided into thirds 
such that there was an equal sized top, middle, and bottom region for each muscle. The 
samples were placed in 10% neutral buffered Formalin (Protocol, Fisher Scientific; 
Waltham, MA) for 24 hours, and stored in 70% ethanol until further analysis. Samples 
were embedded in a Tissue Tech paraffin embedding system prior to sectioning on a 
Reichert-Jung microtome. Eighteen, 5 µm sections from each of the top, middle, and 
bottom regions of the defect area, for a total of 54 sections per muscle, were subjected to 
histologic or immunohistochemical staining. Three sections per region were stained per 
method resulting in a total of nine stained sections per technique per muscle. These 
sections were quantified as described below and the results were expressed as mean ± 
standard error for each region within each subgroup. Hematoxylin and eosin staining was 
performed, as was Masson’s trichrome (Sigma-Aldrich; St. Louis, MO) staining to 
identify regions of collagen-containing ECM, as well as cells within the ECM. To 
visualize blood vessels, the rabbit anti-human von Willebrand Factor (vWF) polyclonal 
antibody (1:300: Kit, Dako; Carpinteria, CA) was used to identify endothelial cells. The 
signal was enhanced with biotinylated polyclonal goat-anti-rabbit IgG with streptavidin-
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HRP. Color was developed after incubation with 3,3-diaminobenzidine (DAB). Muscular 
infiltration into the ECM was further confirmed by immunofluorescent staining for the 
muscle specific cytoskeleton protein, desmin. Sections were exposed to mouse 
monoclonal anti-desmin antibody (1:500: Sigma-Aldrich; St. Louis, MO). Sections were 
then incubated with F(ab’)2 Goat Anti-Mouse IgG Fluorescein (1:100, λ = 495nm: 
Thermoscientific; Waltham, MA) and counterstained with Hoescht 33258 (λ = 395 nm: 
AnaSpec; San Jose, CA) to identify nuclei. To identify newly regenerated myofibers, an 
immunofluorescent stain for the skeletal muscle transcription factor, myogenin was 
performed. Sections were exposed to rabbit polyclonal anti-myogenin antibody (1: 500: 
Santa Cruz Biotechnologies; Santa Cruz, CA). Sections were then incubated with F(ab’)2 
Goat Anti-Rabbit IgG Fluorescein and counterstained with Hoescht 33258 (λ = 395 nm: 
AnaSpec; San Jose, CA) to determine nuclear colocalization. H&E, Masson’s trichrome, 
and vWF sections were visualized with a Nikon Diaphot microscope mounted with an 
Optronix Microfire digital camera interfaced with a Dell 8250 computer for storage and 
analysis of images. The area of each region of the ECM implant stained blue for collagen 
relative to red staining cytoplasm was quantified using LabView. The number of vWF 
positive structures within each region of the ECM implant of each rat was counted to 
determine the number of blood vessels/mm2. A vessel was only counted if its lumen was 
greater than 20 µm in diameter. Immunofluorescent desmin and myogenin were 
visualized with a fluorescence microscope (Leica DM LB2) and photographed with a 
digital camera (Leica DFC340FX). The percent area of each region of the ECM implant 
positive for desmin was quantified using a LabView program developed by Derrell 
Sloan. Additionally, the number of desmin positive fibers was quantified on three 
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sections within each region of the ECM in at least 3 animals per group at 28 and 42 days 
of recovery. Fibers showing nuclear localization of myogenin were counted in randomly 
selected fields from three sections within each region of the ECM from at least three 
animals per group at 28 and 42 days of recovery. Counts were performed by investigators 
blinded to the treatment. 
Statistical Analysis 
Means of all measurements were analyzed utilizing unpaired Student’s T-test and 
two-way ANOVA with Tukey’s post hoc test where applicable.  Data are represented as 
mean ± SEM unless otherwise stated. Significance is defined as p < 0.05. 
RESULTS 
 Bone marrow MSCs were analyzed for cell surface markers by FACS analysis. 
Cells cultured under identical conditions and from the same passage as those injected into 
the ECM were consistent with described MSCs. Over 99% of cells were positive for 
CD90 and negative for CD45, CD34, and CD146. 
The portion of the LGAS removed to create the defect was 223 ± 5 and 228 ± 6 
mg wet weight for ECM-ONLY and ECM-CELL, respectively, which was nearly 20% of 
the mass of the LGAS. No significant differences in defect size existed between groups 
or within groups at any time point. Over the course of 42 days after defect creation, the 
overall morphology of the ECM repaired LGAS was well maintained (Figure 4.2) in both 
groups, and no difference existed in the LGAS mass. 
 The maximal isometric tetanic force produced by the LGAS of the ECM-CELL 
group was significantly higher after 42 days of recovery than after 14 or 28 days of 
 63
recovery, and was also significantly higher than the force of ECM-ONLY at all time 
points ( p < 0.05) (Figure 4.3). No significant functional recovery of the LGAS occurred 
over 42 days in ECM-ONLY. Specific tension (SPo), the maximal tetanic force per unit 
of cross-sectional area, of the LGAS in the ECM-ONLY at 14 days of recovery was 83% 
± 8 of the contralateral LGAS, and 84% ± 6 of the contralateral LGAS after 42 days of 
recovery, which indicated no recovery of SPo occurred. SPo increased significantly in the 
ECM-CELL group LGAS relative to the contralateral from 77% ± 12 at 14 days of 
recovery to 94% ± 9 at 42 days of recovery (p < 0.01). 
 Histological analysis of the defect area in ECM-ONLY and ECM-CELL at 14, 28, 
and 42 days with Masson’s Trichrome stain shows increasing cellularity (Figure 4.4) and 
the appearance of blood vessel-like structures, which were confirmed by staining with 
von Willebrand Factor, within the ECM (Figure 4.5). Quantification of the Masson’s 
trichrome staining indicated that the cytosolic, red-stained, area relative to collagen, blue-
stained, area averaged across the top, middle, and bottom regions increased from 
recovery day 28 to recovery day 42 in both groups (Figure 4.6). Values for ECM-CELL 
were higher than ECM-ONLY after 42 days of recovery (p < 0.05). Quantification of 
vWF stained blood vessel walls demonstrated an increase in the number of blood vessels 
within the ECM implant in the ECM-CELL when compared to ECM-ONLY after 42 
days of recovery ( p < 0.05) (Figure 4.6). 
The muscle specific protein desmin and the transcription factor myogenin were 
used to identify myofibers within the ECM implant (Figure 4.7). After 42 days of 
recovery, regions of the ECM nearest the transected myofibers in the ECM-CELL group 
were densely populated with desmin-positive myofibers (Figure 4.8). The number of 
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desmin positive fibers per square millimeter was significantly higher after 42 days of 
recovery in the ECM-CELL group compared to all other groups (p < 0.05) (Figure 4.9). 
Significantly more myogenin positive nuclei were found in the MSC-seeded ECMs at 28 
and 42 days of recovery (Figure 4.9).  
When the defect implant area was examined by region (top, middle, or bottom), 
the appearance of cellular material and blood vessels was less evident in the ECM-ONLY 
compared to the ECM-CELL (Figure 4.10). Values for the number of myofibers and 
blood vessels in the middle third, were significantly lower than the values for the 
respective top and bottom regions which bordered the transected myofibers, although 
ECM-CELL middle region values were generally higher than the corresponding ECM-
ONLY values (See previously mentioned graphs). 
DISCUSSION 
 The repair of a physical deformity after traumatic injury is important for the 
psychological well being of victims [107]. Therefore, developing an implant capable of 
filling in an area of missing tissue to prevent physical deformity is important, but the 
development of an implant capable of full functional repair of the muscle in addition to 
aesthetic restoration of the area would be ideal. 
The data presented here prove that defect injuries that do not functionally 
regenerate at all without treatment, can be surgically repaired with an ECM seeded with 
MSCs such that partial functional recovery occurs and the overall aesthetic appearance is 
similar to non-injured muscle. This is an important step for the field of muscle 
regeneration. The functional restoration over 42 days when implanted ECMs were seeded 
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with MSCs is due to the increase in the number of blood vessels and myofibers growing 
within the implant, suggesting that the injected, homologous, bone marrow derived cells 
participate in the regeneration process. 
The adherent fraction of cells derived from the bone marrow are generally 
considered to be a population of cells known as marrow stromal cells or mesenchymal 
stem cells (MSC) which are multipotent and capable of differentiating into a number of 
different tissues [79, 108]. To confirm that the adherent bone muscle cells used in this 
study were MSCs, FACS analysis was performed. The cells were CD90+, CD45-, CD34-
, and CD146- which is consistent with published reports of rat MSCs [109-111] Due to 
the multipotent nature of MSCs, they are a good cell population to use to aid in the 
regeneration of a loss of a large volume of tissue such as the muscle defect model used in 
this study. Another reason MSCs are an attractive cell therapy candidate is because they 
are easily obtained and cultured from the bone marrow, and are immune privileged. In 
fact, they are already in use in tissue regeneration applications clinically [112]. 
The improved functional and histological regeneration observed after 42 days in 
the ECM-CELL group is likely the result of a number of different positive effects 
attributed to the implanted MSCs. Research from the lab of Blau et al., proved that 
endogenous cells from the bone marrow participate in muscle regeneration due to 
physiologic stress [75].  While the participation of these bone marrow cells in muscle 
regeneration appears to be rare (< 3.5%), they progress from the bone marrow and into 
the muscle where they become muscle progenitor and/or satellite cells that can be 
activated in response to muscle injury [20, 113]. The addition of exogenous MSCs to 
dystrophic skeletal muscle is able to partially restore the expression of dystrophin within 
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the fibers [23, 85, 114, 115]. Conflict exists as to whether or not the addition of MSCs 
contributes to skeletal muscle as a result of differentiation into myofibers, fusion of 
MSCs with existing myofibers with or without differentiation, or by the secretion of 
trophic substances by the MSCs. Differentiation of MSCs along a myogenic lineage and 
fusion to form myotubes does occur in vitro [78, 80, 85, 116] and evidence that it also 
occurs in vivo [86, 114]. Following irradiation and GFP+ marrow replacement, 
subsequent injury to skeletal muscle showed, that under these conditions, as many as 
12% of myofibers may express GFP, indicating significant fusion, but these results might 
not translate to the direct injection of MSCs into injured areas [117]. Fusion events do 
appear to occur when tagged MSCs are injected directly into injured skeletal muscle, 
although they are relatively rare and it is difficult to determine whether or not the MSCs 
differentiated along a skeletal muscle lineage prior to fusion [118]. Some researchers 
have noted improvements in cardiac and skeletal muscle regeneration after stem cell 
treatment without either differentiation of the cells to a myogenic lineage or fusion with 
resident cells [88, 119]. MSCs release cytokines and growth factors such as vascular 
endothelial growth factor and improve vascularization and perfusion of damaged tissues 
including skeletal muscle [120]. The increase in the number of blood vessels in the ECM-
CELL after 42 days is likely a result of this mechanism. Further evidence for the 
paracrine actions of MSCs is the improved regeneration of cardiac muscle following 
infarction by the injection of cell-free MSC conditioned media into the infarct site [121]. 
Interestingly, recent evidence proves that MSCs need not even be in the local area of 
injury to exert their effects. Shabbir et al. showed by injecting MSCs or MSC-
conditioned media into distant skeletal muscle and saw significantly improved function in 
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a heart failure model [122]. Even without tracking the cells injected in this study, at least 
some of the beneficial effects are likely explained by the trophic factors released by the 
MSCs. Natsu et al. treated skeletal muscle laceration with bone marrow-derived MSCs 
and as was seen in this study, the muscle improved functionally without evidence of 
fusion or differentiation of the injected cells [88].  
While this is the first time that MSCs have been seeded on a decellularized ECM, 
other myogenic progenitor cells have been seeded on decellularized ECMs implanted into 
skeletal muscle, although functional assessment of these has been limited. Similar to what 
others have seen with cell-seeded constructs of ECM implanted into defected skeletal 
muscle of the abdominal wall, the ECMs of the ECM-ONLY and ECM-CELL groups 
were both capable of supporting the growth of myofibers as well as blood vessels [9, 71, 
72]. Gamba et al., however, did not have myofiber ingrowth into decellularized ECM 
constructs without addition of exogenous cells as opposed to what was observed in this 
study in the ECM-ONLY groups [7]. The muscle defect model used here is probably 
provides a more suitable environment for regeneration. The LGAS used in this model is 
an active, load bearing muscle that is subjected to work during normal cage activity, 
whereas the rabbit’s abdominal muscle that was defected in the Gamba et al. study, is not 
subjected to the same relative functional demands. Mechanical stimulation and stretch of 
damaged/regenerating myofibers is known to improve regeneration [98], and it is likely 
that the activity levels of the LGAS aided in the regeneration of myofibers into the defect 
area as was observed.  
Terada et al. lacerated myofibers and kept the transected ends a designated 
distance from each other to determine the maximal distance that they could grow to 
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bridge the gap [39]. A distance greater than 2-3 mm was too far for the myofibers to 
bridge, which was consistent with what was seen in the ECM-ONLY LGAS. Despite the 
fact that cells were injected throughout the top, middle, and bottom of the ECM in the 
ECM-CELL group, only a limited number of desmin and myogenin positive fibers were 
found in this region. Both groups had did have myofiber ingrowth, but most blood vessels 
and myofibers were located in the top and bottom thirds of the ECM implant area, less 
than 3mm from the border of the ECM with the LGAS. Many of the cells expressed 
myogenin indicating that they were newly regenerated myofibers. These myofibers were 
likely from the growth of injured myofibers into the ECM from the superior and inferior 
portions of muscle remaining after the defect injury. Since the injected MSCs were not 
tagged or tracked, differentiation and/or fusion of the MSCs cannot be ruled out, but the 
significantly higher number of fibers expressed in regions closer to the border with native 
muscle tissue indicate that engraftment of cells was not the main method of regeneration. 
Also, cells injected directly into the middle of the ECM would have been further away 
from a blood supply, and many of the cells could have died from lack of nutrients before 
the vascular supply grew to the area, although analysis of the matrix when the cells were 
injected 7 days post-injury, suggests that blood vessels were in the area. As an implanted 
ECM remodels, it releases factors that attract myogenic progenitor cells and stimulates 
their proliferation and differentiation [52, 54, 55]. This in combination with the trophic 
factors released by the bone marrow derived cells would stimulate the regeneration of 
myofibers transected during the creation of the defect, and this likely explains the higher 
population of myofibers and blood vessels in the top and bottom region of the ECM 
relative to the middle region. 
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After 42 days, the regeneration of tissue into the injured area in the ECM-CELL 
group is capable of contributing to significant improvements in function. This 
improvement of function implies that at least some of the regenerated myofibers were 
reinnervated, although nerve innervation was not measured. Evidence exists that despite 
improvements in the short term, cell-seeded ECMs implanted into muscle might not show 
the same improvements over the long term [71]. Regenerating myofibers that are not 
reinnervated will degenerate [123]. Since innervation state of the regenerating myofibers 
was not studied, the myofibers observed in the ECM might not be permanent and 
allowing longer recovery periods after the procedure might have yielded different results. 
Since the improvement in function was observed, it is likely that at least some of the 
fibers were innervated. Future research however, should focus on the neurotization of the 
constructs at the time of implantation as this is likely to vastly improve function [124]. 
Another technique that could improve the function in this model further is the use of a 
larger number of cells. Winkler et al. determined that the addition of 1 x 107 MSCs to a 
severe muscle crush injury significantly improved the functional recovery of the muscle 
more than 2.5 x 106 MSCs improved functional recovery [118]. Addition of only 1 x 106 
MSCs did not show any significant functional improvement. In the present study, only 
1.5 – 2 x 106 cells were injected into the 1 x 1 cm ECM repaired defect and significant 
functional improvement was observed. Had this number been higher, the possibility 
exists that additional functional improvement would have occurred. Further 
improvements in functional recovery using this model might be observed with the 
addition of growth factors or by the use of physical therapy regimens involving 
mobilization and exercise to stimulate the regenerative process. 
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In conclusion, the data presented demonstrate for the first time, the return of 
function to a large muscle defect by the addition of MSCs seeded on a decellularized 
ECM implant. Translation of this technique to the clinic could significantly improve the 





FIGURE 4.1: DEFECT CREATION - Removal of defect from LGAS. Repair with ECM 
and BMC Injection 
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FIGURE 4.2: MORPHOLOGY - (A) Non-operated LGAS (B) Defect LGAS 0-day 


























FIGURE 4.3: FUNCTION POST-DEFECT INJURY - Maximal isometric, tetanic tension of 
defect LGAS relative to contralateral limb 14, 28, and 42 days post injury. * Indicates 




FIGURE 4.4: HISTOLOGY RECOVERY COMPARISON - Masson’s Trichrome stain of 
sections from implanted ECM at designated recovery times. Magnification = 100x. Note: 





FIGURE 4.5: VON WILLEBRAND FACTOR - Masson’s Trichrome stain of sections of 
implant from 42 Day Recovery of ECM-ONLY (left) and ECM-CELL (right) with insets 
demonstrating the appearance of vWF positive blood vessels. Magnification: Trichrome 
= 200x; inset vWF = 400x. Scale = 100 µm.
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FIGURE 4.6: CELLULAR AREA & BLOOD VESSELS WITHIN DEFECT - *Significantly 
different from same ECM-ONLY region (p < 0.05).  § Significantly different from Top 




FIGURE 4.7: DESMIN & MYOGENIN IMMUNOFLUORESCENCE - (A) ECM-ONLY at 28 
days, (B) ECM-CELL at 28 days, (C) ECM-ONLY at 42 days and (D) ECM-CELL at 42 
days.  Increased myofiber filtration, desmin and myogenin positive structures with 
recovery and following cell injection into the defect area.  Stained with Masson’s 
trichrome (center), desmin (lower left) and myogenin (lower right).  Circular spaces are 






FIGURE 4.8: MASSON’S TRICHROME & DESMIN IMMUNOFLUORESCENCE – 
Neighboring sections of ECM-CELL 42 day recovery stained with Masson’s Trichrome 




FIGURE 4.9: DESMIN POSITIVE FIBERS & MYOGENIN POSITIVE NUCLEI - 
*Significantly different from same ECM-ONLY region (p < 0.05). § Significantly 





FIGURE 4.10: ECM MIDDLE - Masson’s Trichrome of sections from the middle third of 
the implants after 28 days recovery. ECM-ONLY (left) and ECM-CELL (right). Scale 






Chapter V: General Discussion 
 The goal of this dissertation was to develop a skeletal muscle defect model that 
resulted in long-term functional deficits and to determine the effectiveness of a surgical 
repair technique using extracellular matrix with and without the addition of bone marrow 
derived cells. The results of these studies are summarized below. 
 SUMMARY OF RESULTS 
1.  Complete functional recovery of an LGAS lacerated to a depth of 1 cm through its full 
thickness occurs over the course of six weeks without any intervention. This 
demonstrates the natural regeneration potential of skeletal muscle and proves that this 
laceration model is not suited for the study of long-term viability of tissue engineering 
constructs. 
2.  The removal of 10% of the LGAS mass results in a functional deficit that remains 
constant over the course of at least 28 days. The removal of 20% of the LGAS mass 
results in a functional deficit that remains constant and shows no signs of regeneration 
over the course of at least 42 days. The lack of functional recovery over the course of 
six weeks and the subsequent remodeling of the muscle’s size and shape indicate that 
functional loss is permanent. 
3.  Repair of the LGAS defect with decellularized skeletal muscle ECM prevents the 
muscle remodeling that occurs when no ECM is implanted. With ECM repair, the 
overall macroscopic morphology of the muscle is maintained and is relatively normal 
from an aesthetic perspective. 
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4.  While an implanted ECM alone does not lead to the recovery of function, the ECM 
does allow for the incorporation of regenerating tissues such as blood vessels and 
myofibers. This is an important result, because any construct implanted to restore 
function must allow for the ingrowth of muscle cells and blood vessels to provide 
oxygen and nutrients.  
5.  Addition of bone marrow MSCs to the ECM implant partially restores function to the 
defected LGAS after 42 days of recovery. 
6.  Addition of bone marrow MSCs to the ECM implant in the LGAS increases the 
number of regenerating myofibers and blood vessels throughout the defected area. The 
increase in blood supply and myofibers in the implant within the defected muscle is 
likely the reason for the partial restoration of function observed after 42 days of 
recovery. 
CONCLUSIONS 
 This study describes a reproducible skeletal muscle defect model that results in a 
permanent loss of function. This model can be used to better understand the regeneration 
process of muscle following traumatic injury involving significant tissue loss. This study 
also demonstrates the ability of a decellularized ECM construct to maintain morphology 
and incorporate regenerating tissue when implanted into a muscle defect. This 
incorporation of regenerating tissues can be further enhanced by the addition of 
exogenous bone marrow derived MSCs, which also lead to a partial restoration of 
function in the defected muscle.  
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Compared to the other defect models used in previous research, the model 
developed here is superior for the study of the functional aspects of muscle regeneration 
after tissue loss. This model was created specifically for its relative ease of the functional 
assessment of various types of engineered constructs designed specifically for skeletal 
muscle regeneration. The LGAS is a muscle that is very involved in daily activities of the 
rat and therefore experiences much different demands than other muscles generally used 
in tissue engineering research. These demands however, are very similar to the demands 
that must be met by engineered tissues if they are to replace large muscle defects in the 
clinic. The ease with which the LGAS can be perturbed by various exercise and physical 
therapy regimens also makes this model ideal to study muscle tissue engineering. The 
goal of skeletal muscle tissue engineering is to replace lost muscle with functional 
muscle, and this defect model more closely matches those demands than any other model 
currently used in research. 
The lack of functional recovery in the ECM without the addition of cells is likely 
due to the limited number and size of myofibers incorporated within the ECM and the 
fact that the fibers that grow into the ECM do not penetrate more than a few millimeters. 
However, the addition of the MSCs partially restores the function and increases the 
number of myofibers and blood vessels that are found within the ECM. The exact 
mechanism by which the exogenous cells aid in the functional regeneration was not 
determined, although it is likely due to trophic factors secreted by the cells which are 
known to enhance regeneration [88] and/or the differentiation and fusion of the cells to 
form myofibers which can also occur [86, 125], although it is likely that these events are 
rare. While the importance of understanding the exact mechanism by which bone marrow 
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derived cells produce beneficial effects should not be understated, the improved 
functional regeneration seen in this defect model with the addition of the cells is 
promising and could have tremendous clinical implications. 
FUTURE DIRECTIONS 
 Due to the strengths of this defect model, the use of a number of different tissue 
engineered muscle constructs is possible. The efficacy of different constructs could easily 
be compared by implantation of one into one leg and the other into the contralateral leg. 
Experimentation with muscle constructs grown in vitro utilizing explanted 
microcirculatory beds such as those proven to be effective by Chang et al. [126], could be 
a good way to ensure long-term viability of constructs used to repair large defects. 
Several techniques specific to the ECM and cells used in this study should also be 
considered for future research. The neurotization of the ECM during implantation by 
transplantation of a nerve to the ECM is likely to vastly improve function [124]. Function 
could be further improved by the implantation of more cells. While partial restoration of 
function occurred with the addition of 1.5 – 2 million cells to the ECM, based on research 
of skeletal muscle crush injury performed by Winkler et al., it appears that the number of 
bone marrow derived cells used in this defect model was less than optimal and addition 
of 10 million cells might have better restored function [118]. Additionally, addition of 
growth factors or the use of physical therapy regimens involving mobilization and 
exercise to stimulate the regenerative process could further enhance the repair of the 
ECM-implanted skeletal muscle defect. The versatility of this model and the promise of 
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decellularized ECMs and bone marrow derived cells for skeletal muscle repair make this 
a very exciting field to research. 
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Appendix A: Expanded Methods 
I. Skeletal Muscle Extracellular Matrix Isolation 
1. Place whole skeletal muscle into a 50 ml conical tube of deionized (DI) water at 4° C 
for 12-24 hours. 
2. Remove muscle from DI water and place in chloroform at room temperature for 2-4 
days depending on the size of the muscle (Soleus 2 days; Gastrocnemius 4 days) Place 
on rocker to agitate solution. 
3. Pour off chloroform into waste container and rinse muscle three times with DI water. 
Immerse muscle in 2% sodium dodecyl sulfate (w/v) and place on rocker. 
4. Change SDS solution every two to three days until muscle is opaque and only ECM 
remains. Larger muscles might require SDS to be injected into the middle of the 
muscle in several places every few days. 
5. Rinse muscle three times with DI water and then immerse in a 2% antibiotic/ 
antimyctotic (A/A) DI water solution. Store at 4° C for 24 hours. 
6. Rinse muscle three times with DI water and then immerse in 2% A/A PBS and place 
on rocker. Change solution twice daily to rinse out SDS over 3-4 days. 
7.  Place muscle in a 2% A/A, PBS solution at 4° C for storage. 
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II. A. Isolation of Rat Bone Marrow Adherent Cells  
1.  Remove femurs and tibia of 2 to 4 month old rats. 
2.  After removing epiphyses and gaining access to marrow cavities, whole bone marrow 
plugs will be  flushed out from tibial and femoral medullary cavities using a 10ml 
syringe (16 gauge needle) with DMEM supplement with 10% FBS and 1% antibiotic-
antimyctotic. 
3.  Marrow samples will be collected and mechanically disrupted by sequential aspiration 
through 16, 18, 20 gauge needles attached to the same 10ml syringe. 
4.  The resulting cell suspension will be centrifuged for 5ml at 1000rpm with cells 
collected and resuspended in serum-supplemented medium.  
5.  A small volume of the resuspension will be mixed with 4% acetic acid to lyse red 
blood cells. Nucleated cells will be counted using a hemocytometer. 
6.  After counting, cells will be plated at 5X107 cells/100mm culture dish as primary 
culture and incubated in 5% CO2 at 37oC, with fresh medium changes every 3 days. 
7.  When large cell colonies develop (~ 75% confluent, usually 12-14 days later), cultures 
are washed twice with PBS and cells are trypsinized with 0.25% trypsin in 1mM 
EDTA for 5 min at  37oC.  
8.  After centrifugation (1000g, 5 min), cells will be resuspended with serum supplement 
medium, counted, and plated at a density of 5-7X105 cells/100 mm dish. The resulting 
culture will be referred to as first passage culture. 
B. Culturing of Bone Marrow Adherent Cells 
Making Media: 
1. Determine the total volume of media that is needed.  
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a. 35 ml for each flask. 
b. Add an additional 10 ml for each flask that is being split. 
2. Then calculate how much FBS, AA, EMEM, sodium bicarbonate, non-essential 
amino acids, and sodium pyruvate that is required. 
a. Volume of EMEM= 0.77*total volume of media 
b. Volume of FBS/sodium bicarbonate = 0.10*total volume of media 
c. Volume of AA/non-essential amino acids/sodium pyruvate = 0.01*total 
media 
3. Add all the ingredients into a sterile container and then place into a water bath at 
37°C for at least 15 minutes before use. 
Changing Media: 
1. For each flask that needs to be changed, aspirate out the old media and add in 35 
ml of new media. 
a. Remember flasks that are 75% or more confluent must trypsinized and 
split/freeze. 
Trypsinization: 
1. Aspirate out all the old media. 
2. Add in 10 ml of DPBS with Ca and Mg into each flask and then aspirate out. 
3. Add in 6 ml of trypsin into each flask and place the flasks into incubator. 
a. After 5 minutes, take out the flasks and place under microscope to see if 
majority of the cells are dislodged. If not, place flasks back into incubator 
for additional 2-3 minutes. 
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b. Afterwards, again check for dislodgement. If necessary, tap the side of the 
flasks to promote dislodgement. 
4. Add in 1 ml of FBS into each flask. 
5. Transfer the trypsin+FBS solution from each flask into 15 ml conical tubes. 
a. Each flask has its own conical tubes and make sure to keep track which 
tubes belong to which flasks. 
6. Rinse each flask with 8 ml of DPBS without Ca and Mg and then transfer the 
DPBS solution of each flask into the proper 15 ml conical tube. 
7. Place the conical tubes into a centrifuge and spin them at about 4°C for 7 minutes 
at a speed of about 1250 
8. Afterwards, you should get a pellet of cells on the bottom of each conical tube. 
Splitting: 
1. Aspirate the supernatant of each tube. Be careful not to remove any cells. 
2. Add in about 10 ml of media into each tube and then evenly mix up the pellet of 
cells inside each tube.  
3. Split each tube of cells into the desired ratio. 
a. example: 1:5 – equally divide one tube of cells into 5 new flasks. 
b. Make sure that fresh media is already inside the flasks so that the cells are 
being added onto the media. 
Freezing: 
1. Make media with 10% DMSO. 
2. If necessary, place the tubes into the centrifuge again to reform the pellets. 
3. Add in 1.0-1.5 ml of media with DMSO into each conical tubes.  
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4. Mix up the pellet of cells in each (15ml) conical tube and then transfer the 
solution of cells into a 1.5 ml conical tube. 
5.  Place the 1.5 ml conical tubes into the -80°C freezer.  
a. After 1-2 days, the conical tubes can then be placed in liquid nitrogen. 
Thawing: 
1. Take out the 1.5 ml conical tubes containing the frozen cells and place them into a 
37°C water bath until the cells are no longer frozen. 
2. Transfer the cells from the 1.5 conical tubes to 15 ml conical tubes.  
3. Add 0.4-0.5 ml of FBS into each 15 ml conical tubes. (if desired) 
4. Fill the 15 ml conical tubes with DPBS without Ca and Mg and then place them 
into centrifuge to spin the cells into pellets. 
a. spin at 4°C for 7 minutes at a speed of about 1250 
5. Follow the splitting procedure to split the cells into flasks. 
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III. Muscle Defect Creation and Repair 
Prior to beginning any surgical procedures sterilize any instruments that will come into 
direct or indirect contact with the subject. Rats should be anesthetized and unresponsive 
to tactile stimuli prior to surgery. 
1. With a scalpel, cut a two centimeter incision on the lateral side of the lower limb 
parallel to the distal portion of the tibia.  
2. Separate the biceps femoris muscle from the tibia to expose the lateral side of the 
lateral gastrocnemius muscle, and separate the lateral gastrocnemius from the soleus 
muscle along a one centimeter portion just above the Achilles tendon.  
3.  Place a small aluminum foil plate between the gastrocnemius and the soleus to prevent 
the soleus from being damaged during creation of the defect.  
4. To create the defect, insert two #9 scalpel blades, separated by a spacer, distal to the 
neuromuscular junction with the proximal most scalpel blade in line with the tibial 
tuberosity.  Cut the lateral gastrocnemius such that there are two lacerations through 
the full thickness of the muscle.  
5.  The medial edge still connected to the rest of the muscle should be excised with fine 
surgical scissors.  
6.  Measure and weigh the portion of muscle excised. 
7.  For rats in the defect/repair groups:  immediately after the creation of the muscle 
defect in the lateral gastrocnemius, cut a piece of ECM to the exact size of the defect 
removed and implant it into the defect’s place.  
8.  Suture the ECM to the remaining muscle stumps using a modified Kessler stitch (5-0 
Prolene suture) with care taken to include the epimysium.  
 92
9.   Mark the border of the implanted ECM with simple sutures (5-0 Prolene)  and insure 
that the implanted ECM and the cut ends of the lateral gastrocnemius remain in 
contact. Place the sutures were at the medial, proximal, and distal borders of the ECM 
and lateral gastrocnemius.  
10. Close the wound by suturing the cut area of the biceps femoris back together with 
simple interrupted polypropylene sutures (5-0, Prolene, Ethicon). Close the skin 
incision with simple interrupted stitches silk suture (4-0, Ethicon) tied with the knot 
underneath the skin to prevent the stitches from being chewed out. 




IV. In Situ Force Measurements 
1.  Using a scalpel, make an incision in the skin down the midline of the posterior portion 
of the lower limb from the popliteal area to the calcaneus.  
2.   Reflect the skin to expose the biceps femoris which inserts along the distal portion of 
the tibia in rats.  
3.   Cut and reflect the biceps femoris to expose the medial and LGAS. 
4.   With care to minimize bleeding and damage to surrounding tissues, isolate the 
gastrocnemius from the superficial skin and biceps femoris as well as the deep soleus 
and plantaris.  
5.   Cut the Achilles tendon and a portion of the calcaneus where it inserts near the foot so 
that the distal end of the muscle is unattached.  
6.   Cut the portion of the tibial nerve supplying the medial gastrocnemius and using the 
calcaneus as an anchor, tie the Achilles tendon to the muscle lever arm of the dual-
mode servomotor (model 310 B, Cambridge Technologies).  
7.   Stimulate the muscle to contract utilizing a stimulator (Model 2100, A-M Systems) 
with leads applied to the tibial nerve one centimeter proximal to its insertion into the 
LGAS.  
8.  Throughout the remainder of the procedure, keep the muscle wet in mineral oil, and 
maintain the temperature between 35 and 37.5°C with a radiant heat lamp.  
9.   Adjust the muscle length to optimal length with a micrometer, and determine 
maximal twitch tension using stimulation of 0.5 Hz.  
10.  Stimulate the muscle at 150 Hz for peak tetanic tension (Po). After each contraction, 
allow the muscle to rest for two minutes. Save all data to the computer. 
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V. Muscle Removal and Preservation 
In order to remove the muscles and preserve them for later analysis, the following 
procedure(s) should be employed: 
1.  Cut the skin above the knee all the way around the leg. Remove the skin from the cut 
end to the ankle using blunt ended scissors. 
2. With rat lying on its back, extend the leg upwards (tape the foot to a clip to make it 
easier) and push hemostats between the hamstrings at the popliteal fossa. Separate the 
hemostats to split the hamstrings and expose the origin of the medial and lateral 
gastrocnemius heads as well as the tibial nerve. 
3. Carefully run blunt ended scissors up and down medial and lateral sides of the leg 
between the gastrocnemius and overlying muscles to separate the tissues from the 
gastrocnemius. 
4. Using blunt ended scissors cut away the rest of the tissue overlying the posterior 
midline of the gastrocnemius. Cut all the way to the calcaneus and peel the tissue off 
of either side of the gastrocnemius. Cut away the flaps of muscle and skin to fully 
expose the gastrocnemius. 
5. Slide forceps or blunt scissors between the Achilles tendon and the tibia. Push them 
through and out the opposite side. Using force, slide the instrument down between the 
tibia and triceps surae muscles towards the knee (be sure to push more on the tibia 
than the muscles so as not to rip the soleus). 
6.  Cut the Achilles tendon and pull the tendon down and away from the rest of the leg. 
The muscles isolated are the triceps surae group - soleus, plantaris, and 
gastrocnemius. The soleus will be removed first. It will by lying on top of the other 
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two muscles as it is the deepest muscle and closest to the tibia. It is also more to the 
lateral side of the limb. Cut the proximal tendon of the soleus close to the knee and 
pull it back towards the Achilles tendon. With a little force and a small snip of the 
scissors at the Achilles tendon end, it will come right off. Place in saline. 
7. The plantaris and the gastrocnemius both have origins on the distal end of the femur. 
The medial and lateral edges of the knee will need to be further isolated and some 
small muscles on either side of it will need to be cut. Using forceps carefully push 
away some of the connective tissue to expose the proximal ends of the plantaris and 
gastrocnemius as well as the popliteal artery. With care not to hit the popliteal artery, 
cut the plantaris as well as the medial and lateral heads of the gastrocnemius as close 
to the femur as possible. 
8. The plantaris and gastrocnemius must be separated by teasing the plantaris’ distal 
tendon away from the Achilles tendon. Once the tendons are separated, the plantaris 
can be pulled away from the gastrocnemius and both can be placed into saline 
solution. The gastrocnemius can be further separated into the medial and lateral 
halves if necessary. Immediately upon removal, the length and weight of all muscles 
must be measured. 
9.  The muscles should be stored according to the proper procedure for specific analysis. 
Usually the muscles will be pinned through the tendons onto labeled wooden sticks 
and immersed in 10% buffered formalin. The muscles must remain in formalin in at 
least a 20:1 formalin volume: muscle weight (grams) ratio for 3 hours after which the 
formalin should be discarded and replaced with fresh formalin. The muscles should 
remain in the formalin for at least 24 hours, but up to 72 hours for larger muscles that 
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cannot be cut to a smaller size. Following formalin, the muscles should be immersed 
in 70% ethanol for at least 24 hours prior to paraffin embedding. 
 If the muscles are to be frozen, they should first be pinned at length or placed in 
cassettes and immersed in isopentane (2-methylbutane) and then immediately placed in 
liquid nitrogen. The muscles should be stored in the -80°C freezer. 
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VI. Paraffin Embedding of Muscle Samples 
Formalin fixed muscle tissue specimens stored in 70% ethanol are embedded in paraffin 
wax for sectioning on a microtome. 
Solution Duration 
80% Ethanol 1 x 45 min 
95% Ethanol 1 x 45 min 
100% Ethanol 3 x 45 min 
Xylenes 2 x 45 min 
Paraffin (58°C) 1 x 60 min 
Paraffin (58°C) Overnight 
 
Note: 
• The dehydration step with 100% ethanol can 45 mins – 1 hour depending 
on time convenience. 
• Clearing with xylene can be between 45 mins – 1 hour to adjust for time. 
Following the overnight paraffin step above, muscles should be embedded in paraffin 
molds using the Tissue Tek embedding center and CryoConsole. Muscle samples should 
be placed in a mold (HistoPrep) of molten paraffin with care given to insure proper 
orientation of the muscle tissue. A labeled tissue processing cassette (Sakura) should be 
placed atop the mold with the muscle before the paraffin has cooled. The embedded 
muscle sample should be cooled to 0°C on the Tissue Tek CryoConsole. The sample can 
then be sectioned on the microtome or stored indefinitely at room temperature.
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VII. Sectioning of Muscle Samples 
1. Paraffin embedded samples should be placed wax side down on ice for at least 10 
minutes prior to sectioning. 
2. Turn water bath and slide warmer temperatures to 40-45°C. 
3. Scrape excess paraffin off of the side of the cassette holding the muscle sample and 
place it into the Reichert-Jung microtome’s specimen holder. Using the screws, adjust 
the sample so that the cutting surface lies parallel to the microtome blade. 
4. Turn the coarse adjustment knob to bring the sample closer to the blade. Once the 
sample is near the blade, set the microtome section thickness to 10 µm. Begin turning 
the hand crank to begin cutting the outer paraffin layer off of the embedded muscle 
sample. Stop when it is apparent that the sample is being cut. 
5. Set the microtome section thickness to 5 µm and continue sectioning. Sections will 
come off in a ribbon. Using a razor blade, isolate two of the sections from the ribbon, 
and carefully float them on the surface of the water in the water bath.  
6. Dip a prelabeled, microscope slide just underneath the floating paraffin muscle 
sections and carefully pull the slide up underneath of the sections so that the section 
lies on the microscope slide without wrinkling or folding. 
7. Lean the microscope slide and sample against the counter to drop dry for several 
minutes and then place them on the slide warmer for at least 45 minutes. Store slides 
for staining procedures. 
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VIII. Deparaffinization Procedure 
Anytime samples have been paraffin embedded, sectioned, and placed on microscope 
slides, they must first be deparaffinized before staining. 
Solution Duration 
Xylene 2 x 8 min 
100% Ethanol 2 x 8 min 
70% Ethanol 2 x 8 min 
50% Ethanol 2 x 8 min 
30% Ethanol 2 x 8 min 
DI Water 3 x 5 min 
 
Proceed to staining. 
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IX. Hematoxylin & Eosin Staining 
If the sections are from paraffin embedded tissue, they must first be deparaffinized. For 
this procedure, use the tall jars with the slots in the slides. If the slides are placed back to 
back, 10 can be stained at once in the same jar, but it is easier to put 5 in the same jar. 
Hematoxylin and Eosin can both be reused, so do not pour them out. Pour them back into 
the bottle. 
Solution Duration 
Harris Hematoxylin (PROTOCOL) 5 min 
Gentle tap water rinse Until water runs clear 
Eosin (PROTOCOL) 2 min 
Gentle tap water rinse Until water runs clear 
70% Ethanol Rinse several seconds 
100% Ethanol Rinse several seconds 
Xylene Rinse several seconds 
 
Allow the stained slides to dry in the hood and then coverslip with Permount (Fisher 
Scientific). 
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X. Masson’s Trichrome Staining 
If the sections are from paraffin embedded tissue, they must first be deparaffinized. For 
this procedure, use the tall jars with the slots for the slides. If the slides are placed back to 
back, 10 can be stained at once in the same jar, but it is easier to put 5 in the same jar. 
The Working Weigert’s Iron Hematoxylin is an equal volume mix of bottles A & B. The 
solution can be reused several times, but over time oxidizes and cannot be reused. The 
slide jars hold ~ 40 ml of solution, so mix 20 ml of A with 20 ml of B. 
The Working Phosphotungstic/Phosphomolybdic Acid solution is a mix of the 2 acids 
with DI water. Mix 10 ml of phosphotungstic acid with 10 ml of phosphomolybdic acid 
and then add 20 ml of water. All solutions from Sigma-Aldrich. 
Solution Duration 
Bouin’s Solution 15 min at 56°C or overnight at room temp. 
Tap water Gentle rinse until clear 
Working Weigert’s Iron Hematoxylin 5 or 6 min 
Tap water Gentle rinse until clear 
DI water rinse 
Beibrich Scarlett Acid Fuchshin 5 min 
Tap water Gentle rinse until clear 




Aniline Blue 5 min 
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1% Acetic Acid 2 min 
Tap water Rinse 
70% Ethanol Rinse 
100% Ethanol Rinse 
Xylenes Rinse 
 
Dry in hood and mount coverslip with Permount. 
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XI. Von Willebrand Factor Staining 
Pre-treatment: Dako Target Retrieval Solution: 
Solution/Step Duration/Notes 
Set-up: Place Coplin jar filled with Target 
Retrieval Solution in water bath. 
Heat water bath to 95-99°C (do not boil). 
Deparaffinize and rehydrate tissue 
sections. 
See Deparaffinization Procedure. 
Immerse room temperature sections into 
preheated Target Retrieval Solution in 
water bath. 
20-40 min 
Remove entire jar with slides from water 
bath. Allow to cool at room temp. 
20 min 
Decant Target Retrieval Solution and 
rinse sections 2-3x with room temperature 
TBST. 
 
Proceed with Staining.  
 
* During target retrieval steps set out TBST and antibody diluent to equilibrate to room 
temperature. Approximately 1L of TBST is needed for the entire procedure.  
If more TBST is needed: 
0.05 mol/L Tris-HCl   For 1L from stock solution:  
0.15 mol/L NaCl   50 ml 1M Tris 
0.05% v/v Tween 20   0.5 ml Tween 
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pH = 7.6    Bring to 1L with DI H2O 




Store @ 4°C 
 
Staining Protocol: 
*Note: Do not allow tissue sections to dry during the staining procedure. 
Solution/Step Duration/Notes 
Follow Pre-treatment Dako Target 
Retrieval Solution Procedure before 
staining. 
 
Equilibrate all kit reagents to room temp. Perform all incubations at room temp. 
1. PEROXIDASE BLOCK: 
 
 
Tap off excess water, carefully wipe 
around specimen to dry. Circle tissue 
section with pap pen. 
 
Cover specimen w/ 3% H2O2 Incubate 5 min 
DI water rinse, Place in fresh TBST bath.  
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2. PRIMARY ANTIBODY AND 
NEGATIVE CONTROL REAGENT: 
 
Tap off excess TBST and dry slide as 
before. 
 
Apply enough user prepared primary 
antibody or negative control reagent to 
cover specimen.  
1:300 dilution of vWF 
5 ul vWF in 1.5 ml diluent for 10 slides 
Incubate 30 min. 
Rinse gently with TBST, place in TBST 
bath. 
 
3.  LINK:  
Immediately tap off excess buffer and wipe 
slide as before. 
 
Apply enough YELLOW drops of Link to 
cover specimen. 
Incubate 15 min (or 30 for enhanced 
sensitivity) 
Rinse slides as in Step 2.  
 
4.  STREPTAVIDIN PEROXIDASE: 
 
 
Dry slide as before.  
Apply enough RED drops of Streptavidin 
to cover specimen. 
Incubate 15 min(or 30) 
Rinse slides as before.  
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5.  SUBSTRATE-CHROMOGEN 
SOLUTION: 
 
Dry slide as before.  
Cover specimen w/user prepared substrate 
chromagen. 
Mix 1 drop of chromagen with 1 ml of 
substrate. 
Incubate 5 min 
Rinse in TBS (no tween), then PBS, and 






Primary (1°) Antibodies: 
• α-Desmin: identifies the wide desmin band, an intermediate filament found near the 
Z-disk in sarcomeres (MW = 50-55 kDa); found predominantly in skeletal, cardiac or 
smooth tissue 
o Sigma, D1033. Stored at 2-8ºC up to one month, -20ºC if stored in working 
aliquots 
• Hoechst 33258: labels nucleic acid (DNA); used to identify nuclei 
o AnaSpec, 83219. Stored at 4ºC, free from light 
• Myogenin (M-255): muscle-specific transcription factor that can induce myogenesis; 
expressed in differentiating muscle cells 
o Santa Cruz Biotechnologies, sc-576. Store at 4ºC up to one year 
Secondary (2°) Antibodies 
• F(ab’)2 Goat Anti-Mouse IgG Fluorescein-Conjugated 
o Thermo Scientific, 31565. Stored at 4ºC, -20ºC if glycerol is added, protect from 
light 
• F(ab’)2 Goat Anti-Rabbit IgG Fluorescein-Conjugated 
o Fischer Scientific, 31579. Stored at 4ºC, -20ºC if glycerol is added, protect from 
light 
• Antibody Label: fluorescein- or rhodamine-conjugated 2° antibodies are appropriate; 
may contain a fluorochrome (ex. FITC) 
 108
o Two-step biotin/avidin system may be used to increase amplification; avidin will 
bind to multiple sites on biotinylated 2° antibody; high affinity, essentially 
irreversible reaction 
o Excitation Wavelengths 
 Fluorescein: 495 nm; broad spectrum; easily photobleached 
 Rhodamine: 570 nm 
 Hoechst: 395 nm 
Blocking Agents: 
• Bovine Serum Albumin (BSA): can stabilize enzymes and enzymatic reactions; also 
prevents adhesion of enzymes to equipment surfaces 
o Fischer Scientific, BP1605-100 
o Stored at 4ºC 
• Normal Rat Serum: used to inhibit non-specific binding of antibodies during 
immunofluorescent staining procedures 
o MP Biomedicals, 64294 
o Stored at 2-8ºC (both freeze-dried and reconstituted) 
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Desmin/Hoechst Staining Protocol 
Solutions: 
• α-Laminin/α-Desmin 
• F(ab’)2 Goat Anti-Goat IgG Fluorescein  
• Hoechst 33258 
• Xylenes 
• Ethanol 
• Tris-buffered saline (TBS) 
• TBST 
• Tween 20 
• Phosphate-buffered saline (PBS) 
• Bovine serum albumin (BSA) 
• Normal rat serum 
• Mounting medium 
Deparaffinization & Hydration: 
• Place slides in slide holders and immerse slides in each solution, contained in 
Columbia staining dishes: 
o Xylenes: 2 x 8 minutes 
 Xylenes must be handled under the hood; be careful to not spill and always 
used glove when handling xylenes 
o 100% Ethanol: 2 x 8 minutes 
o 70% Ethanol: 2 x 8 minutes 
o 50% Ethanol: 2 x 8 minutes 
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o 30% Ethanol: 2 x 8 minutes 
o DI H2O: 3 x 5 minutes 
 Avoid drying (may cause background resulting from non-specific binding); if 
dry, rehydrate with DI H2O for 15-30 min 
Antigen Exposure & Retrieval: 
• Immerse slides in 2 N HCl for 30 – 60 minutes @ 21ºC 
• Immerse slides in 1x TBST (0.1% Tween 20) for 4 hours – overnight @ 21ºC 
o PBS may be used but may precipitate; TBST is preferred 
o Tween 20 is used to decrease surface tension, allowing for increased antigen 
exposure 
• Immerse slides in 10% normal rat serum in 1x TBS (1.0% BSA): 2 hours @ 21ºC 
o Rat serum is preferred but goat serum may be substituted 
o Solution can be reused once within one week if stored at 4ºC 
Primary Antibody Incubation: 
• Dry slides for 5 minutes and place in humid boxes 
o Humid boxes will prevent drying during incubation; they are covered and consist 
of TBS-soaked tissue paper and glass rods suspending the slides over TBS 
• Apply several drops (until section is covered) of the primary antibody: 
o α-Desmin: 1:500 in 1x PBS (1.0% BSA) 
• Incubate for 12 hours – overnight @ 4ºC 
Secondary Antibody Incubation: 
• Wash slides with 1x TBST (0.1% Tween 20): 3 x 5 minutes 
• Dry slides for 5 minutes and place in humid boxes 
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• Repeat the above incubation procedure with the secondary antibody 
o F(ab’)2 Goat Anti-Mouse IgG Fluorescein: 1:100 in PBS 
• Incubate for 60 – 90 minutes @ 4ºC; must be protected from light 
Counterstain Incubation: 
• Wash slides with 1x TBST (0.1% Tween 20): 3 x 5 minutes 
• Dry slides for 5 minutes and place in humid boxes 
• Repeat the above incubation procedure with desired counterstain 
o Hoechst 33258 (pentahydrate bis-benzimide): 1 μL/mL H2O 
• Incubate for 45-60 min @ 4ºC; must be protected from light 
o Hoechst used in place of DAPI because it will not precipitate, while DAPI may in 
the presence of TBS 
Mounting: 
• Wash slides with 1x TBS: 3 x 5 minutes 
o Last wash is not TBST because Tween 20 causes coverslips to come off easily 
• View slides before mounting as they may need an additional PBS wash to remove 
background; PBS has a lower pH and is easier on the slides 
• Dry slides for 20 – 30 minutes 
• Mount slides by pipetting several drops of mounting medium onto slides and cover 
with coverslips 
o May also used antifade mounting reagent (Prolong Gold, Invitrogen) to protect 
fluorescence and better maintain slides 
o Slides can be viewed for 1-2 weeks using regular mounting medium 
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Myogenin/Hoechst Staining Protocol 
Solutions: 
• MyoD/Myogenin 
• F(ab’)2 Goat Anti-Rabbit IgG Fluorescein  
• Hoechst 33258 
• Xylenes 
• Ethanol 
• Tris-buffered saline (TBS) 
• TBST 
• Tween 20 
• Phosphate-buffered saline (PBS) 
• Bovine serum albumin (BSA) 
• Normal rat serum 
• Mounting medium 
Deparaffinization & Hydration: 
• Place slides in slide holders and immerse slides in each solution, contained in 
Columbia staining dishes: 
o Xylenes: 2 x 8 minutes 
 Xylenes must be handled under the hood; be careful to not spill and always 
used glove when handling xylenes 
o 100% Ethanol: 2 x 8 minutes 
o 70% Ethanol: 2 x 8 minutes 
o 50% Ethanol: 2 x 8 minutes 
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o 30% Ethanol: 2 x 8 minutes 
o DI H2O: 3 x 5 minutes 
 Avoid drying (may cause background resulting from non-specific binding); if 
dry, rehydrate with DI H2O for 15-30 min 
Antigen Exposure & Retrieval: 
• Immerse slides in 2 N HCl for 30 – 60 minutes @ 21ºC 
• Immerse slides in 1x TBST (0.1% Tween 20) for 4 hours – overnight @ 21ºC 
o PBS may be used but may precipitate; TBST is preferred 
o Tween 20 is used to decrease surface tension, allowing for increased antigen 
exposure 
• Immerse slides in 10% normal rat serum in 1x TBS (1.0% BSA): 2 hours @ 21ºC 
o Rat serum is preferred but goat serum may be substituted 
o Solution can be reused once within one week if stored at 4ºC 
Primary Antibody Incubation: 
• Dry slides for 5 minutes and place in humid boxes 
o Humid boxes will prevent drying during incubation; they are covered and consist 
of TBS-soaked tissue paper and glass rods suspending the slides over TBS 
o Myogenin (M-225) 
• Incubate for 12 hours – overnight @ 4ºC 
Secondary Antibody Incubation: 
• Wash slides with 1x TBST (0.1% Tween 20): 3 x 5 minutes 
• Dry slides for 5 minutes and place in humid boxes 
• Repeat the above incubation procedure with the secondary antibody 
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o F(ab’)2 Goat Anti-Rabbit IgG Fluorescein 
• Incubate for 60 – 90 minutes @ 4ºC; must be protected from light 
Counterstain Incubation: 
• Wash slides with 1x TBST (0.1% Tween 20): 3 x 5 minutes 
• Dry slides for 5 minutes and place in humid boxes 
• Repeat the above incubation procedure with desired counterstain 
o Hoechst 33258 (pentahydrate bis-benzimide): 1 μL/mL H2O 
• Incubate for 45-60 min @ 4ºC; must be protected from light 
o Hoechst used in place of DAPI because it will not precipitate, while DAPI may in 
the presence of TBS 
Mounting: 
• Wash slides with 1x TBS: 3 x 5 minutes 
o Last wash is not TBST because Tween 20 causes coverslips to come off easily 
• View slides before mounting as they may need an additional PBS wash to remove 
background; PBS has a lower pH and is easier on the slides 
• Dry slides for 20 – 30 minutes 
• Mount slides by pipetting several drops of mounting medium onto slides and cover 
with coverslips 
o May also use antifade mounting reagent (Prolong Gold, Invitrogen) to protect 
fluorescence and better maintain slides 
o Slides can be viewed for 1-2 weeks using regular mounting medium 
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XIII. Measurement of Muscle Fiber Length and Angle 
1. Pin the muscle at resting length and fix overnight in 10% Formalin. 
2. Immerse the muscle in 20% nitric acid for 12 - 24 hours to dissolve connective tissue. 
3. Replace nitric acid solution with a 50% glycerol solution. 
4. Measure the resting length of the whole muscle and measure the angle of pinnation, 
then separate the muscle into several bundles. 
5. Tease single fibers out from the bundles from proximal, middle, and distal portions and 
measure their length under 10x magnification. Measure at least 12 fibers from each 
muscle to get the mean fiber length.
Appendix B: Raw Data 
I: Laceration Data 





situ  Force 
(N)
CON in 


















L4201 480 495 25 21.5 3.1 4.4 2651 596 232 2676 554 212
L4202 485 502 40 32.5 5.5 7 2965 715 239 3061 664 260
L4203 513 513 39.5 36 8 2715 597 214 2804 555 240
L4204 527 531 42 48 6 7 2891 719 229 3012 675 226
L4205 475 521 47 42 8.7 9.4 3142 702 260 3119 680 214
L4206 560 580 46 46 7 7.6 3202 790 294 3406 750 295
L4207 465 475 29 38 6.3 7.9 2616 526 193 2574 535 185  
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II: Small Defect Data –Sprague Dawley Rats 
0 Day Recovery





























D001 552 172 41 8 49 9.3 1356 1631 1457 1784
D002 518 124 45 8.1 51 8.8 1335 1491 1345 1614
D002-2 140 44 51
D003 517 134 42 9.2 48 9 1349 1578 1376 1712




































D1401 575 227 566 42.5 42 6.7 6.6 1412 1422 1387 1746
D1402 576 123 560 32 47 7.5 8.1 1364 1643 1423 1808
D1403 560 202 555 40.5 47 7.1 7.5 1351 1487 1369 1806
D1404 479 154 487 22.5 25 5.2 5.1 1432 1364 1279 1723
D1405 494 154 508 1374 1389 1268 1707
D1406 530 155 534 44 6.8 7 1276 1540 1498 1939
D1407 537 140 549 38 40 7 7.7 1492 1583 1901 1920  
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III. Large Defect Data 
0 Day Recovery





























D005 520 301 44.5 8.2 52 9.8 1241 1335 1699 1291
D006 598 289 41 8 52 10 1290 1613 1634 1299
D007 551 315 42 6.5 46 10.5 1284 1385 1714 1287
D008 549 263 43 8.2 53 8.3 1244 1517 1785 1415
D009 551 333.3 35 9.5 53 10.5 1341 1627 1847 1432
D010 485 275 33 6.1 44 10.2 1295 1320 1632 1382
D011 560 355 38 7 53 10
D012 516 347 34 9.8 1263 1513 1804 1724
14 Day Recovery
































D1408 516 330 517 37 42 6.1 11 1181 1246 1132 1573
D1409 498 239 480 34.25 44.75 7.2 9.6 1265 1278 1157 1551
D1410 615 354 615 38 52 1536 1705 1404 1937
D1411 580 308 578 46 54 8.4 1470 1579 1380 1854
28 Day Recovery
































D2801 434 325 450 39 48.2 8.6 10.6 1233 1073 1178 1492
D2802 475 242 494 43.5 52 9.8 11.6 1381 1350 1316 1633
D2803 488 386 506 41 50.5 9 12.3 1287 1661 1301 1997
D2804 470 216 495 37.5 47.5 10.2 11.6 1296 1316 1272 1547
D2805 400 281 420 37 42 1161 1112 1062 1395
D2806 437 271 464 26 46 7.8 11.7 1201 1245 1155 1394
D2807 437 327 448 42.5 49 8.1 10.1 1223 1238 1212 1605
D2808 470 353 485 38 8.4 1263 1238 1224 1547
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IV: Lewis Rat Defect Data 
A. Defect Only 







































D013 502 270 502 15.7 23.5 4.8 11.9 254.8 482.2 1178 1168.6 231.9 491.7 1262.2 1294.9 33 32.5
D014 535 226 535 17.2 20.33 4.1 4.8 221.7 560.7 1319.5 1219.1 233.3 540.3 1442 1444.7
D015 510 250 510 11.2 22.4 2.7 3.3 195 458 1028 1034 179 438 1066 1255









































D0701 463 264 468 13.4 23.5 3.6 10.6 231.3 490.8 1162.5 1116.7 232 477.1 1141.6 1355.7 32 32
D0702 502 299 499 14.8 22 4.3 239 532.7 1203 1081.6 211.2 473.4 1155.2 1255 31 30
D0703 516 202 521 14.2 21.3 2.9 265 528 1193 1072 206 470 1188 1211 33 33
D0704 506 212 493 16.9 23 1.75 4.3 280 509 1219 946 237 440 1048 1265
D0705 540 238 523 17.6 22.4 4.1 5.5 244 525 1210 1069 231 476.2 1147.1 1288.9 32 31
D0706 496 233 490 16.4 20.7 3.88 5.4 231 506.3 1183 1040 218 449.8 1120.1 1252 31.5 31









































D1413 461 280 468 15.1 23.2 7.2 8.7 253.6 556.5 1160.7 1083 229 486.7 1121.2 1249.6 31 30
D1414 463 202 496 18.5 23.9 5.3 8.2 227.1 494.5 1146.1 1157.9 209.3 462.2 1148.9 1255.5 30 30
D1415 454 250 476 15.1 21.4 5.7 7.8 237.2 511.5 1212.6 1044.8 213.3 500.6 1137.5 1220.2 30 29
D1416 476 202 502 17.5 21.6 3.8 230 430 1248 1134 202 494 1172 1250 31.5 31
D1417 501 210 524 15.2 20.8 2.5 4.4 200 584 1265 977 226 496 1150 1365 31 30
D1418 463 242 455 15.1 21.5 2.54 5.3 269 524 1155 1000 219 466 1016 1246 33.5 33









































D2810 465 235 505 17.9 23.1 3.3 4.0 249.0 511 1194 1148 221 517 1090 1263 31 30.5
D2811 479 265 505 16.6 22.2 3.6 229.0 530 1168 1088 201 466 1019 1278 32 31
D2812 515 215 545 17.7 23.8 3.1 4.7 250.0 519 1329 1178 222 498 1219 1250 31.5 31
D2813 509 237 552 17.7 22.4 3.8 3.8 242.0 522 1256 1113 232 479 1213 1418 34 33
D2814 517 212 540 18.1 23.1 4.2 4.4 255.0 553 1215 1226 219 513 1185 1400 33 32
D2815 467 245 494 15.4 19.8 3.7 4.1 236.0 532 1255 940 201 451 1092 1208 32 32









































D4201 465 292 465 23.5 25.2 3.3 4.1 266 683 1350 1382 245 583 1261 1590 32 31
D4202 475 209 525 14.7 20.2 2.1 230 491 1240 1120 211 478 1121 1311 33 32
D4203 443 212 479 13.3 20.5 2 3.1 220 466 1109 979 222 454 1056 1219 32 32
D4204 468 266 517 18.1 22.9 3.4 4.5 270 533 1195 1030 219 461 1129 1264 32 31.5
D4205 450 263 476 14.6 21 3.6 4.7 245 490 1162 955 205 427 1047 1167 31 30











































M0701 417 315 417 12.9 20.2 3.8 4.5 204 435 1080 1737 192 414 970 1135
M0703 496 211 486 20.2 22.4 3.6 4.2 221 529 1236 1304 204 460 1117 1250 32 31.5
M0704 498 236 19.1 21.5 4.06 5.2 191 478 1189 1515 185 439 1049 1262 34 34
M0705 493 211 490 15.4 23.9 3.7 5.2 221 487 1178 1382 221 490 1126 1260 33 33
M0706 420 197 421 14.8 20.8 3.1 4.7 176 441 1521 955 164 431 1049 915 30 30







































M1406 480 240 504 16.3 22.3 2.9 3.6 224 483 1109 1081 204 427 1107 1161 32.5 32
M1407 485 218 490 16.1 21.3 3.2 3.8 220 484 1160 1214 225 473 1090 1285 35 36
M1408 478 217 487 14.6 22 2.85 4.5 243 513 1270 1095 214 467 1110 1251 32 32
M1409 470 235 498 16.1 21.4 3.4 4 212 523 1211 1295 207 436 1130 1276 32 31
M1410 519 208 526 15.1 19.6 2.4 2.4 266 540 1286 1034 226 509 1167 1237 31 32
M1411 479 212 488 16.2 18.8 3.2 4.2 212 473 1192 1033 181 432 1067 1244 33 33



































Def L Gas 
Length
Con L Gas 
Length
M2811 507 205 508 16.6 20.6 3.4 4.3 234 527 1161 1105 205 440 1041 1313 32 32
M2812 492 210 503 16.2 19.1 3.5 3.8 230 532 1168 1095 205 437 1072 1238 32.5 33
M2813 461 211 493 16.6 21 3.2 3.5 240 537 1202 1025 185 453 1094 1249 32 32
M2814 495 224 510 15.4 19.7 3.1 4.4 240 497 1265 1085 205 439 1050 1335 30.5 31
M2815 512 246 521 13.9 21.3 2.9 4.1 240 513 1197 1029 200 469 1020 1232 31 32
M2816 546 287 552 15.6 20.6 3.3 4.2 255 529 1240 1101 207 454 1079 1309 31.5 31.5



































Def L Gas 
Length
Con L Gas 
Length
M4201 455 303 525 16.5 22.55 2.5 4.5 286 572 1376 1231 219 497 1174 1233 30.5 30.5
M4202 427 279 505 14.9 23.1 3.9 6.1 245 575 1240 1285 258 524 1209 1431 32 30
M4203 487 216 515 18.1 23.7 2.9 4.3 228 508 1240 1100 205 498 1142 1301 32 32
M4204 503 205 525 18.95 24.5 4.1 4.7 234 511 1285 1189 214 464 1139 1323 32 32.5
M4205 463 228 500 19.3 22.4 3.3 4.9 243 542 1199 1073 193 480 1096 1243 33 33
M4206 476 189 516 19 23.5 4.4 7.2 218 515 1166 1208 202 473 1096 1200 31.5 31.5
M4207 513 226 531 16 23.7 3.1 4.9 235 529 1244 1108 211 470 1144 1334 33 33.5
M4208 452 207 475 14.7 19.3 3.1 2.6 206 474 1072 959 185 401 1030 1111 31 31
M4209 546 287 550 15.3 21.8 3 3.8 269 510 1172 1077 223 453 1071 1318 31.5 32
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C1401 521 228 502 12.5 20.4 2.2 4.5 234 522 1145 1207 210 469 1087 1227 33 32
C1402 479 268 12.9 19.6 2.9 4.1 206 474 1091 949 192 401 971 1140 32 31
C1403 414 209 417 14.8 20.8 2.4 4.9 195 457 1029 845 421 988 1028 31 31
C1404 490 226 475 15.9 20.7 2.5 4.2 193 436 957 1182 409 957 1080 32 32
C1405 423 211 415 15.1 19.8 3.2 4.5 193 448 901 905 353 808 922 32.5 32
C1406 473 221 461 15.4 20.8 2.9 4.6 212 456 1031 953 156 396 869 1038 32 32









































C2801 509 195 511 14.5 21.8 3.5 4.5 223 505 1230 1081 208 467 1052 1289 31.5 31.5
C2802 522 266 536 16.7 20.9 3.8 4.5 266 521 1240 1376 271 514 1200 1448 32.5 32.5
C2803 547 285 540 15.1 21.7 2.2 3.9 154 498 1248 999 213 441 1042 1267 32 33
C2804 456 255 420 197 410 913 1140 208 459 1057 774
C2805 416 203 469 15 20.5 3.6 5.8 153 495 1000 949 423 1177 973 31 31
C2806 427 219 445 15.1 19.8 2.6 4.4 192 424 1002 983 366 900 1036 31.5 30.5
C2807 443 465 15.4 20.2 3.3 4.3 249 505 1006 1066 174 504 1062 1156 30 30









































C4201 479 239 513 16.4 17.5 3.1 3.2 226 528 1139 1141 235 483 1209 1325 31 31.5
C4202 503 211 512 15.8 20.4 3.6 3.2 214 468 1095 1055 201 448 1009 1166 30 30
C4203 520 222 525 241 481 1182 1030 191 1104 1262 31
C4204 520 243 507 18.9 21.5 238 531 1187 1035 175 475 1070 1110 31.5 31.5
C4205 500 227 497 18.8 22.5 3.5 4.4 240 469 1152 1126 220 455 1101 1186 33.5 33
C4206 519 206 521 16.9 21 3.5 4.5 233 489 1129 1023 198 435 1079 1225 30 30
C4207 496 211 515 16.5 22.8 2.7 4.4 232 478 1179 1073 219 1050 1205 1205 30 30
C4208 535 226 550 20.7 20.2 3.1 2.9 218 510 1214 1274 201 1184 1327 1327 32 31.5
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C. ECM-CELL 
V: Stained Muscle Sections 
A: Control 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
D0703 3 1 1
D0704 2+ M1
D0705 10um 1
D1413 8 1 1 1 1
M0701 6 2 1 1 1
M0704 18 1 1 1 1 1
M1403 6 ll 1 1
M1408 4+ T1 M1 B1
M2802 6 ll T2
M2807 T1 T3
M2814 1+ 1
M2815 6 1 2 4 5 6
M4201 6 M2 T2
M4207 6 I M1
M4209 9 T2, M3 T1
C1401 6 l 1 1 1 1
C1402 6 I 1 1 1 1
C1403 6 1 1 1 1 1
C4204 6 1 3 6 2
C4207 6 I 1 1
C4208 7 I 1 7 6 5
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B: Defect Top 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
D016 6 T1 M3
D0701 18 T2,M3,B1 T5,M1 B6 M6 T1
D0702 18 M2,B5 T2 B4 M5 M3
D0703 18 T1-T3, M1-M5, B1, B2, B4, B5 T3,B4 B3 M6 T4
D0704 6 1 1 1 1 1
D0705 6 3 4 1 6 2
D0706 6 5 1 3 2 4
D1412 4 l 1 1
D1413 6 2 5 1 6 4
D1414 6 T3 M2,M3 M1 T2
D1415 9 M1 T2 M3 M2 B1
D1416 6 M3 M2 T2 M1
D1417 6 M1 M2 T1 T2 M3
D1418 6 T2 T1 M1 M2 T3
D2810 6 5 4 1 6 3
D2811 9 T1, M1, B1 M4,B2 M2 B3 M3
D2812 6 2 3 5
D2813 6 4 1 3 6
D2814 6 6 4 2 1 3
D2815 6 6 3 1 4 5
D4201 5 T4 M2 M1 T1
D4202 6 4 6 2 1 3
D4203 6 2 6 4 T3
D4204 6 2 6 4 1 3
D4205 9 5 1 7 9 2
D4206 6 4 2 6 5 3
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C: Defect Bottom 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
D016 6 M3 T1
D0701 6 4 6 2 5 3
D0702 6 3 4 1
D0703 6 5 6 2 1 3
D0704 6 3 2 4 1,5
D0705 6 1 2 3
D0706 6 4 2 1 3 5
D1412 6 3 4 1 6
D1413 18 B5 T3 M1 T6
D1414 6 2 6 4 5
D1415 6 T2 M3 M1 T3
D1416 18 T1,M1 M4,B3 T6 M2 B5
D1417 6 2 6 1 3 5
D1418 6 4 5 3 1 6
D2810 6
D2811 6 3 4,5 2 1,6
D2812 6 2 6 4 5 3
D2813 6 M2 T3 M1 M3 T2
D2814 6 6 T1 M2 T2 M3
D2815 6 T1 M2 M1 5 M3
D4201 7 M2,B3 B1 M1 B2
D4202 6 M3 T3 M1 M2
D4203 18 T4 M3 M2 T1,M4
D4204 6 T1 T3,M3 M1
D4205 9 M2 T2 M3 T1 M1
D4206 6 M1 T1 M2 T2 M3
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D: ECM-ONLY Top 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
M0701 4+ 1,2
M0703 19 T1, M4, B1 T2,M3,B2 T5, M2 B7 M5 B4
M0704 8 T1,T6,T2 T5, B2 T4, M6, B4
M0705 17 T1, M1, B1 T2,T5,M2 M3 M4,B2 T3,M6,B4
M0706 20 M4, B21, B32 M3,B4 T3,M1 T2,T5 M6,B6
M1406 18 T3, M5,B3 T1, M1,B6     T6, M2, B2 B5 T4, M6, B4
M1407 19 T1, M4,M5, B4 T2,M6,B7 T6, M2, B3 M3
M1408 19 T2,M3,M5, B1 T1,B6      T6, M2, B3 T4 T3,M6,B4
M1409 20 T1,T4,M2,M5,B1,B5 T7,M7 T6, M3, B2 T3,M4,B4
M1410 18 T2,M4,B6 T7,M2,B3 M2,B1 T3,M6,B4
M1411 18 T1,B3 T6,M1,B4 T2,M3,B2 T3,M4,B5
M2811 22 T1, M1, B1 M3,M4,B22 T5, M2, B2 B31 T3, M7, B4
M2812 20    T1,M2, B6 T3,M3,B1,B4 M1, B3 T6,M5 T4, M6, B5
M2813 18 T1, M4,B4 T3,B3,B5 T2,M2 T4, M6
M2814 18 T3,M4,M5,B6 T1,M2,M3 T6,M1,B2,B3 T2 T4,M6,B4
M2815 21     T4,T6,M3,B1 T3,T7,M1,M2,B3 T5,M4,B2 T1,B5 T2,B4
M2816 18 T1,M1,B4 T6,M2,B3 M4,B1 T4,M6,B5
M4201 18 T1, M2, B2 T5,M4,B4     T6,M3,M5,B3,B6 T3,B1 M6, B5
M4202 22 T1, M3,    T2,T5,M4 T6, B1 M4,B3 T3, M6, B4
M4203 16 T1, M1, B2 M5 T3, M2, B3 M4
M4204 18 T4,M6,B8 T5,M5,B2 T3,M2,M5,B3,B6 T1,M3 T6, M2, B4
M4205 18 T4, M4,B3 T1,T5,M1 T6, M2, B2
M4206 20 T6, M2, B2 T2,M5,B1 T5
M4207 18 T4,M3,M4,B4 M1,M6,B5 T2,T6,B3,M2 B1 T1,T3,M5
M4208 18 T1,M7,B1 M5,B5 T4, M3, B3 T2,B2 T3,M6,B4
M4209 20 T4,M1,B4 T5,M4,B B3 B2
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E: ECM-ONLY Middle 
Sample  # of Sections H&E Masson's Desmin  vWF Myogenin 
       
M0701 18 M1,B3 T2,M1,B5 T2,B2 M6,B4 M3,B1 
M0703 18 T2,M6 T3,M1,B1 T6,M3 B2 M4,B6 
M0704 18 T3,M3,B1 T1,M1,B3 M2,B4 M6,B6 B2 
M0705 18 T1,M1,B6 T3,M2,B3   T4,M4,B5   
M0706 21 M6 T2,M1,B4 M2,B5 T1,B6 T3,M5 
       
       
M1406 18 T3,B4 M6,B6 T4,B5 M1,M6 M5,B1 
M1407 18 T6,M6,B3 T1,B2 T3,M2 M5,B1 M1 
M1408 18 M2,B1 T6,B3 B4 M1,T1 M5,B6 
M1409 18 T5,M2,B1,B6 T4,M6,B3 T6,M2,B2 M5,B4 M4 
M1410 18 T6, M1 T1,B2 M4,B6 B5 T3,M5 
M1411 18 B3 M1,B6 T3,M4 T2,B5 T1,T6 
       
       
       
M2811 18 T2,M5,B5 T4,B6,M1 T3 T6,B4 T5,M2 
M2812 18 T2,M3,B3 T3,M5,B4   T4,M2 T6,B1 
M2813 18 T1,B6 M2,B4 T3,M3,B3 T6,M1,B1 M5,B5 
M2814 18 T3,M1 M6,B2 T1,B6 B5 M6,B3 
M2815 18 T3,M3,B1 T1,M1,B3 M2,B5 M6,B6 B2 
M2816 18 T6,B2 B3 T4,B4 T5,M6 B6 
       
       
M4201 18 T3,M5 M3,B1 T6,B5 M4 M2 
M4202 18 T1,M1,B1 T3,M3,B5   T2,M4   
M4203 16 T2,M6 T3,M1 T6,M3 B1,B2 M4,B6 
M4204 18 M2,B3 T4,M3 B3 T1,B5 T3,B1 
M4206 18 M3, B2 T1,T2,M1 T6,M2,B3   T4,M6,B4 
M4207 18 M6,B1 M4 T3,B2 T1,B6 T2,B4 
M4208 19 T1,M1,B1 T3,M3,B3 M5,B6 T2,M2 T5,T6 
F: ECM-ONLY Bottom 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
M0701 6 1,3,5 2,4,6
M0703 18 T1,M2,B4 T6,M1,B1 T5,M3,B3 M4,B2 T3,M5,M6,B5
M0704 18 T3,M4,B6 T1,M5,B1 T6,M2,M3,B3 T2,M6,B5 T5,M1,B2
M0705 19 T1,B6 T2,B2,B5 M1,M5,B1 M3,B5 T3,M6,B4
M0706 18 T4,M4,B6 T3,M5,B4 T1,M6,B6 M2,B1 T2,M1
M1406 18 T4,M3,B5 T1,M1 T5,M2,B1 T2,M4 M3,B3
M1407 18 T3,M2,B6 T2,M1 T1,M5,B5 T6,M6,B1 M4,B3
M1408 18 T2,B1 M1,M6,B7 T6,M2,B3 T1,M3 M5
M1409 18 T1,M1,B5 T3,M5,B1 T5,M3,B2,B3 T2,B6 T6, M4, B6
M1410 18 T6, M3, B3 T2,M1,B1 T5, M2, B2 T3,M6,B4
M1411 18 T1,T4,M4,M6,B1,B6 T2,B2,B5 T5, M2, B3 T6
M2811 18 T1,T5,M5,B1 T3,M1,M3 T6, M5, B3 M4,B5,B6 T4,M6,B4
M2812 18 T3,B1,M1 T5,M3,B3 T6,M4,B2 M6,B4
M2813 18 T2,M2,B6 T1,B5 T6 T2,M3 T3,M6,B2
M2814 10 T2,M1,B3 B5 T5, M3, B3 M6,B4 T3,M5,B1
M2815 20 T4, M4, B3 T3,M1,B1 T5,T6,M2,B2 T2,M6,B4
M2816 18 T2,M1,B3 T1,M1,B4 T6,M2,B3 M4,B1 T4,M6,B5
M4201 18 T2,T3,M3,M4,B2 T1,B1 T6, B3, M2 T4, M6, B4
M4202 18 T2 T6, M2, B2 T5,B3 T4,M6,B4
M4203 18 T1,M1,B1 T5, M3, B2 M4,B2 T3,M5,M6,B5
M4204 20 T3, M3, B10 T2,M4,B4 T6, M2, B3 B2 T3,M5,B5
M4205 18 T2,M4,B3 M5,T4,B1 T6, M2, B2 T5 T4,M6,B4
M4206 18 T2,M4,B4 M2,M6 T6, M3, B2 T1,M1 T3,M5,B3
M4207 18 T3,M1,B1 T1,M3,B5 T5, M2, B3 T2,B6  T4,M6,B4
M4208 18 T2,M4,B6 T6, M2, B2 T3,B1 T4,M6,B4
M4209 18 T3,M2,B2 T1,M4,B5 M3, B3 M1,B6 T4, M6, B4
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G: ECM-CELL Top 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
C1401 18 T3,M3,B1 T2,T4,B5 M2,B3 T7,B6 T5,M4,B4
C1402 21 T1,T5,M1,M3 T2,T4,T7,M5 T6, M2, B3 T3, M4, B4
C1403 18 T2,M3,B3 T3,M5,B4 M1,B6 T4,M2 T1,M6
C1404 18 T5, M2, B1 T4,M6,B3 T6,M2,B2 B4 M5
C1405 18 T3,M4,B3 T4,M5,B5 T1,M2 M2,B2 T6,B6
C1406 19 T4,M3,B5 T1,M1 T5,M2,B1 T2,M4 B3
C2801 18 T1,M5,B2,B6 T2,T3,M1,M4,B3 T5,M3 T6,B1 T4,M6,B4
C2802 18 T1,T2,M2,B? M3,B2 T6,M5 M4,B1 T3,B5
C2803 18 T1,T4,M6,B3,B5 T3,T5,M5,B1,B2,B6 T6,M2,B3,B4 T2 M1,M6
C2804 18 T1,M6,B4 T3,M2,B6 T5,M5,B3 T2,M4 T6,M3
C2805 18 T4,M2,B1 T5,M4,B3 T4,T6
C2806 13 T6,M2,B6 T3,M1,B3 T2,B4 T5,M3
C4201 19  T2,T3,M2 T1,M6,B3 T6,M3,B2 M4,B1 T4, M5, B4
C4201-2 18 T5, M2, B1 T4,M6,B3 T6,M2,M6,B2 M5,B4
C4202 18 M3,B2 B4 T6, M1,B1 B6 M4
C4203 18 T4,M1,B4 T2, M5, B5 T6 T3 M2,B3
C4204 18 T2,M2,B4 T4,M6,B6 T6,M2,M4,B3 T1,M3 M5, B3
C4207 18 T1,T6,M1,M4,B5 T4,M3,B4 T5, M2, B3 T1,B1,B6 T3,M5,B2
C4208 21 T2,M2,M5,B1,B4 T1,M4,M6, M3, T6 T3, M1, B2
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H: ECM-CELL Middle 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
C1401 18 T5,M4,B3 T1,M5,B4 M1,B1 M6,B6 T6,B5
C1402 18 M3 T4,M1 T3,B2 M1,B5 T2,M6
C1403 18 T2,M3 T3,M5,B4 M1,B6 T4,M2 T1,M6
C1404 21 M6,B2 T1,M3,B7 T2,M5 T6 T3,M4
C1405 18 T4 T2,M2,B5 T3,B1 T1,M6 M5,B3
C1406 18 T4,M3,B5 T1,M1 T5,M2,B1 M4 T2,B3
C2801 18 T1,M3,B3 T3,M1,B5 T6,M2,B3 T4,M6 T5,M5
C2802 18 T3,M3,B2 T5,M5,B4 T1,M2 T6,B6 T2,B3
C2803 18 T3,M5,B5 T2,M2,B2 T5,M1,B1 T1,M6,M2 T6,B3
C2805 18 M2,B1 T5,M4,B3 T4,M3 T4,T6 B2,B4
C2806 18 T3 M2 T2 B4 B1
C4201 18 T1,M5,B5 T3,M3,B3 T6,M2,B3 T4,B6 T5,M4
C4202 18 T1,M3,B5 T3,M2,B3 T6,M1,B6 T2,M4 T5,B1
C4203 18 T2,M2,B5 T5,M1,B6 M3,B4 T6,B2 T1,M2
C4204 16 T2,M2,B4 T4,M6,B6T6,M2, M4, B T1,M3 M5, B3
C4207 18 T4,M6,B4 T2,M4,B2 T1,M2 M5,B5 M3
C4208 18 T3,M3,B3 T1,M5,B5 T6,M2,B4 T2,B4 T1,M2,B1
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I: ECM-CELL Bottom 
Sample # of Sections H&E Masson's Desmin vWF Myogenin
C1401 18 T1, M3, B4 T5,M4,B1,B6 T6, M2, B3 T3,M6, B2
C1402 18 T5,M3,B5,B6 T1,M5, T3, M1, B1 T2,M4 T4,M6,B3
C1403 18 T2,M3,B3 T3,M5,B4 M1,B6 T4,M2 T1,M6
C1404 18 T6,M2,B5 T3,M4,B1 T4,M1,B2 T1,M5 T3,M6, B2
C1405 18 T1,M4,B1 T5,M3,B6 T3,M5,B3 B2 T6,M2
C1406 18 T6,M2,B6 T3 T2,B4 T5,M3 T1,B3
C2801 20 T4,T5,M2,M4,B2 T3,M5,B1 T6,B3 T1,M3 M6
C2802 18 T5,T6,M5,B5 T3,M3, T1,M6 M4,B6 T2,M4
C2803 18 T3,M3,B3 T5,B3,B6 T4,M6,B4 T1,M4 B1,B5
C2804 18 T1,M3,B5 T2,M4,B2 T3,M5 T6,M2 M1,B4
C2805 18 T4,M2,B1 T5,M4,B3 T1,B2 T4,T6 M6,B4
C2806 18 T3,M2,B5 T1,M5 M1,B4 M4,B1 T6,M3
C4201 18 T4,M6,B6 T1,M4,M5,B2 T6,M3,B5 M6,B5 T2,M6,B4
C4201-2 18 T3,M3,B3 T1,M5,B2
C4202 18 T1,M3,B3 T5,M1,B1 T6,M4,B4 T4,M4 T3,M5,M6,B5
C4203 20 T6,M5,B2,B7 T5,M2,B1 T7 T2,B5 T3, M6, B3
C4204 18 T5,M1,B1 T1,T3,M5,B5 T6,M3,B3 T2,B2 T2, M6, B4
C4207 18 T1,T2,M3,B3 T5,B1,B3,B6 T6, M2, B2 M4,M5 T3, M6, B4
C4208 20 T7, M3, B2 T1,T2,M1 T6, M2, B3 M1 T4, M6, B4  
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VI: Masson’s Trichrome Sections: Red Stained Area 
A. ECM-ONLY 14 Day Recovery 
Slide % red
M1406 Top M1 10x Trichrome 5.3
M1406 Top T1 10x Trichrome 11.0
M1406 Top T1 10x Trichrome.2 11.5
M1407 Top T2 10x Trichrome 5.2
M1407 Top M6 10x Trichrome 7.6
M1408 Top T1 10x Trichrome 12.5
M1408 Top B6 10x Trichrome 11.1
M1409 Top M7 10x trichrome 21.4
M1409 Top M7 10x trichrome.2 16.3
M1409 Top T7 10x trichrome 10.2
M1409 Top T7 10x trichrome.2 19.6
M1410 Top B6 10x Trichrome 19.9
M1410 Top M4 10x Trichrome 13.2
M1410 Top T2 10x Trichrome 13.8
M1411 Top T1 10x Trichrome 8.2
M1411 Top B3 10x Trichrome 10.6
M1406 Mid M6 10x Trichrome 4.7
M1406 Mid B6 10x Trichrome 2.8
M1407 Mid T1 10x Trichrome 1.8
M1407 Mid B2 10x Trichrome 2.5
M1408 Mid T6 10x Trichrome 2.9
M1408 Mid B3 10x Trichrome 1.2
M1409 mid T4 10x Trichrome 2.7
M1409 Mid M6 10x Trichrome 0.9
M1409 Mid B3 10x Trichrome 1.8
M1410 Mid T1 10x Trichrome 2.8
M1410 Mid B2 10x Trichrome 5.1
M1411 Mid M1 10x Trichrome 6.4
M1411 Mid B6 10x Trichrome 8.5
M1406 Bot M1 10x Trichrome 6.1
M1406 Bot T1 10x Trichrome 6.8
M1407 Bot M1 10x Trichrome 8.5
M1407 Bot M6 10x Trichrome 2.3
M1408 Bot B7 10x trichrome 12.0
M1408 Bot B7 10x trichrome.2 8.9
M1408 Bot M1 10x trichrome 13.9
M1408 Bot M1 10x trichrome.2 10.2
M1408 Bot M6 10x Trichrome 9.5
M1409 Bot B1 10x Trichrome 10.1
M1409 Bot M5 10x trichrome 9.2
M1409 Bot T3 10x trichrome 4.2
M1410 Bot B1 10x Trichrome 11.1
M1410 Bot B2 10x trichrome 9.0
M1410 Bot M1 10x trichrome 9.8
M1411 Bot B2 10x Trichrome 16.9
M1411 Bot B5 10x trichrome 13.0
M1411 Bot T2 10x trichrome 7.2
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B. ECM-ONLY 28 Day Recovery 
Slide % red
M2811 Top M4 10x Trichrome 10.3
M2811 Top M3 10x Trichrome 10.3
M2811 Top B22 10x Trichrome 11.5
M2812 Top B1 10x Trichrome 8.8
M2812 Top B4 10x Trichrome 22.7
M2812 Top T3 10x Trichrome 11.4
M2812 Top B1 10x Trichrome 25.6
M2813 Top B3 10x Trichrome 11.5
M2813 Top B5 10x Trichrome 6.8
M2813 Top M5 10x Trichrome 16.0
M2814 Top M2 10x Trichrome 12.7
M2814 Top M3 10x Trichrome 10.6
M2814 Top T1 10x Trichrome 14.0
M2815 Top M2 10x Trichrome 18.7
M2815 Top T3 10x Trichrome 11.8
M2815 Top T7 Trichrome 10x 12.3
M2816 Top T1 10x Trichrome 10.6
M2816 Top B4 10x Trichrome 13.0
M2811 Mid B6 10x Trichrome 2.7
M2811 Mid M1 10x trichrome 1.1
M2811 Mid T4 10x trichrome 0.7
M2812 Mid T3 10x Trichrome 2.2
M2812 Mid M5 10x Trichrome 3.3
M2813 Mid M2 10x Trichrome 4.6
M2813 Mid B4 10x Trichrome 2.1
M2814 Mid M6 10x Tricrhome 3.4
M2814 Mid B2 10x Trichrome 1.2
M2815 mid B5 10x trichrome 3.1
M2815 mid T5 10x trichrome 2.0
M2816 Mid B3 10x Trichrome 4.6
M2811 Bot M1 10x trichrome 8.8
M2811 Bot M3 10x Trichrome 12.0
M2811 Bot T3 10x Trichrome 4.5
M2812 Bot B1 10x Trichrome 10.6
M2812 Bot T3 10x Trichrome 14.0
M2812 Bot M1 10x Trichrome 12.4
M2813 Bot B5 10x Trichrome 13.9
M2813 Bot T1 10x Trichrome 7.7
M2814 Bot B5 10x Trichrome 6.6
M2815 Bot B1 Trichrome 10x 11.6
M2815 Bot M1 10x Trichrome 13.2
M2815 Bot T3 Trichrome 10x 6.7
M2816 Bot M1 10x Trichrome 11.0
M2816 Bot B3 10x Trichrome 6.6
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C. ECM-ONLY 42 Day Recovery 
Slide % red
M4201 Top B4 10x trichrome 9.3
M4201 Top B4 10x trichrome.2 20.6
M4201 Top M4 10x trichrome 11.2
M4201 Top M4 10x trichrome.2 20.2
M4201 Top T5 10x trichrome 19.6
M4201 Top T5 10x trichrome.2 25.3
M4202 Top B2 10x trichrome B2 9.5
M4202 Top M4 10 x Trichrome 5.7
M4202 Top T2 10x Trichrome 11.7
M4203 Top M5 10x trichrome 3.9
M4204 Top B2 10x trichrome 6.1
M4204 Top B5 10x trichrome 12.2
M4204 Top M4 10x trichrome 16.0
M4204 Top T5 10x trichrome 14.1
M4205 Top T1 10x trichrome 16.0
M4205 Top T5 10x Trichrome 15.4
M4205 Top M1 10x trichrome 10.2
M4206 Top M5 10x Trichrome 19.7
M4207 Top M6 10x trichrome 13.2
M4207 Top B5 10x Trichrome 10.5
M4208 Top M5 10x Trichrome 8.6
M4208 Top B5 10x Trichrome 9.0
M4209 Top M4 10x Trichrome 8.4
M4201 Mid T3 10x Trichrome 8.1
M4201 Mid M5 10x Trichrome 7.4
M4202 Mid B5 10x Trichrome 19.5
M4202 Mid B5 10x Trichrome 17.4
M4202 Mid M3 10x Trichrome 19.8
M4203 Mid T3 10x Trichrome 5.6
M4203 Mid M1 10x Trichrome 5.3
M4204 Mid T4 10x Trichrome 6.2
M4204 Mid M3 10x Trichrome 7.1
M4206 Mid T1 10x Trichrome 12.8
M4206 Mid M1 10x Trichrome 11.7
M4207 Mid M4 10x trichrome 3.9
M4208 Mid B3 10x trichrome 3.3
M4208 Mid B3 10x trichrome.2 3.2
M4208 Mid M3 10x trichrome 4.3
M4208 Mid T3 10x trichrome 2.1
M4201 Bot B1 10x trichrome 19.5
M4201 Bot T1 10x Trichrome 17.2
M4202 Bot T2 10x Trichrome 13.3
M4204 Bot B4 10x trichrome 4.9
M4204 Bot M4 10x trichrome 10.9
M4204 Bot T2 10x trichrome 10.8
M4205 Bot B1 10x Trichrome 13.5
M4205 Bot M5 10x trichrome 12.1
M4205 Bot T4 10x trichrome 11.3
M4206 Bot M2 10x trichrome 14.3
M4207 Bot B5 10x trichrome 11.2
M4207 Bot M3 10x Trichrome 13.2
M4207 Bot T1 10x Trichrome 5.0
M4209 Bot B5 10x trichrome 11.6
M4209 Bot M4 10x trichrome 19.4
M4209 Bot M4 10x trichrome.2 6.8
M4209 Bot T1 10x trichrome 5.6
M4209 Bot T1 10x trichrome.2 11.7
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D. ECM-CELL 14 Day Recovery 
Slide % red
C1401 Top B5 10x trichrome 15.7
C1401 Top T2 10x trichrome 10.5
C1401 Top T4 10x trichrome 11.0
C1402 Top T2 10x trichrome 5.7
C1402 Top T4 10x trichrome 3.3
C1402 Top T7 10x trichrome 4.4
C1403 Top B4 10x Trichrome 10.9
C1403 Top M5 10x Trichrome 9.6
C1403 Top T3 10x Trichrome 7.0
C1404 Top T4 10x Trichrome 10.4
C1404 Top M6 10x Trichrome 14.7
C1404 Top B3 10x Trichrome 18.2
C1405 Top B5 10x Trichrome 17.7
C1405 Top M5 10x trichrome 13.3
C1405 Top T4 10x trichrome 15.4
C1406 Top T1 10x Trichrome 9.4
C1406 Top M1 10x Trichrome 11.8
C1401 Mid 10x B4 trichrome 22.5
C1401 Mid 10x B4 trichrome.2 7.9
C1401 Mid T1 10x Trichrome 3.7
C1401 Mid M4 10x Trichrome 10.3
C1402 Mid T4 10x Trichrome 5.2
C1402 Mid M1 10x Trichrome 3.3
C1403 Mid T3 10x Trichrome 4.6
C1403 Mid B4 10x Trichrome 4.2
C1404 Mid M3 10x Trichrome 13.9
C1404 Mid T1 10x Trichrome 11.0
C1404 Mid B7 10x Trichrome 4.1
C1405 Mid T2 10x Trichrome 8.7
C1405 Mid M2 10x Trichrome 10.5
C1405 Mid B5 10x Trichrome 8.0
C1406 Mid T1 10x Trichrome 5.1
C1406 Mid M1 10x Trichrome 10.5
C1406 Mid M1 10x Trichrome.2 1.8
C1401 Bot B6 Trichrome 10x 17.1
C1401 Bot M4 Trichrome 10x 9.1
C1401 Bot T5 Trichrome 10x 20.3
C1402 Bot M5 10x Trichrome 6.7
C1402 Bot M5 10x.2 Trichrome 5.1
C1402 Bot T1 Trichrome 10x 14.4
C1403 Bot T3 10x Trichome 10.5
C1403 Bot M5 10x Trichome 7.1
C1403 Bot B4 10x Trichome 11.4
C1404 Bot T3 10x Trichrome 16.9
C1404 Bot M4 10x Trichrome 21.3
C1404 Bot B1 10x Trichrome 18.3
C1405 Bot T5 10x Trichrome 11.7
C1405 Bot M3 10x Trichrome 14.0
C1405 Bot B6 10x Trichrome 12.7
C1406 Bot T3 10x Trichrome 6.5
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E. ECM-CELL 28 Day Recovery 
Slide % red
C2802 Top B2 10x trichrome 11.4
C2802 Top M3 10x trichrome 23.6
C2803 Top B1 10x trichrome 36.7
C2803 Top B2 10x trichrome 15.0
C2803 Top B6 10x trichrome 20.3
C2803 Top B6 10x trichrome.2 17.6
C2803 Top M5 10x trichrome 12.2
C2803 Top M5 10x trichrome.3 22.6
C2803 Top M6 10x trichrome 28.8
C2803 Top T3 10x trichrome 25.8
C2803 Top T5 10x trichrome 19.9
C2804 Top T3 10x Trichrome 10.3
C2804 Top M2 10x trichrome 13.2
C2804 Top B6 10x trichrome 21.2
C2805 Top B3 10x trichrome 8.4
C2805 Top B3 10x trichrome.2 12.3
C2805 Top B3 10x trichrome.3 8.3
C2805 Top T5 10x Trichrome 10.1
C2806 Top M2 10x trichrome 6.7
C2806 Top T6 10x trichrome 3.4
C2801 Mid B5 10x trichrome 4.5
C2801 Mid M1 10x trichrome 4.2
C2801 Mid M1 10x trichrome 2 8.8
C2801 Mid T3 10x Trichrome 4.1
C2802 Mid M5 10x Trichrome 4.7
C2802 Mid B4 10x Trichrome 6.2
C2802 Mid T5 10x trichrome 5.2
C2803 mid B2 10x trichrome 19.2
C2803 Mid M2 10x Trichrome 13.4
C2803 Mid T2 10x Trichrome 2.7
C2805 Mid T5 10x Trichrome 7.9
C2805 Mid M4 10x Trichrome 2.3
C2805 Mid B3 10x Trichrome 3.0
C2806 Mid M2 10x Trichrome 8.6
C2801 Bot M5 10x Trichrome 12.9
C2801 Bot T3 10x trichrome 7.0
C2802 Bot T3 10x trichrome 12.7
C2802 Bot M3 10x trichrome 17.2
C2803 Bot T5 10x trichrome 11.0
C2803 Bot B3 10x trichrome 11.8
C2803 Bot B6 10x trichrome 17.2
C2804 Bot T2 10x trichrome 6.0
C2804 Bot M4 10x trichrome 7.5
C2804 Bot B2 10x Trichrome 6.9
C2805 Bot T5 10x Trichrome 11.1
C2805 Bot M4 10x Trichrome 12.6
C2805 Bot B3 10x Trichrome 11.1
C2806 Bot T1 10x Trichrome 14.7
C2806 Bot M5 10x Trichrome 17.1
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F. ECM-CELL 42 Day Recovery 
Slide % red
C4201 Top B3 10x Trichrome 17.1
C4201 Top T1 trichrome 10x 14.1
C4201 Top T1 trichrome 10x.2 27.0
C4201 Top M6 10x trichrome 21.5
C4202 Top B4 10x Trichrome 19.3
C4203 Top B5 10x trichrome 28.3
C4203 Top M5 10x trichrome 25.6
C4203 Top T2 10x trichrome 20.0
C4203 Top T2 trichrome 10x 9.6
C4204 Top B6 10x trichrome 11.1
C4204 Top M6 10x trichrome 13.6
C4204 Top T4 10x trichrome 15.1
C4207 Top B4 10x trichrome.2 50.0
C4207 Top M3 10x Trichrome 10.7
C4207 Top M3 10x Trichrome.2 34.3
C4207 Top T4 10x Trichrome 6.6
C4208 Top M4 10x Trichrome 20.3
C4208 Top M6 10x Trichrome 15.4
C4208 Top T1 10x Trichrome 14.6
C4201 Mid B3 10x Trichrome 11.6
C4201 Mid B3 10x Trichrome.2 15.2
C4201 Mid M3 10x Trichrome 19.8
C4201 Mid T3 10x Trichrome 15.8
C4202 Mid B3 10x trichrome 5.9
C4202 Mid M2 10x trichrome.2 4.0
C4202 Mid M2 10x trichrome.4 8.5
C4202 Mid T3 10x trichrome 23.9
C4203 Mid B6 10x trichrome 8.4
C4203 Mid B6 10x trichrome.2 16.3
C4203 Mid T5 10x trichrome 13.8
C4204 Mid T4 10x trichrome 11.0
C4204 Mid B6 10x trichrome 5.8
C4207 Mid B2 10x Trichrome 5.2
C4207 Mid M4 10x Trichrome 4.1
C4207 Mid M4 10x Trichrome 4.7
C4207 Mid T2 10x trichrome 7.0
C4208 Mid T1 10x trichrome 13.3
C4208 Mid B5 10x trichrome 3.5
C4208 Mid M5 10x Trichrome 4.3
C4201 Bot M4 10x Trichrome 25.1
C4201 Bot M5 10x Trichrome 24.3
C4201 Bot B2 10x trichrome 21.4
C4201 Bot M5 10x trichrome 14.2
C4201 Bot T1 10x trichrome 17.8
C4202 Bot B1 10x trichrome 11.3
C4202 Bot M1 10x trichrome 16.3
C4202 Bot T5 10x trichrome 11.8
C4203 Bot B1 10x trichrome 8.9
C4203 Bot M2 10x trichrome 20.8
C4203 Bot T5 10x trichrome 7.0
C4204 Bot B5 10x Trichrome 3.9
C4204 Bot M5 10x Trichrome 15.7
C4204 Bot T1 10x trichrome 16.4
C4204 Bot T3 10x Trichrome 16.3
C4204 Bot T3 10x Trichrome.2 18.7
C4207 Bot B1 10x Trichrome 22.2
C4207 Bot B6 10x Trichrome 26.0
C4207 Bot T5 10x Trichrome 16.6
C4208 Bot M1 10x Trichrome 17.9
C4208 Bot T1 10x Trichrome 21.3
C4208 Bot T2 10x Trichrome 25.7
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VII. Von Willebrand Factor Stained Sections: Blood Vessels 
A. ECM-ONLY 14 Day Recovery  
Slide
Area of interest 
(mm2)
# of Blood 
Vessels BV/mm2
M1406 Top B5 10x vWF 1.001 14 13.99
M1408 Top T4 10x vWF 1.088 12 11.03
M1410 Top M2 10x vWF 0.959 9 9.39
M1410 Top B1 10x vWF 1.003 15 14.96
M1411 Top T2 10x vWF 0.899 5 5.56
M1411 Top M3 10x vWF 0.949 9 9.48
M1411 Top B2 10x vWF 0.910 9 9.89
M1406 Mid M1 10x vWF 1.005 13 12.94
M1406 Mid M6 10x vWF 1.036 9 8.69
M1407 Mid M5 10x vWF 1.115 9 8.07
M1407 Mid B1 10x vWF 1.099 12 10.92
M1408 Mid T1 10x vWF 0.984 3 3.05
M1409 Mid M5 10x vWF 0.977 7 7.16
M1409 Mid B4 10x vWF 0.934 9 9.63
M1410 Mid B5 10x vWF 1.082 4 3.70
M1411 Mid T2 10x vWF 1.022 8 7.83
M1411 Mid B5 10x vWF 1.001 9 8.99
M1406 Bot M4 10x vWF 1.113 38 34.14
M1406 Bot T2 10x vWF 0.897 27 30.10
M1407 Bot T6 10x vWF 1.136 14 12.32
M1407 Bot M6 10x vWF 1.129 10 8.85
M1408 Bot T1 10x vWF 0.803 12 14.94
M1408 Bot T1 10x vWF 0.769 6 7.80
M1409 Bot B6 10x vWF 0.928 17 18.31
M1409 Bot B6 10x vWF 0.938 25 26.64
M1409 Bot T2 10x vWF 1.083 4 3.69
M1409 Bot T2 10x vWF 1.117 3 2.69
M1411 Bot T6 10x vWF 0.685 12 17.51
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B. ECM-ONLY 28 Day Recovery  
Slide
Area of interest 
(mm2)
# of Blood 
Vessels BV/mm2
M2811 Top B3 10x vWF 0.748 3 4.01
M2812 Top T6 10x vWF 1.082 17 15.72
M2812 Top M5 10x vWF 0.961 10 10.41
M2812 Top M5 10x vWF 1.024 26 25.39
M2812 Top T6 10x vWF 1.070 19 17.76
M2812 Top T6 10x vWF 1.096 12 10.95
M2813 Top M5 10x vWF 0.796 22 27.63
M2814 Top T2 10x vWF 1.056 10 9.47
M2815 Top B5 10x vWF 1.116 13 11.65
M2815 Top T1 10x vWF 1.104 22 19.93
M2815 Top B5 10x vWF 1.104 20 18.11
M2816 Top M4 10x vWF 1.108 19 17.14
M2816 Top B1 10x vWF 1.098 18 16.40
M2811 Mid B4 10x vWF 1.076 7 6.50
M2811 Mid B4 10x vWF 1.104 22 19.94
M2811 Mid T6 10x vWF 1.011 7 6.92
M2812 Mid T4 10x vWF 1.061 9 8.48
M2812 Mid T4 10x vWF 1.035 1 0.97
M2812 Mid M2 10x vWF 1.045 27 25.84
M2813 Mid T6 10x vWF 1.009 7 6.94
M2813 Mid M1 10x vWF 1.117 16 14.33
M2813 Mid B1 10x vWF 1.003 19 18.94
M2814 Mid B5 10x vWF 1.018 10 9.82
M2815 mid B4 10x vWF 1.049 0 0.00
M2815 mid B4 10x vWF 1.083 10 9.24
M2815 Mid M2 10x vWF 0.984 1 1.02
M2815 mid M2 10x vWF 1.081 11 10.18
M2815 mid T4 10x vWF 1.064 1 0.94
M2815 Mid T4 10x vWF 1.068 14 13.11
M2816 Mid T5 10x vWF 1.060 5 4.72
M2816 Mid M6 10x vWF 1.090 12 11.01
M2811 Bot M4 10x vWF 0.905 19 20.98
M2811 Bot B5 10x vWF 0.938 31 33.03
M2811 Bot B6 10x vWF 1.035 25 24.15
M2812 Bot B2 10x vWF 1.064 6 5.64
M2812 Bot B2 10x vWF 1.068 12 11.23
M2812 Bot B2 10x vWF 1.078 5 4.64
M2812 Bot M4 10x vWF 1.063 9 8.46
M2812 Bot M4 10x vWF 1.107 4 3.61
M2812 Bot T6 10x vWF 1.095 18 16.44
M2812 Bot T6 10x vWF 1.096 12 10.95
M2813 Bot T2 10x vWF 1.091 24 21.99
M2814 Bot B4 10x vWF 1.020 21 20.59
M2814 Bot M6 10x vWF 1.073 20 18.63
M2814 Bot M6 10x vWF 1.079 15 13.90
M2815 Bot T5 10x vWF 1.096 20 18.25
M2816 Bot M4 10x vWF 1.059 20 18.88
M2816 Bot B1 10x vWF 1.029 16 15.55
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C. ECM-ONLY 42 Day Recovery  
Slide
Area of interest 
(mm2)
# of Blood 
Vessels BV/mm2
M4201 Top B1 10x vWF 0.949 7 7.38
M4201 Top T3 10x vWF 0.739 6 8.11
M4202 Top M4 10x vWF 0.991 11 11.10
M4202 Top B3 10x vWF 0.884 9 10.19
M4203 Top M4 10x vWF 1.025 16 15.61
M4204 Top T1 10x vWF 0.952 20 21.01
M4204 Top M3 10x vWF 1.005 19 18.90
M4205 Top T3 10x vWF 1.103 14 12.69
M4205 Top B1 10x vWF 1.088 21 19.30
M4207 Top B1 10x vWF 1.092 17 15.56
M4208 Top T2 10x vWF 1.079 20 18.54
M4208 Top B2 10x vWF 0.955 13 13.61
M4208 Top T2 10x vWF 0.649 5 7.70
M4208 Top T2 10x vWF 1.056 11 10.41
M4201 Mid M4 10x vWF 0.831 3 3.61
M4202 Mid M4 10x vWF 0.967 4 4.14
M4202 Mid M4 10x vWF 0.989 11 11.12
M4202 Mid T2 10x vWF 0.908 5 5.51
M4203 Mid B1 10x vWF 1.000 16 15.99
M4203 Mid M2 10x vWF 1.020 12 11.77
M4204 Mid T1 10x vWF 1.066 15 14.07
M4204 Mid B5 10x vWF 1.071 14 13.07
M4207 Mid T1 10x vWF 1.099 11 10.01
M4207 Mid B6 10x vWF 1.044 13 12.45
M4208 Mid M2 10x vWF 0.938 4 4.27
M4208 Mid T2 10x vWF 0.923 13 14.08
M4202 Bot B3 10x vWF 0.9429 6 6.36
M4202 Bot T5 10x vWF 1.0138 1 0.99
M4203 Bot B2 10x vWF 1.0812 32 29.60
M4203 Bot B2 10x vWF 1.1155 41 36.76
M4203 Bot M4 10x vWF 1.0999 24 21.82
M4203 Bot M4 10x vWF 1.1041 22 19.93
M4203 Bot M4 10x vWF 1.1361 29 25.53
M4204 Bot B2 10x vWF 1.0940 32 29.25
M4205 Bot T5 10x vWF 1.0802 9 8.33
M4206 Bot M1 10x vWF 0.8577 17 19.82
M4206 Bot T1 10x vWF 0.4435 5 11.27
M4207 Bot B6 10x vWF 1.1186 23 20.56
M4207 Bot B6 10x vWF 1.1361 35 30.81
M4207 Bot T2 10x vWF 1.0550 29 27.49
M4207 Bot T2 10x vWF 1.0543 32 30.35
M4207 Bot T2 10x vWF 1.0702 24 22.43
M4208 Bot B1 10x vWF 1.0727 3 2.80
M4208 Bot T3 10x vWF 0.9689 19 19.61
M4208 Bot T3 10x vWF 0.9793 27 27.57
M4209 Bot M1 10x vWF 1.1257 17 15.10
M4209 Bot M1 10x vWF 1.0120 31 30.63
M4209 Bot B6 10x vWF 1.1186 15 13.41
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D. ECM-CELL 14 Day Recovery 
Slide
Area of interest 
(mm2)
# of Blood 
Vessels BV/mm2
C1401 Top B6 10x vWF 1.100 10 9.09
C1401 Top B6 10x vWF 1.078 13 12.06
C1401 Top T7 10x vWF 1.084 27 24.91
C1401 Top T7 10x vWF 1.071 34 31.76
C1403 Top M2 10x vWF 1.077 27 25.08
C1403 Top M2 10x vWF 1.057 16 15.14
C1403 Top T4 10x vWF 1.075 31 28.83
C1403 Top T4 10x vWF 1.071 32 29.89
C1403 Top T4 10x vWF 1.080 34 31.49
C1404 Top B4 10x vWF 1.063 19 17.88
C1405 Top B2 10x vWF 1.102 40 36.30
C1405 Top B2 10x vWF 1.094 30 27.43
C1405 Top B2 10x vWF 1.108 28 25.28
C1405 Top M2 10x vWF 1.088 43 39.52
C1405 Top M2 10x vWF 1.081 31 28.69
C1406 Top T2 10x vWF 1.050 14 13.34
C1406 Top M4 10x vWF 1.047 13 12.41
C1401 Mid B6 10x vWF 1.039 11 10.58
C1401 Mid M6 10x vWF 1.125 4 3.56
C1401 Mid M6 10x vWF 1.091 6 5.50
C1402 Mid M1 10x vWF 0.982 6 6.11
C1402 Mid B5 10x vWF 0.895 3 3.35
C1403 Mid M2 10x vWF 1.047 13 12.42
C1403 Mid T4 10x vWF 1.076 18 16.73
C1404 Mid T6 10x vWF 1.032 4 3.88
C1405 Mid M6 10x vWF 1.083 12 11.08
C1405 Mid T1 10x vWF 1.083 14 12.92
C1406 Mid M4 10x vWF 1.078 3 2.78
C1402 Bot M4 10x vWF 1.018 22 21.60
C1402 Bot M4 10x vWF 1.021 17 16.66
C1402 Bot T2 10x vWF 0.974 7 7.19
C1402 Bot T2 10x vWF 1.023 16 15.63
C1403 Bot M2 10x vWF 0.995 26 26.13
C1403 Bot T4 10x vWF 1.028 16 15.56
C1404 Bot T1 10x vWF 0.948 10 10.55
C1404 Bot M5 10x vWF 0.988 11 11.13
C1405 Bot B2 10x vWF 1.004 15 14.94
C1406 Bot T5 10x vWF 1.036 14 13.52
C1406 Bot M3 10x vWF 1.029 19 18.47
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E. ECM-CELL 28 Day Recovery  
Slide
Area of interest 
(mm2)
# of Blood 
Vessels BV/mm2
C2801 Top B1 10x vWF 1.012 25 24.69
C2801 Top T6 10x vWF 1.043 30 28.76
C2802 Top M4 10x vWF 0.998 25 25.04
C2802 Top B1 10x vWF 0.998 23 23.04
C2803 Top T2 10x vWF 1.006 13 12.93
C2804 Top M4 10x vWF 1.100 11 10.00
C2804 Top T2 10x vWF 1.114 13 11.67
C2805 Top T4 10x vWF 1.115 48 43.04
C2805 Top T4 10x vWf 1.037 31 29.91
C2805 Top T6 10x vWF 1.136 13 11.44
C2806 Top B4 10x vWF 1.131 4 3.54
C2806 Top M4 10x vWF 0.906 23 25.38
C2806 Top M4 10x vWF 0.967 15 15.51
C2801 Mid M6 10x vWF 0.929 23 24.75
C2801 Mid M6 10x vWF 0.926 18 19.45
C2801 Mid M6 10x vWF 0.964 20 20.75
C2801 Mid T4 10x vWF 0.949 17 17.92
C2802 Mid B6 10x vWF 0.925 19 20.54
C2802 Mid B6 10x vWF 1.038 19 18.30
C2802 Mid B6 10x vWF 1.030 18 17.48
C2802 Mid T6 10x vWF 1.136 7 6.16
C2803 Mid M2 10x vWF 1.120 9 8.03
C2803 Mid M6 10x vWF 1.025 7 6.83
C2803 Mid T1 10x vWF 1.001 4 4.00
C2805 Mid T4 10x vWF 0.998 8 8.01
C2805 Mid T6 10x vWF 1.004 6 5.98
C2806 Mid B4 10x vWF 0.925 7 7.56
C2801 Bot T1 10x vWF 1.000 13 12.99
C2801 Bot M3 10x vWF 0.993 11 11.08
C2802 Bot M4 10x vWF 0.995 14 14.08
C2802 Bot B6 10x vWF 1.049 25 23.83
C2802 Bot B6 10x vWF 1.136 20 17.60
C2802 Bot M4 10x vWF 1.121 7 6.25
C2803 Bot T1 10x vWF 1.046 11 10.51
C2803 Bot M4 10x vWF 1.061 13 12.25
C2804 Bot M2 10x vWF 0.979 19 19.41
C2805 Bot T4 10x vWF 0.973 7 7.19
C2805 Bot T6 10x vWF 0.990 12 12.12
C2806 Bot M4 10x vWF 1.087 18 16.55
C2806 Bot B1 10x vWF 1.003 6 5.98
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F. ECM-CELL 42 Day Recovery 
Slide
Area of interest 
(mm2)
# of Blood 
Vessels BV/mm2
C4201 Top M4 10x vWF 0.961 29 30.16
C4201 Top B1 10x vWF 0.980 31 31.63
C4202 Top B6 10x vWF 0.951 15 15.77
C4203 Top T3 10x vWF 1.001 36 35.95
C4204 Top T1 10x vWF 0.880 16 18.17
C4204 Top M3 10x vWF 0.929 14 15.07
C4204 Top M3 10x vWF 0.949 15 15.81
C4204 Top T1 10x vWF 0.731 10 13.69
C4207 Top B6 10x vWF 1.091 37 33.90
C4207 Top T1 10x vWF 1.070 29 27.10
C4207 Top B1 10x vWF 1.084 38 35.07
C4208 Top M5 10x vWF 1.036 24 23.16
C4201 Mid T4 10x vWF 0.991 16 16.14
C4201 Mid B6 10x vWF 1.006 11 10.93
C4202 Mid T2 10x vWF 1.040 10 9.61
C4202 Mid M4 10x vWF 1.033 9 8.71
C4203 Mid B2 10x vWF 1.066 10 9.38
C4204 Mid M4 10x vWF 0.871 8 9.18
C4207 mid B5 10x vWF 1.107 20 18.07
C4207 Mid M5 10x vWF 1.063 16 15.06
C4207 Mid M5 10x vWF 1.072 19 17.72
C4208 Mid B4 10x vWF 1.065 11 10.33
C4208 Mid B2 10x vWF 1.014 15 14.79
C4201Bot M6 10x vWF 0.881 29 32.92
C4201 Bot B5 10x vWF 0.901 33 36.64
C4202 Bot M4 10x vWF 0.754 36 47.73
C4202 Bot M4 10x vWF 1.059 30 28.34
C4202 Bot T4 10x vWF 1.088 24 22.06
C4203 Bot T2 10x vWF 1.050 26 24.76
C4203 Bot B2 10x vWF 1.074 45 41.89
C4204 Bot B2 10x vWF 1.080 33 30.55
C4204 Bot T2 10x vWF 1.016 21 20.68
C4207 Bot M4 10x vWF 1.004 24 23.91
C4207 Bot M5 10x vWF 1.001 20 19.99
C4208 Bot M1 10x vWF 1.010 38 37.64  
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VIII: Desmin  Stained Sections: Desmin Positive Area 
A. ECM-ONLY 14 Day Recovery 
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Slide
% Area Desmin 
Positive
M1406 TOP M2 01 5.2
M1406 TOP B2 01 10.0
M1407 TOP T6 01 3.3
M1407 TOP B3 01 6.5
M1408 TOP M2 01 3.1
M1408 TOP T6 01 7.1
M1409 TOP M3 01 8.3
M1409 TOP T6 01 9.3
M1410 TOP T5 02 23.9
M1410 TOP M2 02 23.0
M1410 TOP B3 01 10.0
M1410 TOP B3 02 3.0
M1411 TOP T6 01 4.7
M1411 TOP B4 01 10.0
M1406 MID T4 01 2.2
M1406 MID B5 01 1.2
M1406 MID B5 02 3.4
M1407 MID T3 01 4.2
M1407 MID M2 01 1.2
M1408 MID B4 01 0.4
M1409 MID T6 01 1.0
M1409 MID M2 01 1.0
M1409 MID B2 01 1.6
M1410 MID M4 01 3.7
M1410 MID B6 01 4.3
M1411 MID T3 01 6.3
M1411 MID M4 01 5.5
M1406 BOT B1 02 18.0
M1406 BOT T5 01 7.9
M1407 BOT T3 01 2.6
M1407 BOT M2 01 5.3
M1408 BOT B4 01 6.7
M1408 BOT B4 02 1.4
M1409 BOT B3 02 15.5
M1409 BOT M3 02 5.4
M1409 BOT T5 02 14.0
M1410 BOT M4 01 12.8
M1410 BOT B6 01 6.8
M1411 BOT T3 01 7.5
B. ECM-ONLY 28 Day Recovery 
Slide
% Area Desmin 
Positive
M2811 TOP T5 01 7.8
M2811 TOP M2 01 11.0
M2812 TOP M1 01 20.9
M2812 TOP M1 02 15.9
M2812 TOP M1 03 12.3
M2813 TOP T2 01 10.4
M2814 TOP B2 02 22.2
M2814 TOP B3 01 12.9
M2814 TOP M1 01 6.7
M2814 TOP T6 01 6.4
M2815 TOP B2 01 8.0
M2815 TOP B2 01 8.4
M2815 TOP M4 01 7.0
M2815 TOP M4 02 9.3
M2815 TOP T5 01 5.3
M2816 TOP T6 01 9.8
M2816 TOP M2 01 11.9
M2811 MID T3 01 3.8
M2811 MID T3 02 1.2
M2813 MID T3 01 2.3
M2813 MID M3 01 6.3
M2813 MID B3 01 5.4
M2814 MID T1 01 0.7
M2814 MID B6 01 1.6
M2815 MID M2 01 1.9
M2815 MID B5 01 4.4
M2816 MID T4 01 1.1
M2816 MID B4 01 2.1
M2811 BOT M5 01 7.8
M2811 BOT M5 02 7.1
M2811 BOT T6 01 15.4
M2811 BOT T6 01 24.7
M2812 BOT B3 02 15.4
M2812 BOT M3 02 15.8
M2812 BOT M3 03 7.5
M2812 BOT T5 01 6.6
M2812 BOT T5 02 11.4
M2813 BOT B3 01 11.0
M2813 BOT T6 01 9.5
M2814 BOT B3 01 20.2
M2814 BOT B3 02 14.9
M2814 BOT M3 01 7.8
M2814 BOT M3 02 8.3
M2814 BOT T5 01 6.1
M2815 BOT M2 01 9.4
M2815 BOT T6 01 10.3
M2816 BOT T6 01 3.6
M2816 BOT M2 01 6.4
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C. ECM-ONLY 42 Day Recovery 
Slide
% Area Desmin 
Positive
M4201 TOP B3 01 23.2
M4201 TOP B6 03 10.8
M4201 TOP M5 01 6.5
M4201 TOP M5 02 17.9
M4201 TOP T6 02 21.1
M4202 TOP T6 01 11.1
M4203 TOP T3 01 6.8
M4203 TOP M2 01 7.7
M4203 TOP B3 01 7.1
M4204 TOP M2 01 8.8
M4204 TOP T6 01 10.9
M4205 TOP T6 01 12.4
M4205 TOP M2 01 16.6
M4205 TOP B5 01 18.1
M4206 TOP T5 01 13.5
M4206 TOP T5 02 11.7
M4207 TOP T2 01 7.7
M4207 TOP M2 01 7.6
M4208 TOP M4 01 9.6
M4208 TOP B3 01 7.4
M4201 MID T6 01 3.8
M4201 MID B5 01 5.5
M4203 MID T6 01 1.3
M4203 MID M3 01 3.5
M4204 MID B4 01 6.1
M4206 MID T6 01 6.2
M4206 MID M2 01 8.1
M4206 MID B3 01 7.5
M4207 MID B2 01 0.9
M4208 MID M5 01 5.7
M4208 MID B6 01 2.5
M4201 BOT B3 01 10.5
M4201 BOT M2 01 18.6
M4201 BOT M2 02 9.1
M4201 BOT T6 01 9.4
M4202 BOT B2 01 13.3
M4202 BOT M2 01 6.4
M4203 BOT M3 01 4.2
M4203 BOT T5 01 6.3
M4204 BOT B3 01 8.5
M4205 BOT M2 01 7.5
M4205 BOT B3 01 9.6
M4206 BOT M3 01 10.1
M4206 BOT B2 01 11.0
M4207 BOT B3 01 18.4
M4207 BOT M2 03 8.8
M4208 BOT B2 01 2.4
M4208 BOT B2 03 7.9
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D. ECM-CELL 14 Day Recovery 
Slide
% Area Desmin 
Positive
C1401 TOP M2 01 7.5
C1401 TOP B3 01 9.3
C1402 TOP T6 01 2.4
C1402 TOP M2 01 5.0
C1403 TOP M1 01 6.2
C1403 TOP B6 01 5.5
C1404 TOP T6 01 19.9
C1404 TOP T6 02 5.1
C1404 TOP M2 01 8.6
C1404 TOP B2 01 10.0
C1405 TOP T1 01 4.0
C1405 TOP M2 01 5.4
C1406 TOP T5 01 3.5
C1406 TOP M2 01 5.5
C1406 TOP B1 01 9.4
C1401 MID M1 01 2.3
C1402 MID T3 01 1.1
C1402 MID B2 01 5.5
C1403 MID M1 01 2.1
C1404 MID T2 01 8.8
C1404 MID M5 01 8.1
C1405 MID T3 01 3.4
C1405 MID B1 01 2.3
C1406 MID T5 01 10.2
C1406 MID B1 01 4.7
C1406 MID B1 02 5.5
C1401 BOT M2 01 18.0
C1402 BOT B1 02 11.8
C1402 BOT M1 01 6.6
C1402 BOT T3 01 5.5
C1403 BOT M1 01 7.4
C1404 BOT M1 01 7.5
C1404 BOT B2 01 19.5
C1404 BOT B2 02 6.3
C1405 BOT M5 01 9.3
C1405 BOT B3 01 5.2
C1406 BOT T2 01 4.5
C1406 BOT B4 01 2.4
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E. ECM-CELL 28 Day Recovery 
Slide
% Area Desmin 
Positive
C2801 TOP M3 01 9.2
C2801 TOP M3 02 15.3
C2801 TOP M3 03 20.5
C2802 TOP T6 01 13.0
C2802 TOP M5 01 12.1
C2803 TOP B4 01 16.6
C2803 TOP M2 01 11.4
C2803 TOP M3 01 8.1
C2803 TOP T6 01 8.6
C2804 TOP T5 01 10.5
C2804 TOP M5 01 16.3
C2804 TOP M5 02 8.5
C2806 TOP B3 01 4.5
C2806 TOP M1 01 16.1
C2806 TOP M1 02 14.5
C2806 TOP M1 03 17.0
C2806 TOP T3 03 19.6
C2801 MID T6 01 7.8
C2801 MID T6 02 2.8
C2801 MID M2 01 6.1
C2801 MID B3 01 3.8
C2802 MID T1 01 2.4
C2802 MID M2 01 6.9
C2803 MID M1 01 6.2
C2803 MID B1 01 13.3
C2805 MID T4 01 3.5
C2805 MID M3 01 11.9
C2805 MID M3 02 1.5
C2806 MID T2 01 6.6
C2801 BOT B3 01 0.6
C2801 BOT M3 02 2.3
C2801 BOT T6 03 11.9
C2801 BOT T6 01 1.7
C2802 BOT T1 01 10.7
C2802 BOT M6 01 12.2
C2803 BOT T4 01 8.6
C2803 BOT M6 01 13.0
C2803 BOT B4 01 18.6
C2804 BOT T3 01 4.0
C2804 BOT M5 01 3.7
C2804 BOT M5 02 11.9
C2805 BOT T1 01 10.6
C2806 BOT M1 01 10.6
C2806 BOT B4 01 12.4
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F. ECM-CELL 42 Day Recovery 
Slide
% Area Desmin 
Positive
C4201 TOP B2 01 20.9
C4201 TOP M3 01 9.7
C4201 TOP M3 02 12.2
C4201 TOP T6 01 20.1
C4201 TOP T6 02 20.3
C4202 TOP B1 02 16.0
C4202 TOP B2 03 11.3
C4202 TOP M2 01 28.4
C4202 TOP M2 02 18.1
C4202 TOP M2 03 49.9
C4202 TOP T6 01 40.2
C4202 TOP T6 02 8.9
C4203 TOP M1 01 10.7
C4203 TOP T6 01 6.3
C4203 TOP T6 02 21.5
C4204 TOP B3 01 20.5
C4204 TOP B3 02 24.6
C4207 TOP M2 01 4.4
C4207 TOP T6 02 10.1
C4207 TOP M2 01 10.3
C4207 TOP T6 03 17.5
C4208 TOP M3 01 17.0
C4201 MID T6 01 11.6
C4201 MID M2 01 8.4
C4201 MID B3 02 7.2
C4202 MID T6 01 8.6
C4202 MID T6 02 11.7
C4202 MID B6 01 10.6
C4203 MID M3 01 6.9
C4203 MID B4 01 11.6
C4204 MID M2 01 3.4
C4204 MID M4 01 6.1
C4204 MID M4 02 4.4
C4207 MID T1 01 7.7
C4207 MID M2 01 5.2
C4208 MID B4 01 8.6
C4201 Bot T6 01 17.2
C4201 Bot B5 01 14.9
C4202 Bot T6 01 13.5
C4202 Bot M4 02 10.7
C4203 BOT T7 01 9.2
C4204 BOT T6 01 11.4
C4204 BOT M4 01 14.2
C4207 BOT B2 01 4.9
C4207 BOT M2 01 4.8
C4208 BOT M2 01 0.6
C4208 BOT M2 02 6.5
C4208 TOP B3 01 13.0  
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IX. Desmin Stained Sections: Desmin Positive Fibers 





M2811 TOP M2 01 0.0680 12 177
M2811 TOP T5 01 0.0850 9 106
M2814 Top B3 01 0.0658 18 273
M2814 Top T6 01 0.0672 14 208
M2814 TOP B3 01 0.1448 41 283
M2815 TOP B2 01 0.1343 30 223
M2816 TOP T6 01 0.0680 12 176
M2816 TOP M2 01 0.1001 19 190
M2811 MID T3 01 0.2701 5 19
M2811 MID T3 02 0.1698 4 24
M2813 MID M3 01 0.1419 3 21
M2813 MID B3 01 0.1931 5 26
M2814 MID B6 01 0.2872 4 14
M2816 MID T4 01 0.1969 3 15
M2816 MID B4 01 0.3379 7 21
M2811 BOT M5 01 0.1624 25 154
M2811 Bot M5 01 0.1048 20 191
M2811 BOT T6 02 0.1622 21 129
M2811 Bot T6 01 0.1064 8 75
M2812 BOT B3 02 0.1334 23 172
M2812 Bot B3 02 0.0775 14 181
M2812 BOT M3 03 0.1870 16 86
M2812 Bot M3 02 0.1102 20 181
M2812 Bot T5 02 0.0999 9 90
M2812 BOT T5 02 0.1874 13 69
M2813 BOT T6 01 0.1942 47 242
M2814 BOT B3 01 0.1283 35 273
M2814 BOT M3 01 0.1698 17 100
M2815 BOT M2 02 0.1692 30 177
M2815 BOT T6 02 0.2678 10 37
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M4201 Top B3 02 0.0643 22 342
M4201 Top T6 02 0.0537 9 168
M4201 TOP T6 02 0.1779 27 152
M4204 TOP M2 01 0.1460 22 151
M4204 Top T6 01 0.1062 23 217
M4204 TOP T6 01 0.1666 46 276
M4205 Top T6 01 0.1108 28 253
M4205 Top M5 01 0.0588 22 374
M4203 MID T6 01 0.1697 5 29
M4203 MID M3 01 0.2689 8 30
M4206 MID M2 01 0.1585 13 82
M4206 MID B3 01 0.1503 10 67
M4208 MID M5 01 0.3366 13 39
M4208 MID B6 01 0.2165 7 32
M4201 BOT B3 01 0.1322 39 295
M4201 BOT M2 01 0.1635 43 263
M4203 BOT M3 01 0.1449 39 269
M4204 Bot B3 02 0.0467 14 300
M4204 BOT B3 01 0.1622 10 62
M4204 BOT B3 02 0.1426 32 224
M4204 BOT M2 01 0.1369 29 212
M4205 BOT B2 01 0.1411 25 177
M4205 Bot B2 01 0.1016 20 197
M4205 BOT B3 04 0.1676 31 185
M4205 BOT M2 01 0.1706 46 270
M4205 BOT T6 01 0.1928 22 114
M4207 BOT B3 01 0.1176 34 289
M4207 BOT M2 03 0.0963 15 156
M4207 Bot M2 03 0.1297 15 116
M4208 BOT B2 01 0.1571 35 223
M4208 BOT B2 03 0.1739 23 132
M4208 BOT M2 01 0.1823 37 203
M4208 BOT T6 01 0.1230 26 211
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C2801 TOP M3 03 0.0815 37 454
C2801 Top M3 02 0.0895 5 56
C2803 TOP T6 01 0.0840 34 405
C2803 Top B4 01 0.0543 12 221
C2803 Top M5 03 2.8141 167 59
C2803 Top T6 01 0.0745 12 161
C2806 TOP T3 03 0.1239 32 258
C2806 Top B3 01 0.0502 13 259
C2806 Top T3 03 0.1531 24 157
C2801 MID T6 02 0.1764 9 51
C2801 MID M2 01 0.2692 5 19
C2801 MID B3 01 0.3250 11 34
C2802 MID T1 01 0.1524 5 33
C2802 MID M2 01 0.1706 8 47
C2805 MID T4 01 0.2365 6 25
C2805 MID M3 01 0.2924 12 41
C2805 MID M3 02 0.3384 8 24
C2801 Bot B3 01 0.3800 20 53
C2801 Bot T6 01 0.0837 9 108
C2803 BOT M6 01 0.0592 12 203
C2803 BOT B4 01 0.1586 31 195
C2804 BOT M5 01 0.0998 11 110
C2804 BOT M5 02 0.0580 13 224
C2804 BOT T3 01 0.1589 21 132
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C4201 TOP B2 01 0.1240 45 363
C4201 Top B2 01 0.0575 18 313
C4201 TOP M3 01 0.1343 57 424
C4201 Top M3 01 0.0662 16 242
C4201 TOP T6 01 0.1371 54 394
C4201 Top T6 01 0.1055 17 161
C4202 TOP B1 01 0.1757 33 188
C4202 TOP B1 02 0.1359 17 125
C4202 TOP B1 03? 0.1665 59 354
C4202 Top B2 03 0.0859 26 303
C4202 TOP M1 01 0.1510 22 146
C4202 TOP M1 03 0.1811 15 83
C4203 TOP M1 01 0.0890 34 382
C4204 TOP B3 01 0.1961 36 184
C4204 TOP B3 02 0.1614 32 198
C4207 TOP M2 02 0.1431 67 468
C4207 Top M2 02 0.0996 32 321
C4207 TOP T6 02 0.2016 11 55
C4207 TOP T6 03 0.1860 24 129
C4202 MID T6 01 0.2189 21 96
C4202 MID T6 02 0.1850 13 70
C4202 MID B6 01 0.3367 17 50
C4204 MID M2 01 0.1555 9 58
C4204 MID M4 01 0.3751 13 35
C4204 MID M4 02 0.1702 8 47
C4207 MID T1 01 0.2585 20 77
C4207 MID M2 01 0.3737 15 40
C4201 BOT T6 01 0.1071 39 364
C4201 BOT B5 01 0.1208 49 406
C4202 BOT T6 01 0.1256 46 366
C4207 Bot B2 01 0.0721 19 263
C4207 BOT M2 01 0.1882 26 138
C4207 BOT M2 02 0.1967 26 132
C4207 Bot M2 02 0.0980 24 245
C4208 BOT M2 01 0.1707 38 223
C4208 BOT M2 02 0.1824 38 208  
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X. Myogenin Stained Sections: Myogenin Positive Nuclei 
A. ECM-ONLY 28 Day Recovery 
Slide Area (mm2)
Myogenin 
Positive Nuclei Density (#/mm2)
M2812 Top M6 02 0.1151 3 26
M2812 Top T4 02 0.1141 2 18
M2814 Top B4 03 0.1105 2 18
M2814 Top M6 04 0.1076 3 28
M2815 Top B4 02 0.1014 2 20
M2815 Top M6 02 0.1167 1 9
M2815 Top T2 02 0.0857 3 35
M2811 Mid T5 01 0.1300 0 0
M2811 Mid M2 01 0.1165 1 9
M2812 Mid T6 02 0.1521 1 7
M2812 Mid B1 01 0.1490 2 13
M2814 Mid M6 01 0.1259 0 0
M2814 Mid B3 01 0.1708 2 12
M2815 Mid B2 01 0.1401 1 7
M2811 Bot B4 03 0.1096 3 27
M2811 Bot M6 01 0.1308 2 15
M2812 Bot B4 01 0.1428 2 14
M2812 Bot M6 04 0.1596 3 19
M2813 Bot B2 03 0.1178 1 8
M2813 Bot M6 02 0.1570 2 13
M2813 Bot T3 02 0.1329 2 15
M2814 Bot B1 02 0.2023 3 15
M2815 Bot M6 02 0.1023 2 20
M2815 Bot T2 01 0.0924 2 22
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B. ECM-ONLY 42 Day Recovery 
Slide Area (mm2)
Myogenin 
Positive Nuclei Density (#/mm2)
M4201 Top B5 02 0.0959 4 42
M4201 Top M6 03 0.1277 6 47
M4202 Top M6 03 0.0890 2 22
M4207 Top B2 01 0.1296 2 15
M4208 Top T3 01 0.1063 4 38
M4201 Mid M2 01 0.1356 1 7
M4201 Mid M2 02 0.1163 3 26
M4203 Mid M4 01 0.1289 0 0
M4203 Mid B3 01 0.1709 1 6
M4206 Mid T4 01 0.1360 2 15
M4206 Mid M6 01 0.1335 1 7
M4206 Mid B4 01 0.1449 0 0
M4207 Mid T2 01 0.1352 1 7
M4207 Mid B4 01 0.1604 2 12
M4201 Bot M6 01 0.1547 5 32
M4203 Bot B3 02 0.1465 4 27
M4203 Bot M6 03 0.1190 3 25
M4203 Bot T3 02 0.1490 4 27
M4204 Bot B5 02 0.1250 4 32
M4204 Bot M5 02 0.1889 3 16
M4206 Bot B3 02 0.1551 4 26
M4207 Bot M6 02 0.1783 2 11
M4207 Bot T4 03 0.1414 1 7
M4208 Bot M6 03 0.1853 2 11
M4208 Bot T4 03 0.1683 4 24
M4209 Bot B4 02 0.0799 4 50
M4209 Bot M6 02 0.2010 3 15
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C. ECM-CELL 28 Day Recovery 
Slide Area (mm2)
Myogenin 
Positive Nuclei Density (#/mm2)
C2801 Top M6 03 0.1408 12 85
C2803 Top M6 03 0.1515 9 59
C2806 Top B3 02 0.1506 10 66
C2806 Top M3 03 0.1492 7 47
C2806 Top T5 02 0.1666 14 84
C2802 Mid T2 01 0.1831 1 5
C2802 Mid B3 01 0.1362 3 22
C2803 Mid T6 02 0.1523 2 13
C2805 Mid B4 01 0.1307 0 0
C2805 Mid B2 01 0.1406 2 14
C2806 Mid B1 02 0.1156 1 9
C2801 Bot B4 01 0.1207 7 58
C2801 Bot M6 02 0.1871 12 64
C2801 Bot T2 01 0.0951 7 74
C2802 Bot B3 02 0.1589 6 38
C2802 Bot T4 02 0.1537 9 59
C2804 Bot T6 01 0.1155 6 52
C2804 Bot M3 01 0.1487 9 61
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D. ECM-CELL 42 Day Recovery 
Slide Area (mm2)
Myogenin 
Positive Nuclei Density (#/mm2)
C4201 Top M5 01 0.1107 7 63
C4201 Top T4 01 0.1251 5 40
C4202 Top M4 02 0.1529 11 72
C4202 Top M4 03 0.1217 12 99
C4204 Top B3 03 0.1173 15 128
C4204 Top M5 01 0.1823 19 104
C4204 Top T3 03 0.1949 12 62
C4201 Mid T5 01 0.1400 2 14
C4201 Mid M4 01 0.1496 1 7
C4203 Mid T1 01 0.1287 2 16
C4203 Mid M2 01 0.1722 4 23
C4208 Mid B1 01 0.1660 3 18
C4208 Mid M2 01 0.1469 1 7
C4201 Bot B4 02 0.1345 9 67
C4201 Bot M6 02 0.1122 7 62
C4201 Bot T3 02 0.1398 8 57
C4202 Bot B5 02 0.1278 6 47
C4202 Bot M5 01 0.1284 7 55
C4203 Bot B3 02 0.1356 9 66
C4203 Bot T3 02 0.1727 14 81
C4204 Bot T2 03 0.1376 8 58
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